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Abstract
Cytokines are important mediators of immune functions in humans and animals. 
Interleukin (IL)-15 is a pro inflammatory cytokine, which is mainly produced by 
monocytes. It shares many of its functions with IL-2, which is partly due to the shared use 
of receptor subunits on target cells, and serves as a growth and survival factor for T 
lymphocytes. The type IIL-15 receptor is composed of the IL-2RP and y subunits, which 
form a trimeric complex with the high affinity IL-15Ra chain. The expression of IL-15 is 
tightly regulated both at the transcriptional and translational level. The production of IL-15 
is associated with immune responses against bacterial and parasitic pathogens but has also 
been associated with the pathology of human autoimmune diseases, in particular 
Rheumatoid Arthritis (RA). RA is characterized by chronic inflammation within the 
synovial membrane accompanied by infiltration of lymphocytes leading to progressive, 
erosive destruction of cartilage and underlying bone. The severity of RA is associated with 
the overexpression of proinflammatory cytokines within the synovial tissue, in particular 
tumor necrosis factor alpha (TNFa) which is thought to play a central role in maintaining 
the inflammatory processes within the arthritic joint. So far, little is known about the 
processes that initiate and perpetuate RA. IL-15 was found in the synovial tissue of RA 
patients where it stimulated the production of TNFa, placing IL-15 in a central position 
orchestrating the cytokine cascade that causes inflammation and pathology in RA. 
Antagonists to IL-15 may therefore have an important therapeutic potential for the 
treatment of RA in humans.
A major aim of this project has been to clone and express a recombinant IL-15 
antagonist to use as a therapeutic agent in a murine model of RA closely related to the 
human disease, collagen-induced arthritis (CIA). A soluble IL-15Ra was cloned from a 
murine macrophage cell line and expressed in a bacterial expression system. The resulting 
protein has a molecular weight of 26kD and bound to IL-15 specifically. It also had a
neutralizing effect on IL-15-induced proliferation of T cell lines. Administration of soluble 
IL-15Ra to mice prevented the onset of CIA and had a suppressive effect on disease 
severity and incidence. Mice treated with the recombinant IL-15Ra also showed reduced 
serum cytokine production and altered humoral responses against collagen. These results 
consolidate the therapeutic potential of IL-15 antagonists for the treatment of inflammatory 
diseases. To further enhance the therapeutic properties of recombinant IL-15Ra, a second 
expression construct has been cloned fusing the extracellular region of native IL-15Ra to 
the constant region of the murine immunoglobulin heavy chain. This construct was 
expressed in a mammalian expression system and results in a product of 66kD, which also 
bound to IL-15.
The generation of knockout mice by gene targeting is a powerful tool to study the 
function of gene products in vivo. The Cre/lox system provides a novel strategy to generate 
inducible and tissue specific genomic alterations that allow the detailed analysis of gene 
function. The second part of this project was concerned with the generation of a mouse 
model lacking IL-15Ra in a tissue specific way by conditional mutagenesis in embryonic 
stem (ES) cells. Using cDNA encoding the extracellular domain of IL-15 Roc as a 
radiolabeled probe, a murine genomic library was screened. Two clones containing part of 
the gene encoding IL-15Ra were characterized. A DNA construct was cloned to target the 
IL-15Ra gene in murine ES cells. Homologous recombination of the construct with the 
target locus resulted in the flanking of the critical regions of the IL-15Ra-gene by loxP 
sites. Cre-mediated recombination in vitro caused the deletion of loxP site flanked 
sequences within the genome of the targeted clone. Using this technique, two ES cell 
clones have been generated that allow the generation of mice that either lack IL-15Ra in 
all tissues or are suitable for conditional mutagenesis mediated by Cre recombinase. The 
resulting model may provide a useful tool to study the effects of IL-15 in inflammatory 
processes in vivo.
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Chapter 1 General Introduction
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1.1 Interleukin-15 and its Receptor
1.1.1 Historical perspective
IL-15 was first characterized as a soluble factor contained in culture supernatants 
derived from a simian kidney epithelial cell line, CV-l/EBNA (Grabstein, et a l, 1994) and 
an adult human T-cell leukemia line (Burton, et a l, 1994). While testing cell culture 
supernatants for cytokine activity it was found that these cells produced a soluble factor 
capable of inducing the proliferation of the IL-2-dependent cell line CTLL-2 (Gillis and 
Smith, 1977). Purification of the soluble factor with the CTLL-2-stimulating activity via 
anion-exchange and high-pressure liquid cliromatogi*aphy (HPLC) revealed that the 
stimulatory activity could be attributed to a protein of approximately 14-15kD. N-terminal 
amino acid sequencing and subsequent PCR using degenerate primers enabled cloning of a 
92bp cDNA fragment, which was used to screen a cDNA library made from CV-l/EBNA 
cells. A full-length cDNA clone was obtained encoding a 162 amino acid residue precursor 
polypeptide. Further analysis showed that this precursor polypeptide contained a 48 amino 
acid leader peptide, which is cleaved to form the mature protein. Initially designated IL-T 
by Burton et a l (1994), the newly described cytokine was subsequently named IL-15. The 
similar biological functions of IL-15 and IL-2 are partly due to the sharing of receptor 
subunits. The IL-2 receptor is composed of three subunits IL-2Ra, -(3 and -y, whereas the 
IL-15R contains the IL-2 [3 and -y chains in addition to a unique IL-15Ra subunit.
1.1.2 Characteristics of Interleukin-15
Like IL-2, IL-15 is a member of the 4a-helix bundle family of cytokines, which 
also includes IL-3, IL-4, IL-5, IL-6, IL-7 and IL-9. Accordingly IL-15 folding results in a 
protein consisting of three loops connecting four a-helices, which are arranged in an up-up
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down-down-confîguration (Grabstein, et a l, 1994). Although no sequence homology exists 
between IL-15 and IL-2, or any other member of the same cytokine family, IL-15 shares 
the same structural features as IL-2. Mature IL-15 contains 114 amino acid residues 
resulting in a molecular weight of 14-15kD. The mature protein is N-glycosylated on two 
asparagine residues and also contains two putative cystine disulfide cross-linkages at 
positions Cys42-Cys88 and Cys35-Cys85. The first of these disulfide bonds is homologous 
to a similar cross linkage found in IL-2. Human and simian IL-15 share 97% sequence 
identity and there is 73% sequence identity between simian and murine IL-15. In contrast 
to IL-2, which is produced by activated T cells (reviewed by Swain, 1991), mRNA 
encoding IL-15 can be detected by Northem blot analysis in many tissues and was found to 
be most abundant in human placenta and skeletal muscle with detectable levels in heart, 
lung, liver and kidney. High levels of IL-15 mRNA can also be found in adherent 
peripheral blood mononuclear cells (PBMC) and epithelial and fibroblast cell lines 
(Grabstein, et aL 1994).
1.1.3 Regulation of IL-15 expression
In humans, the gene encoding IL-15 was mapped on chromosome 4 by in situ 
hybridization, whereas the murine IL-15 gene is found on chromosome 8. In both species 
the gene encoding IL-15 contains nine exons covering a total area of approximately 35kb 
(Krause, et a l, 1996). The regulatory mechanisms that control the expression of IL-15 are 
very complex and occur mainly at the translational level. IL-15-mRNA expression in 
monocytes is upregulated by interferon gamma (IFNy) and lipopolysaccharicL (LPS) 
(Grabstein, et aL, 1994) as well as in response to several pathogens like Mycobacterium 
tuberculosis and Toxoplasma gondii (Doherty, et aL, 1996). Transcription of IL-15-mRNA 
is regulated by a number of transcription factors, most importantly IRF-1 (Ogasawara, et
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aL, 1998) and NF-kB (Azimi, et aL, 1998). Corresponding conserved elements seiving as 
putative transcription factor binding sites can be found in both the human and murine IL- 
15 promoter regions. Mice with a targeted mutation of the IRF-1 gene are NK cell 
deficient. However, this deficiency can be compensated in vitro by culturing IRF-L'^" bone 
maiTow cells with IL-15. Also, an IRF responsive element (IRF-E) has been located in the 
5'control region of the IL-15 gene (Otheld, et aL, 1998). ÎL-15-mRNA transcription is 
elevated in T cells infected with the human T cell lymphotropic virus type I (HTLV-I). 
This elevation is mediated by the HTLV-1 associated Tax protein and can be abrogated by 
the mutation of a NF-kB consensus sequence located in the 5’ regulatory region of the IL- 
15 gene (Azimi, et aL, 1998). .
However, regulation of IL-15 expression predominantly occurs post- 
transcriptionally at the level of translation and translocation (Grabstein, et aL, 1994; 
Bamford, et al, 1996). The observation that although IL-15-mRNA is readily expressed in 
many tissues, IL-15 cannot easily be detected at the protein level le d to the investigation 
of mechanisms that control translation of the IL-15 protein. A first level of translational 
control is constituted by the 5'untranslated region (5’UTR) of the IL-15-mRNA transcript. 
Wliereas the 5’UTR of most mRNAs is short and does not contain many regulatory 
elements, the 5’UTR of the IL-15 transcript is relatively long and contains multiple AUGs. 
Five AUGs can be found in murine and 12 in the human IL-15 UTR. These AUGs are 
located upstream of the initiation AUG and are known to significantly reduce the 
efficiency of protein translation (Kozak, 1986, 1987, 1989, and 1991). They can also be 
found in the 5’UTR of mRNAs encoding several protooncogenes, growth- and 
transcription factors. Experimental deletion of the 5’ AUGs in an IL-15 expression 
construct transfected into COS cells increased protein production 4-5 fold when compared 
to a control construct containing the wild type AUGs (Bamford, et a l, 1996). Two 
different signal peptides have been described that regulate IL-15 secretion and intracellular
20
trafficking. Initial studies demonstrated that the originally described 48 amino acid signal 
peptide of IL-15 strongly inhibits IL-15 generation. Expression constructs where the 48 
amino acid signal peptide of IL-15 had been exchanged for the leader sequence of IL-2 
resulted in a 17-20 fold increase in IL-15 expression in COS cells, whereas the IL-15 
signal peptide inliibited IL-2 production 40-50 fold in reciprocal constructs (Bamford, et 
aL, 1998). An IL-15 splice variant has been described bearing an alternative second leader 
sequence containing 21 amino acid residues. This alternative signal peptide originates from 
alternative splicing of exon 4a resulting in an insertion of 119 nucleotides encoding an 
alternative start codon and 21 amino acid signal peptide. The murine altemative gene 
segment has a length of 136 nucleotides resulting in a shortened leader sequence of 26 
amino acid residues (Prinz, et aL, 1998). Messenger RNA encoding both splice variants 
can be readily detected in T cells. However, IL-15 containing the shorter leader sequence is 
translated more efficiently than IL-15 containing the 48 amino acid sequence. The 21 
amino acid signal peptide isoform is not secreted and remains within the cell (Onu, et aL, 
1997). The short signal peptide isofoim is preferentially expressed in tissues such as testis 
and thymus and is not secreted, but rather stored intracellularly, appearing in the nucleus 
and cytoplasmic components of the cell. IL-15 may therefore play a role as an intracellular 
signaling molecule. The long signal peptide isoform appears in the endoplasmatic 
reticulum (ER), regulates the rate of protein translation and functions as a secretory signal 
peptide (Tagaya, et aL, 1997; Nishimura, et aL, 1998; Gaggero, et aL, 1999). A third 
regulatory control mechanism influencing IL-15 expression has been described, which is 
located at the 3’ end of the IL-15 coding sequence. For the purpose of antibody detection 
an IL-15 expression construct containing the FLAG coding sequence at its 3’end was 
cloned. The observation that this construct resulted in a 5-10 fold increase in IL-15 
expression suggests the presence of a regulatory element located within the 3 ’ end of the 
coding sequence (or the carboxyl-terminus of the IL-15 protein, respectively). This region, 
unintentionally disrupted by the FLAG coding sequence, appears to contribute to the
21
negative regulation of IL-15 expression. The molecular mechanism by which the C- 
terminal negative element inhibits IL-15 expression has not yet been defined but 
preliminary studies demonstrate that the stability of both IL-15-mRNA transcript and the 
resulting peptide are not altered by the presence of the C-terminal negative element 
(Bamford, et aL, 1998). This observation may indicate the presence of a comparatively 
large pool of IL-15-mRNA transcripts within the cell with only a low-level translational 
activity and peptide secretion; This pool of transcripts may allow for the secretion of large 
amounts of IL-15 within a short period of time in response to immunological stimuli, thus 
providing a means to rapidly activate NK and T cells.
IL-15 also exists in a membrane-bound form constitutively expressed on normal 
human monocytes, as well as on monocytic cell lines but not on human T or B cells. Cell 
surface-bound IL-15 can be upregulated in vitro by IFNy stimulation. Membrane-bound 
IL-15 does not elute with acetate buffer or trypsin treatment excluding the possibility that 
surface IL-15 is associated with its own receptor. These results suggest the presence of an 
integral membrane protein that has not yet been defined. The membrane bound foim of IL- 
15 is biologically active and stimulates T lymphocytes to proliferate in vitro. So far, no 
correlation has been found between the differential usage of signal peptides and the 
expression of membrane bound IL-15. Membrane bound isoforms have been described for 
other cytokines including IL-1, TNFa, and IL-10 (Kurt-Jones, et aL, 1985; Perez, et aL, 
1990; Fleming, et aL, 1996). IL-15 may therefore be capable of mediating part of its 
biological activities in a localized, cell contact dependent mamier as a membrane bound 
cytokine (Musso, et aL, 1999).
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1.1.4 The IL-15 receptor
Two distinct receptors and corresponding signaling pathways have been described 
for IL-15. The type-1 IL-15 receptor mediates the functions of IL-15 in T-, B- and NK 
cells. It shares important receptor components with the IL-2R system (Bamford, et al.: 
Grabstein, et al.\ Giri et aL, 1994). The type-1 IL-15 receptor contains three components, 
two of which, IL-2/15RP (CD 122) and IL-2Ry (CD 132) are also part of the IL-2R 
complex. The murine IL-2R(3- and y- chains are proteins with a molecular weight of 1 lOkD 
and 75kD respectively (Kono, et aL, 1990). They both belong to the hematopoietin 
receptor superfamily (D’Andrea, et a l 1989). Both chains are required for ligand 
internalization and signal transduction (Robb and Greene, 1987; Hatakeyama, et aL, 1989). 
The lack of IL-2Ry in humans is associated with X-linked severe combined 
immunodeficiency (XSCID) underlining the importance of the IL-2R signaling complex 
(Noguchi, et a l, 1993). In addition to the IL-2R(3 and y chain, both IL-2 as well as IL-15 
bind to their own unique receptor subunits, IL-2Ra (CD25) or IL-15Ra, respectively, to 
form high-affinity heterotrimeric receptor complexes.
The shared usage of IL-2R subunits between IL-2 and IL-15 and the observation 
that many non-lymphoid cell types bind IL-15 but not IL-2 (Giri, et al., 1994) suggested 
the existence of a unique IL-15-binding protein as a structural homologue to IL-2Ra. The 
murine T helper cell line DIO manifested a 10-fold higher dose responsiveness to IL-15 
than to IL-2 (Giri, et aL, 1995). IL-15 labeled with ^^^lodine specifically bound to a protein 
of 58-60kD derived from DIO lysates. The gene encoding the IL-15 binding protein was 
cloned from COS-7 transfected with a murine cDNA expression library derived from DIO 
cells. A single clone derived from this library encoded a type I membrane protein with a 
predicted signal peptide of 32 amino acids, 173 amino acid extracellular domain, a
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transmembrane domain of 21 amino acids and a cytoplasmic tail of 37 amino acid residues. 
The protein contains a single site for N-linked glycosylation and is extensively O- 
glycosylated. Little significant sequence homology of IL-15Ra to known proteins was 
found, however the extracellular domain of IL-15Ra exhibits a 45% similarity (28% 
identity) to bovine IL-2Ra. This homology is particularly pronounced within a conserved 
protein binding motif, also named ‘sushi domain’, glycoprotein (GP-)-l motif or ‘short 
consensus repeat (SCR) present in both IL-2Ra and IL-15Ra (Giri, et a l, 1995, Davie, et 
al, 1986; Perkins, et al., 1988) and is also present in several complement receptors (e.g. 
CR2, complement factor H, p-2-glycoprotein I). The protein encoded by the COS-7 clone 
was subsequently named IL-15Ra. The figure below shows a schematic representation of 
IL-15Ra and its subdivision into distinct functional domains compared to the IL-2Ra 
chain.
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Figui'e 1.1 Schematic representation of IL-15Ra (A) and IL-2Ra (B) demonstrating 
the structural similarity between both cytokine receptors. Both cytokine receptors are 
composed of a signal peptide, extracellular domain, and a single membrane spanning 
segment (TM) and cytoplasmic tail. Furthermore, both proteins contain the conserved 
protein binding motif called ‘Sushi domain’, which characteristically contains disulfide 
bridges. One putative N-glycosylation site is located within the ‘Sushi domain’ of IL- 
15Ra, whereas IL-2Ra contains two sites of glycosylation. IL-15Ra contains a single 
‘Sushi domain’, whereas two protein binding domains can be found in IL-2Ra. Arrows 
represent the intron-exon boundaries of the genes encoding IL-15Ra and IL-2Ra. The 
numbering between the arrows refers to the exon number containing coding sequence 
corresponding to each protein domain.
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Transfection experiments and equilibrium binding experiments using -simian 
IL-15 showed that IL-15 binds to IL-15Ra with high affinity (Ka~lxlO^^M"^). This affinity 
is comparable to the binding affinity of IL-2 to the IL-2R complex, however IL-2Ra binds 
IL-2 with low affinity (Ka~10^M’ )^ in the absence of IL-2R(5 and y chains. The additional 
presence of IL-2Rp and IL-2Ry did not significantly enhance the affinity of IL-15 binding 
to its receptor or could not be demonstrated due to the intrinsically high affinity of IL-15 to 
IL-15Ra. IL-2Rp and IL-2Ry alone are unable to bind to IL-15 with any measurable 
affinity, although high concentrations of IL-15 may cause signaling even in the absence of 
the IL-15Ra chain (Anderson; et a l, 1995). IL-15Ra has a wide cellular distribution and 
unlike IL-2Ra is not only expressed on T cells. Macrophages and B cells, as well as 
thymic and bone marrow stromal cell lines express IL-15Ra-mRNA. In addition, mRNA 
encoding IL-15 Roc can be detected in liver, spleen, heart, skeletal muscle, lung and 
activated vascular endothelium. In contrast to the wide tissue distribution of IL-15Ra, IL- 
2Ra is only found on T lymphocytes and NK cells. The induction of IL-15Ra on T and B- 
lymphocytes correlates with the activation of these cells. In contrast to resting cells, 
mitogen- activated macrophages, NK cells, CD4^ and CD8^ T cells express IL-15Ra 
chains (Chae, et a l, 1996). The expression of IL-15Ra-mRNA in T cells cultures is 
increased by the addition of anti-CD3 antibodies, phorbol myristyl acetate (PMA) or IL-2. 
In macrophages, treatment with IFNy or IFNy and LPS greatly stimulated the production of 
IL-15Ra-mRNA. IL-15 has been demonstrated to upregulate IL-2Ra but to downregulate 
its own high affinity receptor on human T and B cells (Kumaki, et a l, 1996).
26
The gene encoding murine IL-15Ra has been mapped on chromosome 2, whereas 
the human gene is located on chromosome 10pl4-15. In both the murine and human 
genomes, the genes encoding IL-15Ra and IL-2Ra are located in close proximity 
(Anderson, et a l, 1995; Leonard, et a l, 1985). The gene encoding IL-15Ra is composed 
of 7 exons and 6 introns. The intron-exon boundaries relative to predicted structural 
domains of IL-15Ra and IL-2Ra show that the positions and coding sequence of several 
exons are in close agreement. The functional, structural and genetic similarities of IL- 
15Ra and IL-2Ra have led to speculation that the genes encoding the two proteins arose 
from a random gene duplication event that predated the phylogenetic separation of mouse 
and man. Human and murine IL-15Ra share an overall amino acid identity of 54%. This 
homology is particularly conserved within the region of the putative ‘Sushi domain’, where 
the amino acid identity between the two proteins derived from mouse and human reaches 
82%L
Several differentially spiced mRNA transcripts for hIL-15Ra exist. In the original 
publication reporting the cloning and characterization of human IL-15Ra (Anderson, et al, 
1995), three splicing variants were described. Apart from the full-length mRNA-transciipt 
encoding the complete IL-15Ra protein, a variant lacking exon 3 (linker/hinge region) has 
been found in a human cDNA library. A further cDNA fragment contains a 120bp- 
insertion encoding a shortened cytoplasmatic domain resulting from splicing of an 
alternate downstream-exon named E7’. E7’ is lOObp shorter than E7, which encodes the 
cytoplasmic tail of IL-15Ra. RT-PCR using specific primers for all three splicing variants 
confirmed the existence of all three differentially spliced forms of human IL-15Ra in 
peripheral blood T cells, the NK-like YT cell line and the myelogenous leukemia cell line 
K562. All three splicing variants identified are capable of high affinity binding to IL-15.
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Recently, Dubois et al. (1999) reported the existence of another five alternatively spliced 
IL-15Ra-transcripts. These splicing variants lack either E2, E3 or both exons and are 
found with either of the two exons (E7 or E7’) alternatively encoding the cytoplasmic tail 
of IL-15Ra. All eight splicing variants are present in PBMCs and can be specifically 
amplified by RT-PCR. The most striking obseiwation for these splicing events is the 
existence of a mRNA-transcript lacking exon 2, encoding the protein binding ‘Sushi motif 
of IL-15Ra. Subsequent cloning and expression of differentially spliced variants of IL- 
15Ra in COS-7 cells showed that proteins resulting from mRNA-transcripts lacking E2 
where unable to bind IL-15. Analysis of the subcellular localization of the different IL- 
15Ra isoforms within COS-7 cells by confocal microscopy revealed that full-length IL- 
15Ra is mainly associated with the nuclear membrane compartment of COS-7 cells. Some 
of the IL-15Ra protein was also localized on the imier site of the nuclear membrane. In 
support of this obseiwation, a putative nuclear localization sequence (NLS) lies within the 
sequence encoded by E2. These NLSs occur in the sequence of a number of ligands, 
including those that activate ST AT transcription factors (Strehlow and Schindler; Johnson, 
et al., 1998) and may be associated with the nuclear routing of proteins. In contrast, IL- 
15Ra lacking the E2-encoded ‘Sushi’ domain was mainly associated with ER, Golgi and 
cytoplasmatic vesicles, but not with nuclear membrane compartments. The deletion of E3 
had no effect on the cellular localization of IL-15Ra, nor did it alter the binding capacity 
for IL-15. External labeling of COS-7 cells with [^^^I]-iodine and subsequent 
immunoprécipitation showed that both the full-length IL-15Ra and the splicing variant 
lacking E2 are routed to the plasma membrane and are expressed at the cell surface of 
transfected cells at low concentrations. Although the biological functions of IL-15Ra 
without E2 remain uncertain, a regulatory role for both IL-15Ra~transcripts in the 
regulation of IL-15 mediated signaling events has been proposed. Truncated IL-15Ra may 
compete with the full-length transcript for the recmitment of IL-2R(3 and y subunits.
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Interestingly, a similarly truncated form of IL-2Ra has been described that results from 
differential splicing and lacks E4 of the IL-2Ra gene, which similarly encodes a protein 
binding ‘Sushi’ domain (Cullen, et al,, 1988). Since two iso forms of IL-15 have been 
described that differ in the length of their signaling peptides, secretion patterns and cellular 
location, IL-15Ra may bind to IL-15 intracellularly and, through its-putative NLS, 
translocate the cytokine-receptor complex into the nuclear- compartment of the cell. Since 
IL-15Ra is a large protein of approximately 60kD making diffusion into the nucleus 
unlikely, it has been speculated that an active transport mechanism mediating nuclear 
translocation of IL-15-IL-15Ra may exist.
IL-15 can also stimulate the proliferation of murine mast cell lines and normal bone 
marrow mast cells. However, the mast cell lines PT-18 and Mc/9 do not respond to IL-2 
and mRNA encoding the IL-2 receptor (IL-2Ra, -(3 or y) is undetectable in these cells. 
These results suggest that an alternative IL-15R complex exists on mast cells. To 
investigate the mechanism underlying IL-15 function in mast cell proliferation, IL-15 has 
been cross-linked to ^^^lodine and used with disuccinimidyl suberate in order to identify a 
putative mast cell-specific IL-15R. Using this technique, an IL-15-binding protein of 60- 
65kD was identified and subsequently named IL-15RX. This receptor, which mediates the 
functions of IL-15 on mast cells has also been refeiTed to as type-2 IL-15 receptor (Tagaya, 
et al, 1996).
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1.1.5 Signaling through the IL-15 receptor
Due to the shared usage of receptor subunits between the type 1 IL-15R and IL-2R, 
signaling through the type 1 IL-15R is characterized by intracellular events mediated by 
signal transduction through the IL-2Ry chain. IL-2Ry, also referred to as ‘common gamma 
chain’ is a component of other cytokine receptors and thus mediates signaling events 
triggered by IL-2, IL-4, IL-7, IL-9 and IL-15. Jakl and Jak3 are known to be coupled 
functionally to the common gamma chain (Witthulm, et a l, 1994). Addition of IL-15 or 
IL-2 to T cells expressing both cytokine receptor subunits triggered the phosphorylation 
and nuclear translocation of STAT3 and STAT5 (Jolmston, et a l, 1995). Furthermore, 
common gamma chain-mediated signaling pathways in T cells involve the phosphorylation 
of cytoplasmic tyrosine kinases p56^‘''^  and p72"^  ^ as well as the expression of the anti- 
apoptotic protein bcl-2. Ras/RaRMAP kinase pathways are also stimulated leading to the 
activation of fos/jun (Miyazaki, et a l, 1995).
The mast cell specific receptor for IL-15 does not signal tlu'ough the common y- 
chain cytokine receptor. Signaling events following the binding of IL-15 to IL-15RX 
therefore differ from those observed in T and B-lymphocytes. IL-15 stimulation of PT-18 
and bone man'ow mast cells caused the phosphorylation of Jak2 rather than Jakl/Jak3 as 
observed for events following IL-15 binding to IL-15Ra. In contrast to type 1 IL-15R 
signaling, no tyrosine phosphoiylation and subsequent nuclear translocation of STAT3 was 
obseiwed in mast cells limiting the activation event to STAT5. The distinct receptor usage 
and signaling cascade induced by IL-15 in mast cells further underline the pleiotropic 
functions of IL-15 and its action in various tissues (Tagaya, et a l, 1996).
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Figure 1.2 Schematic representation of the IL-15 receptors found in different tissues. 
The IL-15-type 1 receptor is found on lymphocytes and many other cell types. It is 
composed of the IL-2RP and y chain and contains a unique IL-15Ra chain for high affinity 
binding to IL-15. Signaling through the type 1 IL-15R involves Jakl and Jak3 as well as 
ST AT 3 and STATS. Mast cells express the IL-15-type 2 receptor, which does not contain 
any components of the IL-2R complex but is composed of a 60~65kD membrane spanning 
protein. Signal transduction in mast cells involves Jak2 and STATS (after Tagaya, et nZ., 
1996).
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1.2 The functions of Interleukin-15
1.2.1 The biological role of IL-15
The initial cloning of IL-15 from CV-l/EBNA and adult human leukemia cells 
revealed a protein capable of replacing IL-2 as a cytokine inducing the proliferation of T 
cells and activation of lymphokine-activated killer cells. Due to the usage of common 
receptor subunits, most crucially the common y chain required for signal transduction, the 
biological effects of IL-2 and IL-15 overlap. However there are major differences between 
the two cytokines in terms of site of synthesis, regulation of expression and receptor tissue 
distribution. IL-15 stimulated the proliferation of the IL-2 dependent cell line CTLL-2 and 
lymphokine-activated killer cells. It also induced the proliferation of activated CD4^ and 
CD8  ^ cells (Burton, et aL, 1994). B cell proliferation and antibody production were 
stimulated by IL-15 in vitro in combination with either CD40L or immobilized anti-IgM 
(Armitage, et aL, 1995). IL-15 upregulated CD69 expression on CD45R0^ cells 
(Kanegane, et a l, 1996) and thus can recmit and expand memory T cells. Unlike IL-2, IL- 
15 causes the stimulation of memory-phenotype CD44'” CD8"^  but not CD4^ cells in vivo 
and purified T cells in vitro, and this correlated with much higher expression of IL-2RP on 
CD8"^  cells than on CD4^ cells (Zhang, et al., 1998). Priming of naive CD4^ cells from 
TCR-transgenic mice by IL-15 led to enhanced IFNy-, but not IL-4 production after 
subsequent stimulation with specific antigen (Seder, 1996). On the other hand activated 
human T lymphocytes were reported to produce both IFNy and IL-4 after IL-15 stimulation 
(Borger, et a l, 1999).
The development and function of NK cells has been demonstrated largely to rely on 
IL-15. Deficiencies in the number of NK cells have been observed in IL-2Rp- but not IL-2
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knockout mice suggesting that IL-2Rp-mediated signals that do not involve IL-2 are 
important for the differentiation and function of these cells (Suzuki, et al., and Otheki, et 
al., 1997). Mice lacking the transcription factor IRF-1 are deficient in NK cell 
development and also exhibit impaired IL-15 mRNA expression. However, the lack of 
IRF-1 affects the radiation resistant cells that constitute the microenvironrpent required for 
NK cell development rather than NK progenitors themselves. Culture of bone marrow cells 
derived from IRF-1'^' mice in the presence of IL-15 led to the generation of NK cells 
suggesting that IL-15 is crucial for the development of this cell type (Otheki, et at.) 
Ogasawara, et al., 1998). Resting human NK cells have been shown to express the IL- 
15Ra chain required for high, affinity binding of IL-15. Picomolar amounts of IL-15 but 
not other cytokines sustained NK cell survival for up to 8 days in the absence of serum. 
One mechanism by which IL-15 promotes NK cell survival may involve the maintenance 
of bcl-2 protein expression. IL-15 also stimulates IFNy production by NK cells (Carson, et 
al, 1997). The cytotoxicity of NK cells induced by herpesvims 6 and 7 was dependent on 
IL-15, since the addition of anti-IL-15 Ah markedly reduced the herpesvirus-induced 
activation of NK cells (Flamand, et al., 1996; Atedzoe, et al., 1997).
IL-15 acted synergistically with IL-12 to promote the responses of human yô T 
cells to non-peptide antigens and induced IFNy production from these cells (Garcia, et a l, 
1998). The importance of IL-15 in innate immunity is further underlined by its chemotactic 
properties. IL-15 is chemotactic for NK cells and promotes NK cell attachment to the 
endothelium (Allavena, et a l, 1997). IL-15 acted as a chemokine for human blood T cells 
(Wilkinson and Liew, 1995) and induced the production of IL-8 and MCP-1 fi'om 
monocytes (Badolato, et al., 1997). IL-15 also stimulated the expression of CC-, CXC-, 
and C-type chemokines and CC chemokine receptors, hut not CXC chemokine receptors 
on T lymphocytes (Perera, et a l, 1999). In addition to its effect on T cells and NK cells,
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IL-15 also had a stimulatory effect on neutrophils. These cells have been shown to express 
the high affinity IL-15Ra chain and to respond to IL-15 by undergoing morphological 
changes that are associated with neutrophil-activation. IL-15 but not IL-2 increased the 
phagocytosis of opsonized sheep red blood cells and stimulated de novo RNA synthesis 
and protein production (Girard, et al., 1996).
A further important biological effect of IL-15 lies in its anti-apoptotic properties. 
IL-15 has been shown to protect activated T and B cells from apoptosis induced by anti- 
Fas, anti-CD3, dexamethasone or anti-IgM. In addition, administration of an IL-15-IgG2b 
fusion protein protected BALB/c mice from hepatic failure and death induced by anti-Fas 
injection and inliibited chemotherapy-induced apoptosis of kératinocytes (Bulfone-Paus, et 
al., 1997; Lindner, et al., 1998). The molecular mechanisms underlying the inhibitoi*y 
effect of IL-15 on apoptosis are so far only partially understood. Apart from the 
stimulatory effect of IL-15 on bcl-2, a possible function of IL-15Ra may be to compete 
with the type 1 TNF receptor (TNFRl, p55) for the binding of TRAF2 (TNFR associated 
factor 2) thereby inhibiting TNF-mediated apoptosis. The cytoplasmic tail of IL-15Ra 
contains sequences homologe;jr to the TRAF2 binding domains of CD30 and CD40. 
Binding of IL-15 to IL-15Ra leads to the binding of TRAF2 to the cytoplasmic domain of 
IL-15Ra (Bulfone-Paus, et al., 1999).
Due to the wide tissue distribution of IL-15 mRNA expression, several biological 
functions have been described for IL-15 that do not directly affect cells of the immune 
system. The expression of IL-15Ra on vasculai' endothelial cells results in high affinity 
binding of IL-15 to these cells, which can not be observed for IL-2. In a murine system, IL- 
15 has been shown to promote angiogenesis in vivo and to induce tyrosine phosphorylation 
in endothelial cells (Angiolillo, et al., 1997). As IL-15 is capable of binding to the type 2
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IL-15R on mast cells and to induce mast cell proliferation in vitro, the stimulatory effect of 
IL-15 on the vascular system may hc^  of some physiological importance. The expression of 
IL-15- and IL-15R-mRNA in murine brain microglia and human neural cell lines as well as 
the effect of IL-15 on NO production and growth in vitro may indicate a role for IL-15 in 
the central nervous system (Lee, et a l, 1996; Hanisch, et a l, 1997; Satoh, et a l, 1998). An 
anabolic effect of IL-15 on skeletal muscle has been described due to the finding that both 
IL-15 and its high affinity receptor are highly expressed by myocytes. IL-15 stimulates 
myogenic differentiation with low concentrations of IL-15 leading to fiber fonnation and 
MHC accumulation (Quinn, et a l, 1995 and 1997).
The biological activity of IL-15 has been further elucidated by the generation of 
mice lacking IL-15Ra using conventional gene targeting techniques (Lodolce, et al.,
1998). These mice appear healthy and breed normally. Despite the wide tissue distribution 
of IL~15Ra in normal mice, IL~15Ra''^‘ mice do not exhibit gross differences in the 
histology of brain, lung, liver, spleen, kidney or intestine. However, IL-15Ra'^' mice are 
markedly lymphopénie due to decreased proliferation and homing of lymphocytes to 
peripheral lymph nodes, thus leading to a reduction of peripheral lymph node size and cell 
content. This reduction in lymph node size, shown to vary from 30%-80% in IL-15Ra‘^‘ 
mice, is not due to the total number of lymphocytes in IL-15Ra deficient mice, which is 
only reduced by 10%-15% when compared to wild type mice. Mutant mice lacking ÏL- 
15Ra have also been demonstrated to lack NK cells (CD3'DX5^ and CD3NK1.D) 
combined with a marked reduction in the number of intraepithélial lymphocytes, 
particularly yôT cells (5-10 fold) compared to wild type mice. Whereas the development of 
B cells in mice lacking IL-15Ra is not affected, mutant mice show a reduction of total 
lymphocyte numbers, particularly for the number of CD8  ^ cells in thymus, spleen and 
periphery. A reduction in the number of CD8^CD44^' and CD8^CD44‘"^  population
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indicates an important role for IL-15 in the development and function of normal CD8^ and 
CD8^ memory cells. Although IL-15 has been described as a cytokine with anti-apoptotic 
properties, mice lacking IL-15Ra show no signs of elevated apoptosis of lymphocytes.
Despite the functional similarities between IL-15 and IL-2 with respect to T cell 
regulation, the phenotype of IL-15Ra'^' mice is strikingly different from both IL-2 or IL-2 
receptor deficient mice, which display severe lymphadenopathy, autoimmunity and 
premature mortality (Schorle, et al., 1991; Sadlack, et al., 1993). Since IL-15 and IL-2 
both transduce signals through the common gamma chain, the functional differences 
between the two cytokines may not only be due to differential tissue distribution but also 
open the possibility of IL-15 signaling through the cytoplasmic tail of IL-15Ra. 
Furthermore, the intracellular trafficking of IL-15 due to the usage of different leader 
sequences and a possible role for IL-15Ra in intracellular signaling and nuclear 
translocation may be important in the complex regulation of cellular responses to IL-15 in 
vivo.
1,2.2 IL-15 in inflammation and autoimmunity
The complex regulatory mechanisms that influence IL-15 expression have led to 
the assumption that high levels of IL-15-mRNA present in monocytes in conjunction with 
low secretion of the mature IL-15-protein may indicate a pool of transcripts enabling rapid 
secretion of IL-15 following activating stimuli (reviewed by Waldmann and Tagaya,
1999). As mentioned earlier, various bacterial and viral stimuli including herpes-virus 
(Flamand, et al., 1996) and hepatitis C (Kakumu, et al., 1997), induce IL-15. Also, IL-15 
has been shown to enhance immune frinctions against the human immunodeficiency virus 
(HIV) in vitro (Chehimi, et al., 1997) and has been reported to act as a survival factor for 
CD4^ and CD 8^  cells in HIV-infected individuals (Naora and Gougeon, 1999).
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Furtheimore, co-expression of IL-15 with an HIV-I DNA vaccine was reported to enhance 
cell-mediated immunity in BALB/c mice (Xin, et al., 1999). Since the importance of IL-15 
for the development of innate immune cells has been clearly demonstrated, these properties 
highlight the putative therapeutic potential of IL-15 for the treatment of infectious diseases.
However, the expression of IL-15 has also been associated with a number of 
chronic autoimmune disorders where the activation of T cells by dysregulated IL-15 
expression leads to increased pathology. IL-15 has been linked with the development of T 
cell alveolitis and IFNy production in the lung of patients with sarcoidosis (Agostini, et al., 
1996, 1999). In Ulcerative Colitis and Crohn’s diseases, the number of IL-15 expressing 
monocytes is elevated (Kirman and Nielsen, 1996) and IL-15-activity is enhanced in 
patients with active inflammatory bowel disease (Sakai, et a l, 1998) and post-operational 
enterocolitis (Mayumi, et al., 1999). Elevated levels of IL-15-mRNA have also been 
described in human autoimmune thyroid diseases (Ajjan, et al., 1997) and renal allograft 
rejection (Pavlakis, et al., 1996). Also, elevated semm levels of IL-15 were detected in 
Systemic Lupus Erythematosus (SLE) patients (Park, et a l, 1999).
1.2.3 IL-15 in human Rheumatoid Arthritis
Although the expression of IL-15-mRNA has been reported in a variety of different 
autoimmune disorders, comparatively little information on the biological role of IL-15 in 
these diseases is available so far. This however is not the case for Rheumatoid Arthritis 
(RA), where the effect of IL-15 on the pathology of the disease has been studied in greater 
detail.
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RA is a common human autoimmune disease with a prevalence of approximately 
1%, more often occurring in females than in males. The clinical syndrome is characterized 
by chronic inflammation within the synovial membrane accompanied by infiltration of 
blood derived T cells, macrophages and plasma cells. All of these cells show signs of 
activation leading to progressive, erosive destruction of cartilage and underlying bone. 
Apart from monocytes, T- and B cells, polymorphonuclear cells (especially neutrophils), 
mast cells, dendritic cells (DC) and fibroblast-like synoviocytes are found in the 
interstitium (Duke, et aL, 1982; Burmester, et ah, 1983; Kermedy, et al., 1988; Cush and 
Lipsky, 1988; Thomas, et a l,  1994). The events that initiate and peipetuate RA remain 
poorly imderstood. Although RA resembles an ongoing immune response, the antigen 
initiating inflammatoiy responses in RA has not yet been characterized.
Cytokines and their receptors as well as high levels of adhesion molecules on 
endothelial cells and leukocytes are known to play a pivotal role in the pathogenesis of RA 
(Pitzalis, et a l, 1994) by regulating the recruitment and activation of inflammatoiy cells in 
the synovial membrane. Within the synovial membrane, several pro-inflammatory 
cytokines, particularly IL-lp, IL-6, GM-CSF, IL-8 and most importantly TNFa ai*e 
upregulated, whereas T-cell derived cytokines such as IFNy, IL-2 and IL-4 are only found 
at low levels (reviewed by Feldmann, et a l, 1996). It remains controversial if the 
pathology of RA is a macrophage- or T cell mediated process. Therapies that target T cells 
such as cyclosporin A or antibodies directed against T cell epitopes are clinically beneficial 
(Homeff, et a l, 1991 and 1993). Also, disease severity and prevalence are associated with 
certain HLA-DR subtypes (Gregersen, et a l, 1987). T cells found in the synovial 
membrane are mostly of the CD45RB^™CD45R0'^CD27' phenotype representing a mature, 
memory T cell population (Thomas, et al, 1992). New data demonstrate that the 
production of pro-inflammatory cytokines and of tissue-degrading enzymes in rheumatoid
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synovitis is T cell dependent and that CDA cells are primary regulators in RA. T cells 
either depleted from or adoptively transferred into NOD-SCID mice engrafted with 
rheumatoid synovial tissue and subsequent injection of anti-CD2 resulted in the 
elimination of 80-90% of tissue-infiltrating T cells. A marked decline in the production of 
IL-lp, TNFa and IL-15 mRNA as well as MMP-1 and MMP-2 could also be observed 
(Klimiuk, et a l, 1999). However so far, no consensus exists over identity of the principal 
regulatory cell representing an optimal therapeutic target for the treatment of RA.
In the relative absence of IL-2, which is usually found only at mRNA levels and is 
not produced by synovial T cells in response to exogenous stimuli (Combe, et a l, 1985), 
cytokines that mediate the activation and proliferation of synovial T cells may be of high 
importance in mediating disease pathology. The biological properties of IL-15 as a 
macrophage-derived activator of T cells and a potent chemoattractant makes IL-15 an 
obvious candidate for T cell activation in RA. Interestingly, IL-15 was found in the j
synovial fluid of approximately 50% of patients with RA and correlated with the presence |
of TNFa. Immunohistochemical localization of IL-15 identified CD68^ macrophages in 
the synovial lining layer as well as synoviocytes as the likely source of IL-15 in RA. The j
chemotactic activity of synovial fluid for peripheral blood lymphocytes could be attributed ;
partially to the presence of IL-15. The responsiveness of T cells to IL-15 could be 1
confirmed by iryecting recombinant IL-15 into footpads of DBA/1 mice primed with 4
Corynebacterium parvum or type II collagen. This treatment induced swelling and T cell ]
accumulation. Furthermore, PBMC from RA patients responded more vigorously to IL-15 1
than PBMC from healthy controls (Mclnnes, et a l, 1996; Thurkow, et a l, 1997; Harada, et 4
a l, 1999). IL-15-activated blood-derived and synovial T cells are able to induce TNFa ; j
i
production from synovium-derived macrophages and macrophage cell lines. For IL-15 to J 
induce TNFa, synovial T cells and macrophages required cell contact, which was mediated
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in part by LFAl-ICAMl and CD69. The ability of synovial T cells to induce TNFa 
production by macrophages depends on the presence of IL-15. Freshly isolated synovial T 
cells of the CD45R0^ memory type and IL-15-activated peripheral blood T cells both 
induce TNFa production. In the absence of IL-15, these cells lose their ability to stimulate 
TNFa production within 16 hours of cultui*e most likely due to the loss of adhesion 
molecules such as CD69, which can be upregulated by IL-15 on peripheral blood T cells 
(Mclnnes, et a l, 1997).
TNFa, mainly produced by macrophages, appeal's to occupy a pivotal position in 
the regulation of synovial inflammation (reviewed by Feldmann, et al. 1996) by 
upregulating other pro-inflammatory cytokines. The importance of TNFa as a therapeutic 
target in RA has also been demonstrated (Elliott, et a l, 1993 and 1994). The recruitment 
and expansion of memoi-y T cells in the synovium by IL-15 may lead to a positive 
feedback loop, where macrophage or fibroblast-derived IL-15 induces T cell recruitment 
and TNFa production by synovial macrophages thiough cell contact. Apart from its central 
ability to induce TNFa production, IL-15 has also been shown to play a role in the 
pathological destruction of bone by stimulating osteoclast formation independently from 
TNFa (Ogata, et al., 1999). Recent reports indicate that IL-15 may work synergistically 
with IL-18, which is also present in the synovial membrane, in upregulating both TNFa 
and IFNy (Gracie, et al., 1999) providing a further possible activation loop in the 
pathogenesis of RA. Further stimulatory effects of IL-15 on B cell antibody secretion and j
neutrophils may result in a cytokine-mediated, non-specific activation of polyclonal T cells 
exacerbating disease pathology in an antigen independent manner. The identification of IL- |
15 as a monocyte-derived T cell activator, which is found in the synovial membrane of j
patients with RA and may operate upstream from the effects of TNFa may provide a |
4
useful target for therapeutic interventions. One part of this project was designed to 4
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elucidate the therapeutic potential of antagonizing IL-15 in a murine model for RA, 
Collagen-Induced Arthritis. :
1.3 Murine Collagen-Induced Arthritis (CIA) as a model for RA
The establishment of arthritic disease following the immunization with type II 
collagen has been described in rats, mice and primates (Trentham, et al., 1977; Courtenay, 
et al., 1980; Yoo, et al., 1988). Murine CIA in DBA/1 mice has widely been regarded as a 
valuable model for the inflammatory processes observed in RA. Following immunization 
of mice with type II collagen in CFA, an accumulation of macrophages and CD4+ cells 
can be observed (Holmdahl, et al., 1988). This stage of accumulation a_nd activation is 
followed by swelling and infiltration of inflammatory cells into the joint accompanied by 
pannus formation and erosion of cartilage and bone. The acute phase of CIA resolves after 
8-10 days showing reduced inflammatory activity accompanied by fibrous and bony 
ankylosis (Caulfield, et al., 1982). The susceptibility of DBA/1 mice to CIA is associated 
with a number of gene loci, most likely genes within the MHC, especially H-2^ and H-2'". 
Outside the MHC, the Mcia2 locus located on chromosome 3 was identified as an 
important genetic factor for susceptibility to CIA (Jirholt, et al., 1998). Although 
heterologous collagen is used for CIA induction, the development of autoreactive T cells 
appears to be essential for disease onset (Holmdalil, et al., 1988). However, the 
development of arthritic lesions following immunization with type II collagen has also 
been reported in mice lacking both mature T and B cells, suggesting a lymphocyte 
independent mechanism of disease onset (Plows, et al., 1999). In terms of lymphocyte
involvement, pathogenesis and cytokine production, CIA closely resembles human RA.
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Although CIA is widely accepted as an experimental model for RA, there are not 
only similarities but also marked differences between the two diseases. Whereas the 
inflammatory infiltration in CIA is mainly composed of polymorphonuclear leukocytes 
(Caulfield, et al., 1982), the RA-infiltrate is dominated by mononuclear cells (Janossy, et 
al., 1982). A further difference between CIA and RA lies in the prolonged, often 
fluctuating inflammatory activity of RA, which is not observed in CIA. A number of 
studies aiming to develop therapeutic strategies have led to the identification of important 
factors in the pathogenesis of CIA including pro-inflammatory cytokines. The table below 
summarizes some of the major immunologic approaches as well as some alternative 
treatments leading to the suppression of CIA by either blocking specific stimulatory 
pathways or by providing a general anti-inflammatory effect.
Table 1.1 Immunotherapy of CIA
Form of treatment
Anti-CD4
Anti-TCRa/p
Anti CD40L
Anti -IL-6R
Treatments 
Antagonizing TNFa
Reference
Antibodies and 
recombinant proteins
Ranges et a l, 1985 
Williams et al., 1994 
Yoshino et al., 1991
et al., 1993
Takagi et al., 1998
reviewed by 
Feldmann et a l, 1996
Comments
Only effective when 
administered at early stage. 
Variable results in rats and 
mice.
Suggests the involvement of 
B cells in CIA.
Single injection ameliorates 
CIA.
Very efficient blockage of 
CIA, also used in human RA.
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Recombinant IL-4 treatment Horsfall et al., 1997
Recombinant IL-IR 
antagonist
anti-IL-laP
anti-adhesion-molecule
treatment
Systemic IFNy injection
Wooley et al., 1993
Van den Berg et a l, 1994 
Joosten et a l, 1996 
Joosten et a l, 1999 
Kakimoto et a l, 1992
Williams et a l, 1993 
Vermeire et a l, 1997 
Kageyama et a l, 1998
anti-Mac-1 Taylor er aZ., 1996
(integrinPz, CDllb/CD18)
IL-11 Walmsley, e? a/., 1998
Studies with knockout and 
transgenic animals
B cell deficiency Svensson aZ., 1998
GM-CSF deficiency
IL-12 deficiency
Campbell et a l, 1998
McIntyre, et a l, 1996
Requires continuous 
administration.
IL-1 is particularly important 
for cartilage- and bone- 
destruction.
Moderately beneficial. Anti-' 
IFNR-deficiency exacerbates 
or inhibits CIA depending on 
genetic background. Anti 
IFNy-antibody-treatment 
exacerbates CIA.
Inhibits spleen cell transfer 
induced CIA into SCID mice. 
Reduced clinical severity.
In contrast to Plows et al 
(1999), suggesting that CIA: 
can be induced in mice 
lacking T and B cells. 
Confirms essential role of 
GM-CSF, which could not be 
shown by ab-treatment. 
Reduced incidence and 
severity.
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IL-6 deficiency
TNF a-o verexpression 
CD28 deficiency
Alonzi et a l, 1998 
Sasai etal., 1999
K.QÏÎQV et al., 1991
Tada et al., 1999
Essential role for IL-6 in 
CIA.
Delayed onset in KO mice 
Mice develop arthritis 
without induction.
Resistance to CIA induction.
IL-10 expression by 
viral transfer
IL-13
Other techniques
Ma, et al., 1998 
Apparailiy, etal., 1998 
Whalen, et al., 1999
Bessis, et a l, 1996
TNFR e ta l, 1991
IL-IR antagonist secretion Bakker, et a l, 1997
oral or nasal administration Trentham, <3 / . ,  1993 
of type II collagen Garcia, et a l, 1999
Viral IL-10 lacks 
immunostimulatory 
properties and may be 
particularly useful for disease 
suppression.
Transplantation of 
transfected fibroblasts 
Adenoviral transfer 
Transplantation of 
transfected fibroblasts 
Tolerization
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1,4 Conventional and conditional gene targeting in mice 
1.4.1 Historical Perspective
Although the mouse has been well established as a laboratory model since the 
beginning of the 20^  ^ century, techniques allowing the active manipulation of the murine 
genome have only been developed over the last 20 years. The first report of a direct 
introduction of foreign DNA into the murine embryo dates from 1974, when Rudolf 
Jaenisch and Beatrice Mintz found that the injection of purified SV40 DNA into the 
hlastocoel cavity of mouse blastocysts led to the detection of viral DNA in many of the 
resulting animals. Furthermore, it was demonstrated that the infection of pre-implantation 
embiyos by the Moloney murine leukemia virus resulted in stable germ line transmission 
of the virus (Jaenisch, 1976).
Studies aiming to elucidate the developmental potential of different parts of the 
murine post-implantational embryo showed that the early embiyonic ectoderm contains 
cells capable of contributing to all three germ layers of the fetus. These studies were 
fui-ther complemented by the use of transplantable teratocarcinoma cells (Stevens, 1970). 
Teratocarcinomas consist of a mixture of different cell types derived from gonadal tumors 
that originate from a population of undifferentiated stem cells known as embryonal 
carcinoma cells (EC cells). Cells derived from these tumors were shown to be able to 
contribute to many normal adult tissues when integrated into the blastocyst (Brinster, 
1974). Studies conducted on teratocarcinorna cells also led to an advancement of culture 
techniques enabling in vitro experimentation (Skr*eb and Cmek, 1980). Experiments 
suggesting that microinjection of DNA into a one-cell embryo might allow the introduction 
of cloned genes into developing embryos were first conducted in 1980. A cloned HSV-tk 
gene injected into cultured fibroblasts led to stable integr*ation and expression of the cloned 
gene in 5-20% of recipient cells (Capecchi, 1980).
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The possibilities enabling gene manipulation were revolutionized when blastocyst- 
derived embryonic stem cell lines (ES cells) were described independently by Gail Martin 
in San Francisco (Martin, 1981) and Martin Evans and Matt Kaufman in Cambridge (UK) 
(Evans and Kaufinan, 1981). ES cells were demonstrated to be capable of contributing to 
many tissue types of the adult mouse including the germ line when injected into the 
blastocyst (Bradley, et al. 1984). The first manipulation of a gene and subsequent germ 
line transmission was demonstrated for the X-chromosome-linked gene encoding 
hypoxanthine phosphoribosyl transferase (Hprt) (Kuehn, et a l 1987). Mutant ES cells 
made JTprt-deficient by retroviral infection were selected and used to generated Hprt- 
deficient male mice. Because of differences in purine metabolism, these mice did not show 
the expected phenotype resembling the Lesch-Nyhan disease caused by TZprt-deficiency in 
humans. However, these experiments showed for the first time that active mutation of a 
gene and introduction into the mouse embryo could directly result in mice carrying the 
desired mutation. Gene targeting using homologous recombination was first achieved for 
Hprt (Thomas and Capecchi, 1987) and c-abl (Schwartzberg, et al, 1989). Since then, 
many mouse models have heen generated using gene targeting through homologous 
recombination both to elucidate the function of newly described genes as well as to 
establish models for human diseases associated with the specific lack of gene function.
1.4.2. Gene targeting through Homologous Recombination
The introduction of a DNA fragment into a mammalian cell can result in the 
integration of the foreign DNA fragment into the mammalian genome. Instead of 
integrating randomly as described for the generation of transgenic animals, DNA 
fragments can recombine with endogenous homologous sequences contained within the 
genome. Remarkably, despite the extensive use of homologous recombination in gene
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targeting, the molecular mechanism underlying recombination events between foreign 
DNA fragments and endogenous sequences as well as cofactors mediating recombination 
events remain largely unknown. A positive correlation is known to exist between the 
frequency at which homologous recombination events occur and the length of homologous 
sequences contained within the foreign DNA fragment to be integrated into, the mammalian 
genome (Thomas and Capecchi, 1987). However, the amount of non-homologous DNA 
contained within a targeting construct was not shown to affect the frequency of tai-geting 
events (Mansour, et al. 1990), nor did the copy number of foreign DNA fragments 
introduced into the target cell (Thomas and Capecchi, 1986). Homologous recombination 
was shown to be more frequent in gene loci that are transcriptionally active during 
transfection time (Nickoloff, et al. 1990).
Since the first demonsti'ation of homologous recombination in a fibroblast cell line 
(Lin, et al., 1985), the technique based on this phenomenon has been used extensively for 
gene targeting and has provided major insights into the function of gene products in vivo in 
a variety of disciplines.
1.4.3 Construction of Targeting Vectors
The frequency of gene targeting through homologous recombination in mammalian 
cells is relatively low. In most cases transfected DNA integi'ates into a random 
chromosomal site. The design of the targeting vector is therefore crucial to optimize the 
chances of a successful gene targeting experiment. A targeting vector is designed to 
recombine with and mutate a specific chromosomal locus. All targeting vectors therefore 
consist of sequences homologous to the desired chi'omosomal integration site and a 
plasmid backbone as minimal components. The use of isogenic DNA (gDNA originating t
from the same mouse strain as the ES cells) to construct the targeting vector can result in
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20-fold increase of the targeting frequency (te Riele, et al., 1992). The length of the 
homologous sequences equally affects the efficiency of the targeting experiment. In 
general, the length of homology should be in the range of 5-8 kb. However gene targeting 
has successfully been achieved with targeting vectors containing a minimum homology of 
only Ikb (Hasty, e ta l, 199\).
To improve the efficiency of targeting experiments, positive and negative selection 
markers are included in targeting constructs. Positive selection markers primarily serve the 
purpose of selecting for cells that have integrated the targeting vector after transfection. 
Cloned into a coding exon of the gene to be targeted, a positive selection marker may also 
serve as a mutagen. In general, targeting vectors can be classified as either replacement or 
insertion vectors. Most gene targeting experiments have been conducted using the 
replacement type vector in which the homologous targeting constmct replaces the 
clrromosomal sequence through a double crossover event. A selectable marker, usually 
neomycin resistance and occasionally hygromycin resistance is placed between two 
homologous regions replacing crucial coding exon sequence of the targeted gene. Insertion 
vectors in contrast, integrate via a single crossover event generating a duplication of the 
target homology separated by the vector backbone (see Figure below). After a successful 
recombination of the insertion vector with the homologous target sequence, spontaneous 
intrachi'omosomal recombination events may occur between the duplicate homologous 
sequences. This may result in the removal of the plasmid backbone and one complement of 
the duplication from the target locus. Insertion vectors also have the advantage of elevating 
the gene targeting frequency by up to 20 fold (Hasty, etal., 1991).
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Exon coding sequence 
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Recombination event
Figure 1.3 Gene targeting vectors can generally be classified as either replacement (A) 
or insertion (B) vectors. Replacement vectors integrate into the genome via two crossover 
events and usually contain a positive selectable marker inteiTupting the target homology 
and replacing coding sequences of the target allele. Insertion vectors integrate via a single 
crossover event and result in the duplication of the target homology separated by the vector 
backbone. Whereas replacement vectors are generally linearized outside the target 
homology prior to transfection, insertion vectors are lineralized inside the target homology.
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Disruption of the coding sequence through replacement with the positive selection 
marker will in most cases ablate a gene’s function. In some cases however, truncated 
proteins may still be generated from the recombinant allele leading to some biological 
activity. Null mutations are therefore more likely to occur by recombining the positive 
selection marker into an upstream coding exon rather than a downstream exon so as to 
minimize the chances of a functional truncated gene product.
1.4.4 Screening for Targeting Events
A targeting construct can be introduced into the cell by either electroporation or 
microinjection, electroporation being the simpler method and more widely used. Following 
transfection of ÈS cells with the line.arized targeting construct, the addition of the 
respective antibiotic to the culture medium selects for ES cells that have integrated the 
targeting construct into their genome. Positive selection markers generally confer 
resistance to an antibiotic, typically neomycin (or G418 as a derivative, respectively). 
However, positive selection markers do not discriminate between homologous 
recombination and random integration events of the targeting construct into the genome. In 
standard targeting experiments with replacement vectors, the vector may also contain a 
negatively selectable gene at one or both ends of the homologous sequences. In cases 
where the targeting construct is integrated into the genome by homologous recombination, 
the negatively selectable marker will typically be lost, whereas random integration will 
incoiporate the negative selection marker. Accordingly, selection against this marker will 
kill most cells, which have integrated the tai'geting vector at a random location while 
correctly targeted cells will survive. A selection marker typically used for negative 
selection includes the gene encoding herpes simplex thymidine kinase (HSV-tk). The 
nucleoside analog gancylovir (I-[2’-deoxy-2’-fluoro-b-D-arabinofuranosyl]-5-iodouracil)
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is converted by the HSV-tk gene into a cytotoxic derivative (Mansour, et al,, 1988). The 
enrichment of targeting events achieved by negative selection may reach up to 20 fold.
Following positive and negative selection of transfected ES cells and their culture 
to obtain ES cell colonies, surviving colonies are clonally isolated and expanded for further 
analysis of gDNA derived from each ES cell colony obtained. For the verification of 
targeting events by homologous recombination either screening by Southern blot analysis 
or PCR can be employed. PCR is a sensitive and fast screening method, which can be used 
for a large number of clones. However homologous recombination events are normally 
confirmed by Southern blot. An external probe is used in Southern blot screenings, which 
is generated from flanking sequences of the homologous region. This external probe 
therefore does not hybridize with the targeting constract, so that random integration is not 
detected. Both external probes from 5' and 3' ends are nonnally used to confirm the gene 
replacement event.
1.4.5 Embryonic Stem (ES) cells
Together with the discovery that homologous DNA fragments can be inserted into 
the genome by homologous recombination, the isolation and culture of murine embryonic 
stem cells has been the major contribution enabling gene-targeting experiments. 
Homologous recombination allows the generation of any desired mutation within a cloned 
genomic sequence and in any cell line growing in culture. Prior to the availability of ES 
cells, gene-tai’geting approaches were limited by the lack of a suitable in vitro system to 
transfer artificial mutations into the germ line. The isolation and culture conditions to 
maintain ES cells were first described by Evans and Kaufman (1981) and Martin (1981). 
ES cells are derived from the inner cell mass of mouse blastocysts. Under stringent culture 
conditions, these cells can maintain their embiyonic developmental potential even after
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many passages and after the introduction of a genetic alteration. This way, mutations 
introduced into ES cells by homologous recombination can be transmitted into the germ 
line to study the effect of targeted gene products in vivo. ES cells can be maintained in 
vitro by culturing in medium supplemented with a soluble factor called leukemia inhibitoiy 
factor (LIE) or differentiation inhibiting activity (DIA) (Smith, et ai, 1988), or by co- 
culturing with mitotically inactivated feeder cells, such as embiyonic fibroblasts or the 
fibroblastic cell line STO. Since the first isolation of ES cells, several different permanent 
ES cell lines have been established and selected for by their ability to transmit genetic 
alterations into the germ line. Since the isolation of ES cells was a direct extension of 
previous work on stem cell teratocaicinomas, a genn cell tumor most prevalent in 129/Sc 
mice, some of the first ES cell lines were isolated from 129/Sv. Since the XY karyotype of 
ES cells appears to be more stable in culture than the XX karyotype, ES cell line are 
derived from male mice resulting in a mostly male chimeric offspring after geim line 
transmission.
1.4.6 The production of chimeric mice
In most cases, only one allele of a gene is targeted by homologous recombination in 
ES cells. Targeted ES cells are returned to the embryonic environment by injection into a 
host blastocyst. ES cells can contribute to many kinds of tissues in the resulting chimeras 
including sperm in the mature animal. This process is called germ-line transmission and 
can be easily detected in the offspring’s coat color. The ES cells are derived from a mouse 
homozygous for the agouti coat color (129/Sv) allele whereas the recipient blastocyst 
originates fi'om a black coat color mouse (C57 B16). The fur of the resulting chimeras has 
patches of both colors because the mouse contains cells derived from both genotypes. 
Breeding of the chimeras to an MFl albino mouse results in some chinchilla coat color 
mice among the litter, indicating that the ES cells contributed to the formation of the germ
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line. By mating germ-line transmission chimeras with wild type mice, heterozygous 
offspring can be generated that carry the mutation in one of the two copies of the gene in 
every cell. These mice are in most instances unaffected by the mutation, because their 
second, undamaged copy of the gene will still be functional. To identify heterozygous and 
wild type mice in this stage, DNA from tail tipping is examined by Southern blot or PCR. 
Mating heterozygous siblings results in offspring having two defective alleles. This process 
follows Mendelian mles of inheritance. Northern blot, RT-PCR and Western blot can be 
employed to examine if the targeted gene and the protein it encodes are completely 
deficient in mice homozygous for the mutation introduced.
1.4.7 Conditional gene targeting using the Cre/lox system
New strategies have been employed recently that allow the in vivo manipulation of 
DNA in ES cells or living animals. These techniques are based on the use of site-specific 
recombinases interacting with specific sequences ranging from 25 to 150bp in length. The 
Cre/lox system consists of two components. Cre {cyclization recombination) is a 38kD 
product of bacteriophage PI that interacts with a 34bp sequence called loxP {locus o f X- 
over PI). The loxP site consists of two 13bp inverted repeats flanking an 8bp core 
sequence. This core sequence is non-palindromic and gives loxP sites directionality. Cre 
mediated recombination requires four Cre-monomers each of them binding to one of the 
13bp inverted repeat regions of the loxP sites. The resulting recombination event between 
two loxP sites results in the excision of the DNA between them as a covalently closed 
circle leaving a single loxP site behind. No additional co-factors or topological 
requirements of the target DNA are needed, which makes the Cre/lox system particularly 
suitable for targeting experiments in mammalian cells (reviewed by Sauer, 1998).
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Figure 1.4 Schematic representation of a loxP site consisting of two 13bp inverted 
repeats flanking a non-palindromic core sequence (A). Cre-mediated recombination 
between two equally directed loxP sites results in the excision of the DNA between them 
as a covalently closed circle (B).
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a. Tissue specific mutagenesis
The basic strategy used to create tissue specific knockout mice uses conventional 
gene targeting techniques and homologous recombination to flank crucial parts of one 
allele of the target gene with loxP sites (Orban, et aL, 1992). Modified ES cells are used to 
generate mice that carry the desired mutation after germ line transmission and homozygous 
animals are obtained through breeding. Homozygous mice carrying loxP flanked 
sequences on both alleles of the target gene usually produce normal levels of functional 
protein as loxP sites can be positioned within intron sequences. Deletion of the gene occurs 
when mice containing the modified gene are crossed with mice expressing Cre in the 
desired target tissue under a tissue specific promoter. Cre mediated excision in double 
transgenic animals then results in tissue specific gene ablation. This approach was first 
used successfully to generate a T cell specific deficiency for the gene encoding DNA 
polymerase p (Gu, et al., 1994). To generate T cell specific deletions, Cre recombinase 
was expressed under the p56^ ^^  promoter. No apparent deletion of loxP site flanked 
sequences was observed in kidney, liver or B lymphocytes. Mating of Cre-transgenic mice 
with homozygous animals containing the mutated DNA polymerase p gene resulted in the 
inactivation of the tai*get gene within the T cell population only.
As an alternative to tissue specific expression of Cre recombinase, Cre-transgenic 
mice have been generated that express Cre in all tissues beginning from the earliest 
developmental stages. These ‘deleter’ strains express Cre under constitutive promoters 
such as the hCMV- (Schwenk, et aL, 1995) or adenoviral Ella  promoter (Lakso, et al., 
1996). These mouse strains are useful tools to derive deletion mutants fi'om chimeric mice 
carrying a loxP flanked target in their genome and result in offspring with a null allele with 
a similar genotype as conventionally made knockout mice.
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Figure 1.5 Generation of tissue specific knockout mice using the Cre/lox system. 
Targeting of a gene in ES cells is used to generate mice with loxP sites flanking crucial 
exons of the target gene (A). A second mouse is mated to these modified animals that is 
transgenic for Cre recombinase and expresses Cre under a suitable promoter (B). The 
double transgenic offspring lacks loxP site flanked sequences due to Cre mediated 
recombination (C).
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In bacteriophage PI, Cre recombinase provides a backup mechanism for the 
cyclization of PI DNA after infection (Segev and Cohen, 1981). Cre also enhances PI 
plasmid stability in bacterial lysogens (Austin, et a l, 1981). Although Cre-mediated 
recombination is very effective, tissue specific mutagenesis of the DNA-polymerase p 
gene as performed by Gu, et al. (1994) resulted in the deletion of the target gene in only 
40% of the T cell population when homozygous mice were crossed with transgenic mice 
expressing Cre under the p56'^^ promoter. However, in these experiments, wild type Cre 
recombinase from bacteriophage PI had been used that is only partially functional in 
eukaryotic cells. The performance of Cre in eukaryotic cells can be improved by 
introducing the so-called ‘Kozak’-alteration (Gu, et al., 1993) that allows efficient 
translation in mammalian cells. Thus improved expression of Cre in mammalian cells has 
been used to generate GalNAc-T- {UDP-N-acetylgalactosamine-polypeptide-N- 
acetylgalactosaminyltransferase) deficient mice lacking GalNAc-T in 100% of the 
thymocyte population. GalNAc-T catalyzes the transfer of the monosaccharide 
acetylglucosamine to serine and threonine residues, thereby initiating O-linked 
oligosaccharide biosynthesis (Heimet, et al., 1995).
b. Marker eviction
As in conventional gene targeting teclinology, the generation of the desired 
mutation in ES cells also results in the integration of the positive selection marker gene 
into the targeted locus. However, the Neo gene itself can adversely affect gene expression 
of neighboring genes (Artelt, et a l, 1991) particularly, if the targeted locus is located 
within a gene cluster. The Cre/lox system offers the possibility of avoiding this potential 
problem by enabling the removal of the selection marker gene from the targeted locus in 
vitro. Marker eviction can be achieved by including a third directly repeated loxP site in
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the original targeting construct. Thus, one loxP-flanked interval is designed for conditional 
mutagenesis and the other flanked interval is the selectable marker gene itself. Transient 
expression of Cre in targeted ES cells can lead to partial excision of loxP flanked 
sequences resulting in the removal of the selectable marker gene only. Complete Cre- 
mediated recombination would remove both the selectable marker gene and the targeted 
loxP flanked genomic DNA segment. Cre mediated recombination of a targeted locus 
containing three loxP sites potentially results in three different mutations. Apart from the 
excision of either the selectable marker gene alone or both loxP-flanked segments, a third 
possible recombination event would result in the removal of the target genomic DNA 
segment leaving the selectable marker gene. For the generation of conditional knockout 
mice, the removal of the selectable marker gene would be ideal, since Cre-mediated 
recombination would automatically result in the deletion of the target gene. ES cell clones 
generated by allowing a complete deletion of loxP-flanked sequences in vitro can be used 
to generate animals carrying a null allele of the target gene.
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Figure 1.6 Schematic representation of a targeting vector strategy using the Cre/lox 
system. Homologous recombination of the lineralized vector with the target sequence (A) 
results in the replacement of the naïve sequence by the targeting constmct (B). The 
construct contains a positive selection marker gene {Ned), which itself is flanked by loxP 
sites. Cre mediated recombination events may result in 3 different genotypes depending on 
the loxP sites used in the recombination event. (C) Deletion of the selectable marker gene 
only, (D) deletion of the target sequence not affecting the selectable marker gene or (E) 
total excision of all loxP flanked sequences.
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The efficiency of DNA transfection in vitro, which may be below 5% of 
electroporated ES cells may present a major problem in generating Cre-mediated mutations 
in targeted ES clones, Since the desired mutation results in the deletion of the selectable 
marker gene other means of selecting for transfected cells have to be .employed. The 
antibiotic puromycin is capable of killing non-resistant ES cells within 48 hours and can 
therefore be employed to select for transient transfection events (Taniguchi, et aL, 1998). 
Gu, et al (1994) have demonstrated that resistance of transfected cells to gancyclovir can 
be used to select for Cre-mediated recombination events if the HSV-tk gene is placed 
within the same gene segment as the positive selection marker cassette. Cre catalyzes 
recombination at chromosomal loxP sites in 80-100% of cells transiently transfected with 
the Cre-expression plasmid (Gagneten, et aL, 1997). Depending on the promoter used to 
control Cre expression the generation of partially deleted loxP flanked gene segments may 
therefore impose difficulties.
c. Inducible mutagenesis
The extent, tissue specificity and time of Cre-mediated recombination in mice that 
are both Cre-transgenic and contain loxP site flanked target sequences depend on Cre 
expression. Apart from the possibility of expressing Cre under a tissue specific promoter 
(e.g. p56’^  ^ for T cell-, CD19 for B cell expression), several other designs allow the 
inducible deletion of target sequences in the adult, double transgenic animal. The temporal 
activity of Cre can be regulated both at the transcriptional and post-translational level. Cre j
transcription can be induced by the injection of IFNa/p into mice that express Cre under j
the control of the Mx promoter. The Mx-gene product is part of the anti-viral defense 
mechanisms and can be induced by interferon. Administration of IFNa/p or double
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stranded RNA (which induces IFNa/p) to double transgenic mice also carrying the 
previously described loxP-flanked DNA-polymerase p gene (Gu, et aL, 1994) resulted in 
near total deletion of target sequences of liver and spleen lymphocytes (Kuhn, et aL, 1995).
Transcriptional control of Cre-recombinase expression can also be achieved by 
regulating Cre expression via a minimal promoter, which in turn is regulated by 
transactivating elements. The DNA binding activity of transactivating elements is 
regulated by the presence or absence of a specific drug, e.g. tetracycline (Gossen, et aL, 
1995; St-Onge, et aL, 1996; Utomo et aL, 1999) or ecdysone (No, et aL, 1996). Tissue 
specific expression of transactivating elements under suitable promoters allows the 
expression of Cre recombinase to be both inducible and tissue specific.
Cre expression can be controlled post-transcriptionally by engineering a fusion 
protein of the recombinase and the ligand-binding domain of a steroid receptor. In the 
absence of hormone, Cre recombinase is kept inactive by the binding of heat shock 
proteins. The addition of hormone results in a sterical change within the ligand-binding 
domain leading to the release of the heat shock proteins and Cre-activation. To avoid the 
responsiveness of the system to natural steroids in mice, mutant ligand-binding domains of 
the estrogen (Zhang, et aL, 1996) and progesterone (Kellendonk, et aL, 1996) were used. 
These mutants are umesponsive to their natural ligands but can be activated by synthetic 
hormone antagonists, e.g. 4-hydroxy-tamoxifen for the mutant estrogen receptor (Feil, et 
aL, 1996).
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d. Detection of Cre expression
The success of Cre-mediated recombination events is crucially dependent on the 
pattern of Cre expression in the transgenic animal. Mosaic expression of Cre in the desired 
target tissue would result in incomplete gene ablation, whereas unexpected expression of 
Cre in extraneous tissues would lead to deletion of loxP-flanked sequences in tissues other 
than the desired cell type. However, mosaic expression is not an uncommon feature in 
transgenic animals that have been generated by random integration. Several methods have 
been described that allow the detection of Cre-expression. The existence of both polyclonal 
and monoclonal antibodies to Cre enables Western blot and immunohistochemical analysis 
of Cre-expression (Sauer, 1987; Schwenk, et a l, 1997). Alternatively, Cre expression can 
be identified by the expression of a reporter gene. A synthetic STOP sequence flanked by 
loxP sites was placed in front of the lacZ gene to generate reporter mice. Cre mediated 
recombination results in the excision of the STOP sequence and subsequent expression of 
the reporter gene. These mice were then used to identify Cre-transgenic mice with desired 
expression of Cre in a defined region of the hippocampus (Tsien, et a l, 1996).
More recently the generation of a double-reporter mouse has been described that 
provides a means of monitoring Cre-function both prior to and after its induction. Before 
Cre-mediated recombination, all cells of the transgenic animal express the lacZ gene. Cre 
expression leads to the excision of the lacZ gene and activates the transcription of the gene 
encoding human alkaline-phosphatase, which serves as a second reporter gene (Lobe, et 
al., 1999). In view of the growing list of Cre-transgenic animals designed to carry out 
specific genomic alterations these methods greatly contribute to the ongoing research to 
further develop the Cre/lox system.
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e. Further applications of the Cre/lox system
The Cre/lox system has been used for applications other than the generation of 
tissue specific and inducible knockout mice. The generation of transgenic mice that 
express a potentially toxic gene product has been facilitated by the generation of dormant 
transgenes that can be activated after the establishment of the transgenic animal. To inhibit 
the expression of a potentially toxic gene product, a synthetic STOP sequence derived from 
SV40 is placed between the transgene and its promoter. The STOP sequence is itself 
flanked by loxP sites. Cre mediated recombination results in the excision of the STOP 
sequence and expression of the transgene (Lakso, et al., 1992).
A further application of the Cre/lox system has been demonstrated for the 
generation of knock-in vectors. The strategy is- generally applicable to generate knock-ins 
at any locus in ES cells providing a useful tool for precise molecular engineering of the 
mouse genome. Homologous recombination is used to place a loxP site flanked selection 
marker cassette immediately 5’ to the position of the natural AT G start codon for the 
coding region of the target locus. The flanking loxP sites have been altered in their central 
spacer region and cannot recombine with each other. However, each of the mutated loxP 
sites can efficiently recombine with other loxP sites, that have been altered in an identical 
manner (Hoess, et al., 1986). A circular ‘knock-in’ vector is then targeted to the modified 
locus of ES cells by introduction of a gene of interest flanked by mutated loxP sites along 
with a Cre transient expression vector. Double crossover recombination mediated by Cre 
replaces the selectable marker gene with the knock-in gene under the control of the 
promoter at the target locus (Soukharev, et al., 1999).
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Figure 1.7 The Cre/lox system has been successfully used to generate gene switches 
(A) and knock-in vectors (B).
(A) To switch on gene expression, the synthetic, SV40 derived STOP sequence is 
excised fi'om the expression locus using Cre mediated recombination between two loxP 
sites. These loxP sites are flanking the STOP sequence thus allowing gene expression.
(B) In a first step, a vector containing a selectable marker gene flanlced by loxP 
sites is integrated into the genome by homologous recombination. These two loxP sites 
flanking the selection marker cassette have been mutated to avoid Cre-mediated 
recombination events to occur between them. Subsequent transfection of targeted cells 
with a circular plasmid containing the gene of interest flanked by two equally mutated loxP 
sites and the addition of Cre results in the Cre-mediated replacement of the selectable 
marker gene by the gene of interest.
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In addition to deletions of DNA segments flanked by equally orientated loxP sites, 
Cre mediated recombination can be used to generate gene inversions if the two flanking 
loxP sites are placed in opposite orientation to each other (Abremski, et al., 1986).
Cre is not only capable of mediating intramolecular DNA recombination (excision 
and inversion) but also catalyses intermolecular recombination events. Cre has therefore 
been used to generate precise chromosomal translocations in mammalian cells (Smith, et 
al\ and van Deursen, et al., 1995). The technique requires the placement of loxP sites at the 
desired rearrangement endpoints by homologous recombination. As these placements 
cannot be achieved by a single targeting construct, each mutation requires a different 
selectable marker gene. The subsequent selection of Cre-mediated recombination is 
facilitated by using H prf ES cells for the two rounds of homologous recombination. 
Complementary halves of loxP-7/prr-fusion gene ai*e placed at each rearrangement 
endpoint to permit Hprt'^ selection after a successful rearrangement event.
1.4.8 Application of conditional mutagenesis in Immunology
Recently, the Cre/lox system has been widely used to generate a number of animal 
models with specific genomic alterations in a vaiiety of research contexts. However, some 
of the models established can also be placed into an immunological background and have 
contributed to the current understanding of lymphoid development, tolerance to self 
antigens, and signaling tlrrough cytokine receptors. Some of the major advances using the 
Cre/lox system in the field of Immunology are highlighted below.
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a. Lymphoid development
Lymphotoxin (LT) a , p and TNFa are structurally homologous cytokines. Their 
genes are closely clustered with the MHC region. LTa and LTp are produced by activated 
lymphocytes and NK cells and can either be expressed as a soluble LT(%3-homotrimer or as 
a membrane bound LTai pz-heterotrimer. Recent reports using gene-targeting tecliniques 
suggest an essential role for TNP, LTa and LTp in secondary lymphoid organ structure 
and function. Whereas TNP appears to be important for the formation of geiminal centers 
in secondary lymphoid organs, mice lacking LTa exhibit a lack of lymph nodes and 
splenic disorganization of B and T cell areas. However, it has also been reported that 
conventional LTa knockout mice show a defect in TNF production. This phenomenon has 
been attributed to transcriptional interference caused by the retention of the Neo selection 
marker cassette in the targeted LTa locus, which lies in close proximity to the gene 
encoding TNF, The Cre/lox system has therefore been used to generate a murine model 
deficient for the LTp gene. Cre-mediated marker eviction also resulted in deletion of the 
LTp gene leaving only a single loxP site behind. These mice show normal levels of LTa 
and TNF niRNA demonstrating that the Cre/lox system can be used to dissect the functions 
of genes located in gene clusters. Results obtained indicate a differential role for LTa 
independently of LTp in the formation of mesenteric and ceiwical lymph nodes 
(Alimzhanov, et al., 1997; Alexopoulou, et ah, 1998).
Absence of IL-2Ry is known to I'esult in abnormal lymphopoiesis and 
immunodeficiency, as evidenced by X-linked severe combined immunodeficiency 
(SCÏDX1) in man, and in the corresponding canine and murine models of SCIDXl 
(Noguchi, et a l, 1993). The Cre/lox system has been used to generate ES cell clones in 
vitro that either lack crucial parts of the gene encoding IL-2Ry or only contain loxP sites in
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intron segments. Mice derived from ES cells with mutant IL~2Ry loci were analyzed for 
their lymphoid development and compared to mice with only loxP sites located in their IL- 
2Ry locus. Lymphoid cells derived from IL-2Ry ''' ES cells were not detected in peripheral 
blood of chimeric animals, although control ES cells resulted in normal T-, B-, and NK- 
cell populations. Mice with germline-defrciency of IL-2Ry developed some mature splenic 
B and T cells but the absolute number of lymphocytes was strongly reduced accompanied 
by a complete depletion of NK cells. Development of gut-associated intraepithélial 
lymphocytes was also reduced, and Peyer's patches were undetectable. T and B 
lymphocytes showed reduced responsiveness to mitogen or IL-4, respectively. Using 
conditional gene targeting, it was concluded that IL-2Ry plays an important role in B- and 
T cell generation and that its function is essential for NK-cell development (DiSanto, et al., 
1995).
b. Peripheral tolerance
The Cre/lox system has been successfully used to study the fate of auto-reactive 
IgM^IgD"  ^mature B cells that recognize a self-antigen after their selection into the long- 
lived peripheral B cell pool. To generate mice whose mature B cells become auto-reactive 
after their release to the periphery, conditional mutagenesis was applied that takes 
advantage of the activity of Cre to mediate gene inversions of DNA segments that are 
flanked by loxP sites with opposing orientations. Prior to Cre mediated recombination 
these mice express a BCR with non-autoreactive specificity and mature B cells of this 
specificity were readily detected in peripheral organs. Cre recombinase expressed under 
the Mx-promoter mediates the inversion of the loxP site flanked DNA segment leading to 
the expression of a BCR that recognizes MHC class I molecules in mice of a certain MHC 
haplotype. The results obtained using this method firmly establish, that mature autoreactive
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B cells that recognize a membrane antigen with high affinity are rapidly eliminated by 
clonal deletion (Lam and Rajewsky, 1998).
c. Signaling molecules
A variety of cytokines including IL-15 require the activation of STATS for signal 
transduction following receptor engagement. However targeted mutation of STAT3 by 
conventional techniques results in early embryonic lethality (Takeda, et a l, 1997). The 
Cre/lox system has been employed to generate mice, in which STAT3 is deficient in a T 
cell specific manner by crossing mice with a targeted insertion of loxP sites into the gene 
encoding STAT3 to transgenic mice expressing Cre under the p56*‘^ '^-promoter. In STAT3 
deficient T cells, IL-6 induced proliferation was severely impaired leading to increased 
apoptosis of STAT3 deficient T cells (Takeda, et a l, 1998).
Notch proteins are large, conseiwed cell surface receptors that regulate cell fate 
specifications and homeostasis of self-renewing tissues (Artavanis-Tsakonas, et al., 1995). 
The function of NotchI was investigated by generating a conditional mutant where an 
essential portion of the gene was flanked by loxP sites. NotchI had been previously shown 
to play an important part in CDA versus CD8'^  T cell lineage decision as well as in TCR 
expression (Robey, et a l, 1996; Washburn, et al., 1997). Deletion of NotchI by 
conventional gene targeting resulted in embryonic lethality at approximately day 10 of 
gestation (Swiatek, et al., 1994). The IFNa/p-inducible Mx-Cre transgenic model was 
therefore used to study the effect of NotchI deletion in the adult mouse. Post-natal deletion 
of NotchI resulted in reduced thymus development and growth retardation. NotchI was 
shown to be important in the development of T cells fi'om the most immature thymocyte 
CD44'^CD25' precursor stage (Radtke, et al., 1999).
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d. Antigen presentation
MHC class II molecules play a crucial role in the development and function of the 
immune system by presenting peptides processed from extracellular proteins to CDA 
helper T cells. MHC molecules also direct the process of positive and negative selection 
during the formation of the T cell repertoire in the thymus. Recently, a murine model has 
been developed that lacks all classical MHC-II genes by generating a large, 80kb deletion 
using the Cre/lox system. This murine model may be useful in providing a genetic 
background to express human HLA genes to investigate the potential role of certain HLA- 
alleles in autoimmunity by avoiding the possibility of unwanted pairing between human 
and murine MHC genes in HLA-transgenic mice (Madsen, et al., 1999).
1.4.9 Comparison of conventional and conditional gene targeting
Conventional gene targeting has been widely used and has had an enormous 
scientific impact on the current knowledge of the function of specific genes and the 
proteins they are encoding. This is not only the case for advances made in the field of 
Immunology but can also be extended towards Physiology, Developmental and Behavioral 
Biology. With many of the techniques involved in the generation of conventional knockout 
mice being now standardized and commercially available, gene targeting has become a 
common approach to study the function of newly chaiacterized genes. Conditional 
mutagenesis using the Cre/lox system requires all the techniques necessary to generate 
conventional knockout mice. Using the Cre/lox system mice carrying a null mutation can 
be produced by either in vitro transfection of targeted ES cell clones with an expression 
plasmid delivering Cre-recombinase or by mating of targeted mice with a Cre-transgenic 
mouse expressing Cre in eaiiy development. Both methods have been used successfully to 
generate null mutations after Cre/lox targeting. Furthermore, the deletion of the Neo
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selection marker cassette after gene targeting in ES cells minimizes the chances for altered 
expression of neighboring genes if the targeted locus is located within a gene cluster. The 
‘recycling’ of selectable marker genes by transient expression of Cre in targeted ES cells 
also provides a useful tool to generate double knockouts in a second targeting round using 
the same selection marker (Abuin and Bradley, 1996).
The Cre/lox system also offers an approach to bypass the effects of mutations that 
would otherwise be lethal to the developing homozygous embryo if the targeted gene is 
crucial for murine development and allows studying the effect of genetic deletion of such 
genes in the adult animal. Expression of Cre in transgenic animals where Cre is controlled 
by an inducible promoter (e.g. estrogen, Mxl) offers the opportunity to investigate the 
effect the lack of a specific gene product may have at defined time points, e.g. after 
stimulation with specific antigen. A further advantage of using the Cre/lox system is the 
chance of crossing targeted mice with transgenic animals that express Cre under
different promoters thus offering the possibility to create mice lacking the targeted gene 
function only in defined tissues and cell types. A growing list of Cre-transgenic animals 
expressing Cre under tissue specific promoters is available offering the chance to limit 
genetic alterations to defined cell types. Tissue specific gene targeting is a refined targeting |
technique that may be very beneficial in order to understand the functions of proteins such 
as cytokines, which often have pleiotropic effects and affect many cell types. One obvious I
problem with this approach is that regulatory sequences and chromatin structure can 
influence tissue specific promoters after random integi'ation of the Cre recombinase 
expression construct. Hence, specific expression of Cre recombinase only in the target cell 
may be paitially compromised. A modified approach to ensure appropriate cell-specific 
Cre expression is to target the tissue-specific promoter-Cre recombinase construct into the 
endogenous gene locus. This has been achieved for the CD19-Cre strain deleting loxP- 
flanked target genes in B cells specifically under the endogenous promoter (Rickert et al..
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1997). To monitor the expression of Cre in transgenic animals, several constructs co­
expressing reporter constructs as well as both polyclonal and monoclonal antibodies are 
available. However, tissue specificity depending on promoter specificity and efficiency of 
Cre-mediated recombination in the intact animal remain two major problems in the 
application of conditional mutagenesis.
The Cre/lox system has also been used to create chromosomal translocations and 
deletions that cannot be achieved by conventional gene targeting techniques. The 
possibility to study the effect of gene products in a tissue specific or inducible manner is 
widely applicable in Immunology. Redundancy and pleiotropic effects of protein mediators 
may create situations, in which conventional gene targeting techniques may not be 
sufficient to elucidate their biological functions in a tissue specific manner.
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1.5 Specific aims of this thesis
IL-15 has been characterized as an important activator of T cells and mediator of 
inflammation. IL-15 expression in the synovial membrane of RA patients accounts for the 
production of TNFa, a crucial mediator of inflammation in the rheumatoid joint. The fact 
that IL-15 may act upstream of TNFa, thereby orchestrating inflammatory processes in 
RA, makes it a potential tai'get for therapeutic approaches.
In lymphocytes, IL-15 acts through a specific receptor. This receptor is composed 
of the IL-2RP and y chain plus the high affinity IL-15Ra. Gene targeting through 
homologous recombination in embryonic stem cells is a sophisticated tool to elucidate the 
function of novel genes and their products. The recently developed technique of 
conditional mutagenesis using the Cre/lox system not only offers the possibility to generate 
conventional knockout mice but also the opportunity to study the effects generated by gene 
targeting in a tissue specific manner. This project was designed to elucidate the possibility 
of using a soluble form of IL-15Ra as a therapeutic agent in inflammatoiy diseases which 
are mediated by IL-15, taking CIA as a model for inflammatory responses closely 
resembling human RA. Secondly, this project aimed to establish a murine model lacking 
IL-15Ra in a tissue specific manner to study the effects of IL-15 in inflammatory 
responses. The objectives of this project where met by two specific aims:
A. To clone and express a soluble, recombinant IL-15Ra in order to antagonize IL-15 
in vivo.
B. To characterize the gene encoding IL-15Ra and to generate a murine model 
lacking IL-15Ra by conditional gene targeting in murine embryonic stem cells.
72
Chapter 2 Materials and Methods
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2.1 Molecular Cloning
2.1.1 Buffers and Solutions
Bacterial Lvsis buffer:
1%SDS / 200mM NaOH 
Denaturing Buffer:
0.5M NaOH / 1.5MNaCl 
DNA ligation buffer
50mM Tris HCl, pH 7.6 / lOmM UgCh / ImM ATP / ImM DTT / 5% w/v 
polyethylene glycol 8000 
DNA loading buffer:
0.25% bromophenol-blue/ 0.25% xylene-cyanole-FF / 150mM Tris.HCl, pH 8.0 / 
lOmM EDTA / 40% sucrose 
GTE buffer:
50mM glucose / 25mM Tris.HCl, pH 8.0 / ImM EDTA 
Hybridization Buffer ('Lambda DNAb
6xSSC / 20mM NaH2P04  / 0.1 % SDS and containing 100 pg/ml of freshly 
denatured salmon sperm DNA (Sigma)
Cburcb-Gilbert-Buffer
7 % SDS / 40mM NaHzP04  / ImM EDTA, pH 7.5, containing 100 pg/ml of 
freshly denatured salmon sperm DNA (Sigma)
Neutralizing Buffer:
0.5M Tris.HCl pH 7.4 / 1.5M NaCl
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PCR buffer TlOxl:
200mM Tris.HCl pH 8.4 / SOOroM KCl 
SM buffer:
lOOmM NaCl / lOmM MgS04 / 50mM Tris.HCl, pH 7.4 / 0.01% gelatin 
20 X SSC buffer:
3 M NaCl / 420 niM Sodium citrate, pH 7.2 
TAB buffer (Freeze and SqueezeV.
25mM Tris / 0.3M Sodium Acetate / ImM EDTA / pH 7.0 
TBE buffer fix):
200mM Tris.HCl, pH 8.0 / 900mM boric acid / 25mM EDTA 
TE buffer:
lOmM Tris.HCl, pH 7.4 / ImM EDTA
2.1.2 Total cellular RNA preparation
Total cellular RNA was extracted from J774 cells using the TRIzol Reagent 
(GibCO, BRL). J774 cells gi'own to confluence, transfen*ed into an Eppendorf tube were 
washed twice in PBS and Iml/lOcm^ of TRIzol was added. After 5 minutes at room 
temperatine, 200pl/ml of chloroform were added and the mixture was shaken by hand for 
15 seconds. After incubation at room temperature for 2-3 minutes, the samples were 
centrifuged in a table microfuge (Hettich, Germany) at 13,000x g for 15 minutes at 4°C 
and the aqueous phase was transfeiTed into a fresh tube. 500pl 2-propanol per milliliter 
TRIzol were added, the samples incubated for 10 minutes at room temperature and the 
RNA precipitated at 13,000x g, 4°C for 10 minutes. The pellet was washed with 75% 
ethanol, dried at room temperature for 5 minutes and dissolved in 40pl DEPC-treated 
water. Amount and quality of purified total RNA was determined by measuring the OD260 
and OD280 in a photospectrometer (Phaimacia, Uppsala, Sweden).
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2.1.3 Reverse Transcribed Polymerase Chain Reaction (RT-PCR)
Total RNA prepared as described above was subjected to reverse transcription. 5pg 
of total RNA was mixed with 80ng random hexamers (Roche Biochemicals) and the 
volume adjusted to 12pl by adding DEPC-treated water. The mixture was heated to 70°C 
for 10 minutes and put on ice for 1 minute. 2pl lOx PCR buffer, 25mM.MgCl, lOOmM 
DTT and Ipl lOmM dNTP were added and the mixture allowed to stand at 28°C for 5 
minutes before adding Ipl (200 u) of SuperScipt™ reverse transcriptase (Gibco, BRL). 
After incubation for 10 minutes at 28°C, the reaction was allowed to proceed at 42°C for 
50 minutes and terminated by incubating the samples at 70“C for 15 minutes before 
placing the samples on ice. 2pl of cDNA synthesized this way were used in subsequent 
PCR reactions.
2.1.4 Polymerase Chain Reaction (PCR)
For amplification of cDNA fragments or genomic DNA samples, 0.1-50ng of DNA 
were mixed with lOpl PCR buffer (lOx), 4-lOpl 50mM MgCL, 2pl lOmM dNTP and 
0.2pg specific 5’ and 3’ primer-oligonucleotide. 5-10 units of Taq-Polymerase (Gibco 
BRL) were added and the volume adjusted to lOOpl with dH2 0 . For genomic DNA 
amplification, diluted DNA samples were heated to 95”C for 10 minutes prior to adding the 
DNA to the PCR-reaction. Mixed samples were overlayed with 50pl of mineral oil 
(Sigma) and amplified in a thermo-cycler (Genius, Techne, Cambridge) under following 
conditions: denaturing at 95®C for 1 minute, annealing at 54-56“C for 2 minutes and 
sequence extension at 72^C for 3 minutes. PCR samples were amplified for 30-35 cycles 
depending on sensitivity of the reaction.
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For detection of Cre catalyzed recombination events of loxP site flanked sequences 
in targeted ES cell clones, 500ng of gDNA were denatured at 94‘’C for 2minutes. A total of 
O.OSpg primer (33-mer oligonucleotides), 1.75pl lOmM dNTP, 5pi PCR buffer containing 
2.5mM MgClz and 15 units of Taq-Polymerase (Roche Biochemicals) were added. 
Reactions were overlaid with one drop of mineral oil and subjected to the following 
program in a thermo-eye 1er (Genius Techne): denaturing at 94®C for 1 minute, annealing at 
66°C for 2 minutes and extension at 72°C for 3 minutes for 35 cycles. PCR products were 
then analyzed by agarose-gel electrophoresis.
DNA oligonucleotides, used for cloning of cDNA fragments by PCR are listed in 
Table 2.1 below.
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Table 2.1 List of PCR-oligonucleotides for cloning and screening
Oligonucleotide DNA Sequence (5’ -  3’) Location
KPN-1 CTCACAGCCAGGGTACC
CCTCCCCCTCTGCAA
Subclone 3.2, 3’ of Exon 3
KPN-IR TTGCAGAGGGGGAGGG
GTACCCTGGCTGTGAG
Reversed KPN-1
3’wt“l GTAAGCATTAGTTCTTC
ACGTTTTCCCAGGGTTC
Subclone 3.2, 3' of Exon 3
3.5-revR-33 GAAATAGCCAACATTTT
GGACCCCTCATCTATT
Subclone 3.5, downstream
IL-15R-anti GCACCAACCAAGAGGA
CCGATGTAGAGATGGC
Murine IL-ldRa-cDNA
IL-15R-sense TTGCTGCTGCTGCTGTTG
CTACTGTTGCTCCC
Murine IL-15Ra-cDNA
IL-15R-3’-6'fl/I GGTGGGATCCGGCACCA
CGTGTCCACCTCCCG
Murine IL-15Ra-cDNA
IL-15R-5’-5^zmHI AGATGTCGACTTTCGTC
ATTTTGGAACTGTGG
Murine IL-15Ra-cDNA
IL-15R-5’-AbaI CAGGGACCCCAGTCTAG
AGTCCCGTTGGGT
Murine IL-15Ra-cDNA
IL-15R-3’-A7zoI TTTCGTCATTTTGGAACT
CGAGGGAGAAATC
Murine IL-15Ra-cDNA
IgG-Fc-5'-A7zoI GCCCAAACTAACTCGAG
GGTGACCCTGGGA
Murine IgGi-Fc-cDNA
lgG-Fc-3-Ecom AAGGACACTGAATTCAT
TTACCAGGAGAGT
Murine ïgGi-Fc-cDNA
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2.1.5 Agarose Gel Electrophoresis
Nucleic acid fragments were analyzed by agarose gel electrophoresis. Gel 
concentration varied according to fragment size or DNA amount, ranging from 0.65 to 
2.0%. Plasmid DNA fragments were separated on 1-2 % agarose gels whereas for lambda 
and genomic DNA 0.6% agarose gels were used. Agarose (Gibco BRL) was dissolved in 
0.5 X TBE buffer by boiling and cooled to 50“C before adding ethidium bromide (Sigma) 
up to a final concentration of lOng/ml. Gels were allowed to set, cast in tanlcs and 
submerged in 0.5 x TBE. DNA samples, mixed 1:10 with DNA loading buffer, were 
loaded into prepared wells set into the agarose gels using a well-forming comb followed by 
electrophoresis at 1-5 V/cm and analysis under ultra-violet light.
2.1.6 Endonuclease restriction of DNA
A variety of restiiction endonucleases and their coiTesponding buffer systems were 
used (all from Roche Bio chemicals). Restriction enzyme buffers were used according to 
the recommendations of the manufactm'er in single enzyme digestions. In case of multiple 
enzyme digests, DNA was first cut with the enzyme requiring lower salt concentration for
1.5 hours at 37”C before adding the second enzyme and raising the salt concentration 
according to the conditions recommended. For plasmid DNA, 10-20 units of enzyme per 
pg of DNA were used in a volume of 20-100pl. For genomic DNA derived from ES cells, 
60 units of restriction enzyme were added to lOpg of DNA and the digest allowed to 
proceed for 4 hours before adding another 20 units and incubating the sample at 3TC  
overnight.
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2.1.7 DNA fragment purification
DNA fragments of interest were excised with a clean scalpel and placed into an 
Eppendorf tube. 1ml of TAB buffer was added and the gel fi*agment incubated in the dark 
for 15 minutes. The buffer was then removed and the gel fragment frozen .within the tube 
by placing it into liquid nitrogen for 5 minutes. The frozen gel fragment was then placed 
into a Spin X centrifuge filter tube (Costar) and centrifuged for 20 minutes at 15,000 x g. 
The resulting DNA solution was extracted with phenol/chloroform followed by 
precipitation with 100% ethanol.
2.1.8 Ligatiott of DNA fragments
To clone DNA fragments in plasmid vectors, vector DNA was cut by restriction 
endonucleases as described previously. To avoid self-ligation of the plasmid vector, 
digested vector DNA was subjected to dephosphorylation by adding 1 unit of calf intestine 
alkaline phosphatase (Roche Biochemicals) and incubating at 3TC  for 4 hours. Plasmid 
DNA vectors were then extracted by phenol:chloroform, precipitated with 100% ethanol, 
washed with 70% ethanol and resuspended in a suitable volume of dHzO. Small amounts 
of cut vector DNA were then analyzed on an agarose gel. DNA fragments with compatible 
restriction site ends were purified from agarose gels as described before. The amount of 
vector- and fragment DNA was analyzed by agarose gel electrophoresis prior to ligation. 
Equimolar amounts of both vector and insert DNA to be ligated, approximately 100-500ng 
DNA, were mixed and incubated in the presence of 1 unit of T4 ligase (Gibco BRL) in 
DNA ligation buffer. The volume was adjusted to lOpl with dHzO and the samples 
incubated at 15”C overnight.
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2.1.9 Cloning and transformation of competent bacteria
Commercially available competent bacteria were used for plasmid transformation. 
For bacterial expression of soluble IL-15Ra, competent E. coli bacteria of the Ml 5 strain 
(Gibco, BRL) were used. For subcloning of DNA fragments, the E. coli strain DH5a was 
used. For transformation, 100 pi of competent cell suspension were thawed on ice. 
Approximately 50ng of plasmid DNA was added and the mixture incubated on ice for 30 
minutes. The samples were then heat shocked at 42°C for 90 seconds and put on ice for 5 
minutes. 900pl pre-warmed LB medium was added and the samples were incubated with 
vigorous shaking at 37°C for 1 hour. The cells were centrifuged briefly, the total volume 
reduced to lOOpl and plated on LB-agar plates containing the appropriate antibiotic. The 
plates were incubated at 37°C overnight to obtain single colonies for further analysis.
2.1.10 Preparation of frozen bacterial stocks
Bacterial cultures grown in LB medium overnight shaking at 3TC  were briefly put 
on ice. One volume of fresh LB medium containing 50% glycerol was added and the 
culture frozen in 200pl aliquots at -80°C until use.
2.1.11 Preparation of plasmid DNA
Small-scale plasmid DNA from 2ml bacterial overnight cultures in LB medium was 
prepared using an alkaline lysis protocol. 2ml fresh overnight culture was spun at 3,000 x g 
in a microfuge (Hettich, Germany) for 5 minutes and the bacterial pellet resuspended in 
200pl ice cold GTE buffer followed by alkaline lysis in 400pl bacterial lysis buffer. After 
incubating 5 minutes at room temperature 300pl 3M potassium acetate, pH 4.8, were 
added and the lysate mixed gently by inverting the tube several times followed by
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incubation on ice for 10 minutes. The samples were then centrifuged at 15,000x g for 10 
minutes. The supernatant was recovered and 1 volume of ethanol was added followed by 
precipitation at 15,000-x g for 10 minutes. The pellet was washed once with 70 % ethanol, 
dried for 5 minutes at room temperature and resuspended in 50pl TE containing 10 u of 
RNase (DNase free) (Roche Biochemicals).
Large-scale purification of plasmid DNA for electroporation of cells was purified 
using a commercially available ‘Maxi-Prep’ kit (Qiagen) following the protocol provided 
by the manufacturer.
2.1,12 Double stranded DNA sequencing
Double stranded plasmid DNA fragments were sequenced using a method based on 
the di-deoxy chain termination method (Sanger, et al. 1977). Approximately lOpg of 
plasmid DNA derived from small-scale plasmid preparations were denatured for 15 
minutes at 3TQ  in 200mM NaOH and a total volume of 10|ll1. Ipl of specific 17-mer 
oligonucleotide (Genosys, UK) at 20pmol/pl was added and the DNA precipitated in 3 pi 
3M potassium acetate, pH4.8 and 75pl ethanol. The samples were centrifuged at 13,000x g 
for 15 minutes at 4"C and the pellet washed once in 75% ethanol The precipitated DNA 
pellet was dried at room temperature for 5 minutes and resuspended in 8pi dH2 0 . The 
sequencing reaction was performed using a commercially available DNA sequencing kit 
(United States Biochemicals) using the reagents provided within the kit following the 
protocol recommended by the manufacturer. Radiolabeled a[^^S]-dATP was obtained from 
Amersham UK. Electrophoresis of sequencing reactions was perfoimed on 6% 
polyacrylamide gels containing 8M urea derived from a prepared gel mix (Gibco BRL) in 
IxTBE buffer. The samples were run at 60W for 2-4 hours at room temperature until the
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bromphenol blue marker provided in the termination mix of the sequencing kit reached the 
lower end of the sequencing gel. Following electrophoresis, gels were fixed in 20% 
methanol, 10% glacial acetic acid for 30 minutes and transferred to Whatman 3MM filter 
paper. The gels were then dried under vacuum at 80°C for 2 hours and subjected to 
autoradiography (Kodak, BioMax) overnight at room temperature.
Table 2.2 List of PCR oligonucleotides used for DNA sequencing.
Oligonucleotide Nucleotide sequence (5’- 3’) Binding location
T 7 primer AATACGACTCACTATAG pBluescript, pcDNAS.l, 
pPNTLoxPNeo (p293)
Reverse primer AACAGCTATGACCATG pBluescript, pcDNA3.1 
pPNTLoxPNeo (p293)
IL-15R-A CAAATGTTGCCCACTGG IL-15Ra cDNAp.161-177
IL-15R-A-reverse CCAGTGGGCAACATTTG IL-15Ra cDNAp.161-177
IL-15R-B CACCATCCCAAACAACT IL-15Ra cDNAp. 371-387
IL-15R-C GGAGAGGTATGTCTGTA IL-15RacDNAp. 81-97
IL-15R-D CTCACAGCCAGAGAGCC IL-15RacDNAp. 261-277
IL-15R-E ATGACCTTGGAGCCTAC IL-15RacDNAp. 451-467
IL-15R-F CAGTCACAAGTCCTCCC IL-15Ra cDNA p. 411-427
3.5-T7-rev CCTTCAGACTCAGGGAT Subclone 3.5 near 5’ end 
facing subclone 3.3
3.5-reverse primer-rev TGGACCCCTCATCTATT Subclone 3.5 near 3’ end 
facing subclone 3.2
3.3-T7-rev TCGATTTGTGTAGCCTG 5’ end of subclone 3.3
3.3-reverse primer-rev CGATGGAGGACTCTCTT 3’ end of sub clone 3.3
3.2-1-rev TCTGGCTCCCACAGCTC Subclone 3.2, 41-57bp 3’ of 
exon 2
3.2-2-rev TGTTGCCTAGGTTTGCA Subclone 3.2, 90-106bp 3’ of 
exon 3
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2.1.13 Southern Blot analysis of lambda and genomic DNA
Lambda or genomic DNA was digested using restriction endonucleases. 
Approximately lOpg genomic DNA or Ipg lambda DNA were subjected to agarose-gel 
electrophoresis as described previously. The gel was then photographed under ultra-violet 
light with a fluorescent ruler set alongside the gel. After washing two times in dH^O the 
gel was incubated for 15 minutes in 10 volumes of denaturing buffer. The gel was then 
washed twice in dHzO and incubated for 45 minutes in 10 volumes of neutralizing buffer. 
One sheet of Whatman 3MM of similar width and longer shape was placed on a Perspex 
block within a bath filled with one liter of 20 x SSC buffer, so that the longer ends of the 
Whatman 3MM filter paper were in contact with the buffer. The neutralized gel was then 
washed twice in dH20 and placed upside down on top of the prepared Wliatman 3MM 
filter paper placed inside the transfer chamber. The Whatman 3MM filter paper not 
covered by the gel was covered by parafilm to allow capillary transfer through the gel only. 
One sheet of positively charged nylon membrane (Roche Biochemicals) of the same size as 
the gel and marked for orientation was briefly soaked in 2 x SSC before placing it on top of 
the gel. Two additional sheets of filter paper fitting the size of the gel were briefly soaked 
in 2 X SSC and placed on top of the nylon membrane. Air bubbles between the layers of 
filter paper were removed and two additional layers of filter paper placed on top. Finally, 
several layers of paper towel and a 500g weight were positioned on top of the blot 
assembly. Capillaiy transfer was allowed to proceed overnight at room temperature. The 
nylon membrane was then removed, briefly rinsed in 2 x SSC, dried between two layers of 
Wliatman 3MM filter paper and heated at 120”C for 20 minutes.
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2.1.14 Radioactive labeling of nucleic acid probes
Nucleic acid probes were purified as described previously. 20-50ng of probe DNA 
in 25 pi (IH2O were denatured at 100“C for 10 minutes and chilled on ice. 4 pi of 10 x 
concentrated random hexamer mix (Roche Biochemicals) and 6 pi 0.5mM nucleotide mix 
(dCTP, dGTP, dTTP) and 4pl a[^^P]-dATP (Amersham) were added to the mixture. The 
reaction was started by adding 20 u of Klenow enzyme (Roche Biochemicals) and allowed 
to proceed at 3TC  for Ih. To stop the reaction, 60pl TE buffer were added. Radiolabeled 
DNA probes were purified using Nick columns (Pharmacia) equilibrated with 2ml TE. 
lOOpl reaction mix was applied to the column and the solution allowed to enter the resin 
following the addition of 400 pi of TE. Radiolabeled probe DNA was eluted by adding an 
additional 500pl of TE. The purified probe was then denatured for 10 minutes at 100®C 
prior to usage.
2.1.15 Hybridization of nucleic acids
After transfer of nucleic acids to nitrocellulose filters or charged nylon membrane 
(both firom Roche Biochemicals) as described for Southern blot analysis, pre-hybridization 
was performed in hybridization buffer for 2-3 hours at 65°C before adding a purified 
radiolabeled DNA probe. Hybridization was carried out overnight in a hybridization oven 
(Scotlab) at 65“C. The membrane was then washed twice for 30 minutes in 2xSSC, 0.1% 
SDS and twice for 30 minutes in 0.2xSDS, 0.1% SDS at 65“C. |
■!
Genomic DNA transforred to nylon membrane using the same method was 1iprehybridized in Church-Gilbert buffer at 65°C for 2-3 hours before adding radiolabeled I 
probe DNA. Hybridization was carried out overnight at 65°C. The membrane was washed 
two times with 5% SDS, 40mM NaH2? 04 , ImM EDTA at 65®C for 30 minutes and with I
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1%SDS, 40mM NaHzP04 , ImM EDTA for another 30 minutes. Autoradiography (Kodak 
BioMax-MS) was carried out at -80'*C for 1-3 days depending on the intensity of the 
signal.
2.1.16 Preparation of competent bacteria
A frozen stock of the E. coli strain XL 1-Blue was plated out on LB agar and grown 
overnight at 37°C until single bacterial colonies formed. A single colony was picked and 
added to 10ml of LB medium containing 0.2% maltose and lOmM MgS0 4 - The culture 
was grown overnight shaking vigorously at 3TC  and centrifuged at 2000x g for 10 
minutes. The pellet was then resuspended in ice cold lOmM MgS04 , the concentration 
adjusted to OD600 -  0.5 and the suspension stored at 4®C until use.
2.1.17 Lambda phage library screening by plaque hybridization
In order to characterize the genomic organization of the gene encoding murine IL- 
15Ra, a XFIX II mouse genomic library (129SV, prepared by Dr. Allen Bradley, 
Stratagene) was screened using a cloned cDNA fragment encoding sIL-15Ra as a 
radiolabeled probe.
Titering of the LFIX II mouse genomic librarv. Two parallel serial dilutions of the XFIX II 
mouse genomic library were made in SM buffer. lOOpl of diluted phage (10'^ -  10'^) were 
used to infect 200pl of competent XL 1-Blue prepared as described above. After 30 
minutes at 3TC  the suspension was added to 3 ml of top-agarose pre-heated to 50°C in a 
water bath. Samples were mixed carefully and the top-agarose plated on LB-agar in * 
100mm Petri dishes (Costar). The plates were incubated for 12 -16 hours at 37°C and the
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phage-plaques foimed in the bacterial layer counted. The concentration was determined by 
relating the number of plaques per plate to the corresponding dilution thus calculating the 
number of p.f.u./p,l for the A.FIX II mouse genomic library.
First screening of the X.FIX II mouse genomic libraiw. 500pl of competent XL 1-Blue were 
mixed with 25pi phage library at approximately 4x10^ p.f.u./ml to obtain 50,000 plaques 
per plate. After incubation at 37°C for 30 minutes, the suspension was added to 5ml melted 
top-agarose at 50°C. The top-agarose was then plated on LB-agar in 150mm Petri-dishes 
(Costar) and the plates incubated at 3TC  for 12-16 hours. The plates were chilled at 4‘*C 
for 2 hours and the plaques transferred to nitrocellulose filters (Roche Biochemicals) for 2 
minutes. Duplicates were made and the second filter allowed on the plates for 5 minutes. 
The 150mm plates were then stored at 4”C until needed. Phage DNA transferred to 
nitrocellulose filters was denatured in 1.5M NaCl, 0.5M NaOH for 5 minutes and 
neutralized in 1.5M NaCl, 0.5M Tris.HCl, pH8.0 for 7 minutes. The filters were then 
rinsed briefly in 0.2M Tris.HCl, pH 7.6, 2xSSC, dried on Whatman 3MM filter paper and 
heated at 80°C for 2 hours. Hybridization with a radiolabeled DNA probe was done as 
described previously. Following hybridization and washes, filters were subjected to 
autoradiography at -SO^ ’C overnight. Comparing the intensity of autoradiographic signals 
against background identified putatively positive lambda phage clones.
Groups of lambda phage clones identified were localized on 150mm Petri dishes by 
comparing their position in relation to the signal produced on film. These clone groups 
were picked from the LB-agar within a 5mm diameter and incubated in 0.5ml SM buffer at 
4“C overnight. The titer of the phage suspension generated that way was determined as 
described before.
87
Second screening of À.FIX II mouse genomic librarv. Groups of lambda phage clones 
identified in the first screening round were subjected to a second screening. Competent 
XL 1 “Blue were infected as described before and plated in top-agarose on 100mm Petri 
dishes to obtain 100-200 plaques per plate. The plaques were then transferred to 
nitrocellulose membrane and hybridized to IL-15Ra-specific radiolabeled DNA probe as 
described before. Putatively positive lambda phage clones identified in the second 
screening were picked as single clones and incubated in 0.5ml SM buffer at 4®C before the 
titer of the phage suspension was determined. Some clones were subjected to a third 
screening identical to the second screening round to obtain single clones.
2.1.18 Purification of Lambda DNA
50ml of LB medium containing lOmM MgS04 , 0.2% maltose were inoculated with 
a single plaque and surrounding XL 1-Blue picked from a LB-agar plate prepared as 
described for the screening process. The culture was grown shaking overnight at 37°C. 
When the culture became slightly clear I ml of chloroform was added and the culture 
continued for one additional hour. The lysate was then centrifuged at 4,500x g for 10 
minutes in a JA17 rotor (Beckman) and the supernatant treated with DNase and RNase 
(lOmg/ml each) for Ihour at 37"C. One volume of 20% PEG, 2.5M NaCl was added, 
mixed well and the samples stored on ice for 1-2 hours before centrifugation at 10,000x g 
for 30 minutes. The pellet was resuspended in 600pl SM buffer and extracted 3-4 times 
with chloroform to remove remaining PEG. ISpl 0.5M EDTA and 30pl 5M NaCl were 
added and the samples extracted with 350pl buffer-saturated phenol. The aqueous phase 
was recovered and extracted with 350pl chloroform followed by precipitation in 875pi 
ethanol The lambda DNA pellet was washed with 75% ethanol, dried at room temperature 
for 5 minutes and resuspended in 50pl TE buffer. Sometimes, lambda phage DNA was
prepared using a commercially available kit (Lambda Midi Kit, Qiagen) following the 
procedure recommended by the manufacturer.
2.2 Expression and purification of recombinant IL-15 receptor fusion proteins
2.2.1 Buffers and Solutions
Acrvlamide solution
30% w/v acrylamid / bisacrylamidû(29:l) in dHiO 
Buffer B
8M urea / O.IM NaHzP04 / O.OIM Tris.HCl, pH 8.0 
Buffer C
8M urea / O.IM NaH2P04  / O.OIM Tris.HCl, pH 6.3 
Cell lvsis buffer
25mM Tris.HCl, pH 7.4 / 150mM NaCl / 1% Non,c(et p-40 / ImM EDTA / 2mM 
EGTA / lOmM NaF / ImM DTT / 50pg/ml leupeptin / 50pg/ml aprotinin / 
50pg/ml PMSF 
Low salt Wash buffer (Western Blot)
O.OIM Tris.HCl,,pH 7.6 / O.IM NaCl / 0.1% Tween-20 
High salt Wash buffer tWestern Blot)
O.OIM Tris.HCl, pH 7.6 / 0.5M NaCl / 0.1% Tween-20 
Resolving (lower) gel buffer tSDS-PAGE)
1.5M Tris.HCl, pH 8.8 / 1% SDS 
Stacking (upper) gel buffer fSDS-PAGE)
0.5m Tris.HCl, pH 6.8 /1%  SDS
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TBS
25mM Tris.HCl, pH7.4 / 150mM NaCl / lOOpM vanadate 
Western Blot Transfer Buffer
20mM Tris / 40mM glycine / 20% v/v methanol 
SDS-PAGE buffer
25mM Tris / 250mM glycine / 0.1% SDS 
SDS-Sample buffer
IM Tris.HCl, pH6.8 / 200mM DTT / 4% SDS / 0.4% bromophenol blue / 20% 
glycerol
2.2.2 Cloning of recombinant soluble IL-lSRa
Total RNA was extracted from J774 cells that had been stimulated for 18 h with 
murine recombinant IFNy (100 U/ml, a kind gift of Dr. G. Adolf, Bender Wien, Austria). 
The RNA was then reverse transcribed into cDNA as described above. sIL-15Ra was 
cloned using nested PCR, and two restriction sites (RawHI and Sail) were introduced 
during the second amplification. The following primer sets were designed from the 
published cDNA sequence of murine IL-15Ra; Set I, 5TTG CTG CTG CTG CTG TTG 
CTA CTG TTG CTC CC-3'; 5'-GCA CCA ACC AAG AGG ACC GAT GTA GAG ATG 
GC-37 Set II, 5'-GGT GGG ATC CGG CAC CAC GTG TCC ACC TCC CG-3'; 5'-AGA 
TGT CGA CTT TCG TCA TTT AAC TGT GG3' (sequences in italics are the BamBl and 
Sail site, respectively). The PCR product was confirmed by sequencing, cloned into the 
pQE-30 expression vector (Qiagen, Dorking, U.K.), and then expressed in the Escherichia 
coli M l5 strain (Qiagen).
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2.2.3 Rapid screening for recombinant sIL-15Ra protein expression
The E. coli strain M l5 transformed with the pQESO expression vector carrying an 
insert encoding sIL"-15Ra was used to produce recombinant protein. Single bacterial 
colonies were obtained by plating transformed bacteria on LB-agar (Gibco BRL) 
containing lOOpg/ml ampicillin and 25pg/ml kanamycin as described before, 12 single 
colonies were picked and cultured in 2ml LB medium supplemented with 2% glucose 
shaking at 37"C overnight. Each culture was then duplicated by adding 500pl into 2x 1.5ml 
of fresh, pre-warmed LB (containing ampicillin and kanamycin). The cultures were shaken 
for another 30 minutes until ODeoo was between 0.7 and 0.9 when compared to fresh 
medium. 20pl of 200mM IPTG were added to one set of cultures, the other half serving as 
non-induced controls. Incubation was continued shaking at 3TC  for 3-5 hours after which 
time cultures were transferred to fresh 2ml Eppendorf tubes. After centrifugation at 3,000x 
g the supernatant was aspirated and the bacterial pellet resuspended in 200pl buffer B The 
resuspended bacterial suspension was then frozen at -70°C for 20 minutes, thawed at room 
temperature whilst inverting several times to allow complete bacterial lysis. The samples 
were then centrifuged at 15,000x g for 10 minutes and the supernatant transferred to a fresh 
tube. 40pl of 50% slurry nickel-agarose (Ni-NTA, Qiagen) were added and the samples 
mixed at room temperature for 30 minutes. The nickel-agarose was then spin-washed 3 
times with buffer C at 13,000x g before adding 20pl of buffer C containing lOOmM 
EDTA. The samples were mixed carefully and spun at 13,000x g to recover the 
supernatant. 20pl supernatant from IPTG-induced and non-induced samples were mixed 
with 2x SDS-loading buffer and heated to 95”C for 10 minutes before analysis via SDS- 
PAGE loading induced and non-induced samples of the same bacterial clones next to each 
other on the gel for comparison.
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2.2.4 Large scale purification of sIL-15Ra
100 ml of 2xYT medium (containing lOOpg/ml ampicillin, 25pg/ml kanamycin) 
were inoculated with-a single colony of E. co/z-MlS transformed with the pQE30 vector 
carrying an insert encoding sIL-15Ra. The cultui'e was incubated with shaking at 37“C 
overnight and added to 900ml of fresh 2xYT (Gibco BRL), containing antibiotics, pre- 
warmed to 37*^ C. The culture was further incubated with shaking for approximately 2 hours 
until ODeoo > 0.7 . 10ml of 200mM IPTG was added and incubation with shaking was 
continued at 3TC  for 5 hours. The bacterial suspension was then pelleted by centrifugation 
in a JAIO rotor (Beckman, USA) at 4000x g, 4®C for 20 minutes. The supernatant was 
removed and the pellet resuspended in 20ml of buffer B. The suspension was incubated 
with Stirling at room temperature overnight followed by centrifugation at 14000x g in a 
JA17 rotor (Beckman, USA). The supernatant was recovered and 1ml of 50% slurry nickel 
agarose (Ni-NTA, Qiagen) was added. Recombinant protein carrying a 6xHis tag was 
allowed to bind to Ni-NTA for one hour by gently shaking the samples at room 
temperature. The Ni-NTA was then spin-washed 3 times with buffer B before loading onto 
a filter column (Qiagen). The Ni-NTA was allowed to settle by gravity and was washed by 
applying buffer B until the OD280 of the flow-through was below 0.001. The Ni-NTA was 
then washed with buffer C until OD280 < 0.001. One column volume (approximately 10ml) 
of buffer C containing 20mM imidazole was added to elute nonspecific protein bound to 
Ni-NTA. Recombinant IL-15Ra bound to Ni-NTA was eluted by adding 2-3ml buffer C 
containing 300mM imidazole and dialyzed in 2000ml PBS containing 2%NaCl at 4°C 
overnight.
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2.2.5 Measurement of protein concentration
The concentration of protein samples was measured using the Coomassie Method. 
Reagents were purchased from Pierce, Illinois, and the concentration of protein samples 
measured following the protocol provided by the manufacturer.
2.2.6 Cloning of recombinant IL-lSRa-IgGi-Fc fusion protein
Spleens derived from male DBA/1 mice that had undergone at least 2 weeks of 
Collagen Induced Arthritis were homogenized and the cells washed two times with PBS. 
After counting the cells in a Neubauer cell counting chamber, 10*^  cells were used to extract 
total RNA as described above. RT-PCR was performed using the total RNA as a sample to 
generate cDNA. 2pi of cDNA were used in a PCR reaction using specific primers (5’ Fc- 
XhoL 5 ’-GCCCAAACTAACTCGAGGGTGACCCTGGGA-3 ’and 3’ Vo-EcoRl: 5’- 
AAGGACA-CTGAATTCATTTACCAGGAGAGT-3’) so as to amplify a 945bp product 
encoding murine IgGi-Fc. This PCR product was subjected to restriction enzyme digestion 
using the endonuclease restriction sites contained in the primer sequences. The digested 
DNA was purified on a 1% agarose gel and cloned into the pcDNA3.1 (Invitrogen, 
Netherlands) expression vector pre-cut with endonucleases Xhol and EcoRI using the 
method described previously.
The cDNA fragment encoding IL-15Ra was cloned using a nested PCR approach 
as described for cloning the cDNA fi'agment encoding sIL-15Ra. The first PCR 
amplification was performed using the same set of primers as for the first PCR reaction 
used for sIL-15Ra cloning, generating a 723bp DNA fragment. This fi'agment was used as 
a template in a second PCR reaction such that two restriction enzyme sites {Xbal and Xhol)
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were introduced, and a 668bp fragment was generated (5’-CAGGGACCCCAGTCTAG^ 
GTCCCGTTGGGT-3 ’ and 5 ’-TTTCGTCATTTTGGAAÇTÇGAGGGAGAAATC-3 ’). 
This fragment was cut with Xbal and Xhol and purified via agarose gel electrophoresis 
before cloning it into the pcDNA3.1 expression vector already containing the DNA 
fragment encoding IgGi-Fc. The cloning product was confirmed by DNA sequencing using 
both external and internal sequencing primers.
2.2.7 Screening for expression of IL-lSRa-IgGi-Fc fusion protein by DOT blot
COS-7 cells transfected with the pcDNA3.1 plasmid including the DNA insert 
encoding the IL-15-IgG-Fc fusion protein were serially diluted and grown in 100mm tissue 
culture dishes for 10 days in the presence of G418 to obtain single colonies. These colonies 
were picked and transferred to 48 well plates. The cells were then grown in DMEM 
containing G418 until confluent. 1ml of supernatant from each clone was removed and 
stored at 4”C until needed. The cells were allowed to grow until clones of high expression 
were identified by DOT blot. To assess fusion protein expression in COS-7 cell 
supernatants, Trans-Blot membrane (BioRad, Hempstead, U.K.) was cut to fit into a DOT 
blot transfer chamber (Hoeffer, USA) and soaked in Western Blot Transfer buffer for 1 
minute prior to placing it into the chamber. The chamber was then shut and 1ml of cell 
culture supernatant from 48 COS-7 cell clones was transferred into the wells of the transfer 
chamber. Protein within the supernatant was bound to the membrane by connecting the 
DOT blot chamber to a vacuum pump and allowing the supernatant to be transferred 
tlii'ough the membrane for 10 minutes. The membrane was then washed briefly in low salt 
wash buffer and unspecific binding of antibodies blocked by incubating the membrane in 
2% BSA/low salt wash buffer for Ihour at room temperature. lOOng/ml simian IL-15 (a 
kind gift of the Immunex Corp., USA) in 1% BSA/low salt wash buffer was added for 
Ihour at room temperature. The membrane was then washed twice with low salt wash
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buffer, twice with high salt wash buffer and again twice with low salt wash buffer for 5-10 
minutes each. Binding of IL-15 was detected by adding lOOng/ml rat-anti-human IL-15 
mAh (biotinolated, R&D systems, USA) in 1% BSA/low salt wash buffer for one hour at 
room temperature followed by washing the membrane as described before. Avidin- 
peroxidase, conjugated (1/1000 dilution, Sigma, Poole, U.K.), was added in 1% BSA/low 
salt wash buffer followed by washing the membrane as described previously before 
developing by enhanced chemiluminescence (Amersham International, Little Chalfont, 
U.K.).
2.2,8 Large scale purification of IL-lSRa-IgGi-Fc fusion protein
COS-7 cell clones identified to produce high amounts of the IL-15Ra-IgGi-Fc 
fusion protein were grown to confluence in 165cnf tissue culture flasks (Costar) in 
medium containing FCS and G418 (see below). Wlien confluent, the medium was 
aspirated and the cells grown in DMEM in the absence of FCS and G418 for 3 days. The 
cells were then washed twice with warm PBS and harvested by detaching the cells from 
the tissue cultiue flasks with a sterile cell scraper (Costar) followed by centrifugation at 
450x g for 5 minutes in a Mirage-2000 centrifuge. The supernatant was discarded and the 
cells resuspended in 4ml COS-7 cell lysis buffer. Lysis was allowed to proceed on ice for 
30 minutes and the lysate transfen’ed to fresh 1.5ml Eppendorf tubes. The lysate was then 
cleai'ed by centrifugation at 13,000 x g for 10 minutes at 4®C in a table centrifrige (Hettich, 
Geimany). Protein A-coated beads (Amersham, UK) were washed twice in PBS and 1ml 
per 4ml of lysate were added. Binding of the IL-15Ra-IgGi-Fc fusion protein to Protein A 
coated beads was done by shaking the suspension gently at 4”C for 2 hours. The beads 
were then spin washed four times in ice cold PBS before adding 1ml / 4ml lysate of 2xSDS 
sample buffer (not containing bromophenol blue). The samples were incubated at 100”C
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for 10 minutes to elute the fusion protein from the protein A. Eluted protein was then 
dialyzed in PBS at 4°C overnight before measuring protein concentration.
2.3 Protein analysis and detection
2.3.1. Polyclonal antibody production
SOOpg of sIL-15Ra were subjected to 10% SDS-PAGE and the gel stained in 
Coomassie Blue (not containing methanol) for 10 minutes. The gel was then de-stained 
slowly in water until the protein band of 26kD was visible. This band was excised from the 
gel, transferred into a fresh 1.5ml tube and fi'ozen in liquid nitrogen. The frozen aciylamide 
gel was then homogenized and 1ml of PBS was added before freezing in liquid nitrogen 
for 2 minutes. After incubation at 37”C for 30 minutes the homogenized gel was stored at 
4”C overnight and spun in a SpinX filter tube (Costar) in a table centrifuge at 13,000 rpm 
for 5 minutes. After measuring the concenti'ation of sIL-15Ra in the preparation, 250pl of 
CFA were added to 250pl containing lOOpg of gel-purified sIL-15Ra and passed through 
a syi'inge needle several times to obtain a homogenous mixture. 10ml blood was taken 
from a rabbit as pre-immunization sample, before injecting 500pl subcutaneously to two 
sites (250pl/site). After 14 days, lOOpg of gel-purified sIL-15Ra mixed in IF A were 
applied to two sites subcutaneously as a boost injection. 24 days after the initial 
immunization, blood was taken from the rabbit and serum antibody titers against sIL-15Ra 
determined by ELISA. A third injection similar to the first boost injection was given on 
day 40 to further increase anti-sIL-15Ra-titer in the serum.
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2.3.2 Purification of polyclonal antibodies
Antibodies contained in rabbit and sheep that had been immunized with gel- 
purified sIL-15Ra were purified to increase specificity and to reduce background in 
ELISA. The polyclonal antibodies obtained were used to detect sIL-15Ra in serum of 
injected mice.
a. Purification by affinity to Protein A
Polyclonal antibody derived fi”om a rabbit immunized with sIL-15Ra according to 
the schedule previously described was purified using a commercially available Avid- 
Chrome Protein A antibody purification kit (Sigma, USA). Antibodies were purified 
according to the protocol provided by the manufacturer. In brief, 2ml rabbit serum was 
filtered through a 0.45pm syringe filter before adding 4ml of binding buffer. The Protein A 
cartridge provided in the kit was equilibrated by slowly passing 4ml of binding buffer 
through the cartridge at no more than 1 ml/minute flow rate. The sample was then applied 
to the cartridge at a flow rate of no more than 0.5ml/minute followed by 6ml of binding 
buffer. The desalting cartridge provided was then attached to the bottom end of the Protein 
A cartridge and serum antibodies eluted with 5ml of elution buffer at 0.5ml/minute.
b. Purification by precipitation with ammonium-sulfate
Polyclonal anti-sIL-15Ra antibody raised in sheep (SAPU, UK), where purified by 
sequential precipitation in aqueous saturated (NH4)2S04  to reduce background-binding 
levels and to raise antibody specificity. Protein contained in 1ml of sheep anti-sIL-15Ra 
antiserum was precipitated by adding 30% (v/v) aqueous saturated (NH4)2S04 at 4°C and 
incubation on ice for 30 minutes. Samples were centrifuged at 6000x g in a table 
centrifuge. The protein pellet was resuspended in 1ml PBS at 4°C. 30% (v/v) of aqueous
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saturated (NH4)2S04 was added at 4“C and protein allowed to precipitate on ice for 30 
minutes. The supernatant was then discarded and the protein pellet slowly resuspended in 
PBS. Supernatant and resuspended protein pellets from both precipitation steps were 
dialyzed in PBS at 4°C overnight and analyzed for binding activity to sIL-15Ra.
2.3.3 Enzyme linked immunosorbent assay (ELISA)
a. General ELISA protocol
96-well ELISA plates (Immulon 4, Dynatech Laboratories, Chantilly, VA) were 
coated overnight at 4°C with capture antibody or recombinant protein at 2-4pg/ml in O.IM 
bicarbonate coating buffer (pH 9.2). Plates were then washed twice with PBS/0.05% 
Tween20 (PBS/Tween) and blocked by adding 200pl/well 10%FCS/PBS for 2 hours at 
3TC. The plates were then washed twice as before and protein-saniples were added at 
graded dilutions or concentrations. After incubation at 37”C for 1-2 hours, the plates were 
washed four times with PBS/Tween and detecting antibody was added at appropriate 
dilutions either recommended by the manufacturer or determined experimentally. After 
incubation for Ihour at 3TC, the plates were washed six times with PBS/Tween. For HRP- 
conjugated detecting antibodies, lOOpl/well TMB microwell peroxidase substrate 
(Kirkegaard & Periy Laboratories, MA, USA) were added and the optical density 
measmed at 630nm. For biotinylated detecting antibodies, 50pl/well peroxidase- 
conjugated extravidin (1:1000 Sigma, USA) was added for 30 minutes at 37°C and the 
plate was washed eight times with PBS/Tween prior to adding TMB substrate. Where 
indicated, secondary detecting antibodies were used.
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b. Binding of recombinant sIL-15Rg to simian IL-15
For ELISA assays, microwell plates were coated with 1 pg/ml of sIL-15Ra in 0.1 
M NaHiCO] overnight at 4°C. After blocking with 10% PCS (Life Technologies), graded 
concentrations of simian rIL-15 or 500 pg/ml mIL-2 (Genzyme, Cambridge, MA) were 
added. After washing with PBS/Tween, biotin-conjugated anti-murine IL-2 or anti-simian 
IL-15 (200 ng/ml) was added respectively, followed by avidin-peroxidase (1:1000 dilution, 
Sigma, Poole, U.K.), and developed with lOOpl/well of TMB substrate.
c. Cytokine ELIS As
Murine TNPa, IFNy, IL-4, IL-6, and IL-10 were assayed using paired antibodies 
(PharMingen, San Diego, CA) according to the manufacturer's instructions. Lower limits 
of detection were as follows: IL-4, IL-6, and TNFa were all at lOpg/ml; IL-10 was at 
80pg/ml; and IFNy was at 150 pg/ml. Serum anti-collagen II Ab titers in pooled sera were 
measured by ELISA. 96-well plates (Iimnulon 4, Dynatech Laboratories) were coated with 
4pg/ml bovine type II collagen in O.IM NaH2C03 overnight at 4°C, blocked with 10% 
FCS/PBS, and serial dilutions of sera were added. Bound total IgG was detected with 
HRP-conjugated goat anti-mouse IgG (Genzyme). IgGl and IgG2a were detected with 
biotin-conjugated anti-mouse IgGl and IgG2a (PharMingen) respectively, and developed 
as described above. Plates were read at 630nm.
d. Anti-sIL-15Rg antibody titers in serum of immunized rabbits
Polyclonal anti-sIL-15Ra antibody was raised in a rabbit. Antibody titers were 
determined by ELISA. Plates were coated with 2pg/ml of sIL-15Ra in O.IM NaHzCO] 
overnight at 4“C. After blocking at 37°C for 2 hours in 10% FCS/PBS, serial dilutions of 
anti-serum were added for Ihour at 37°C with rabbit pre-immune serum serving as a
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negative control. An HRP-conjugated donkey-anti-rabbit IgG-mAb was used as a detecting 
antibody.
e. Anti-sIL-15Rq antibodv in treated mice
Measurement of anti-sIL-15Ra-antibodies in the serum of mice treated with the 
sIL-15Ra was determined by ELISA. 96 well ELISA plates were coated with 4pg/ml of 
sIL-15Ra in lOOmM NaHzCO] at 4^0 overnight. After blocking with 10% FCS/PBS for 2 
hours at 37”C, seinm of mice treated with sIL-15Ra as well as serum derived from control 
mice were added in double dilutions. Following washes with PBS/Tween, anti-sIL-15Ra 
antibodies were detected by HRP-conjugated goat anti-mouse IgG (Genzyme) and 
developed using the TMB substrate as described before.
f. Determination of serum sIL-15Rg concentrations
To measure the concentration of sIL-15Rg in murine serum, 4pg/ml of polyclonal 
sheep anti sIL-15Rg antibody (purified by ammonium-sulfate precipitation) was coated on 
96-well plates (Immulon 4, Dynatech Laboratories, Chantilly, VA) in 0.1 M NaH2C03 at 
4°C overnight. Serum from mice injected with sIL-15Rg was added and incubated for 2 
hours at 37“C. Polyclonal rabbit-anti-sIL-15Rg (Protein A affinity-purified) used as a 
primary detecting antibody was added at 4pg/ml in 10% FCS/PBS for Ihour at 37”C. A 
donkey anti-rabbit IgG mAb conjugated with HRP (Genzyme) was used as a secondary 
detecting antibody. Plates were developed using lOOpFwell TMB substrate and read at 
630nm as described above.
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2.3.4 Preparation of total protein extracts from J774 cells
Treated cells (10^ cells/sample) were washed two times with ice cold TBS and 
harvested with a cell scraper (Costar). The cell suspension was then spun at 450x g in a 
Mirage 2000 centrifuge and the cell pellet resuspended in 0.5ml cell lysis buffer. The cells 
were lysed on ice for 30 minutes and the lysate transferred to an Eppendorf tube followed 
by centrifugation at 13,000x g at 4°C for 10 minutes. Supernatants containing solubilized 
protein were stored at -80“C until use.
2.3.5 Sodium Dodecyl Sulfate-Polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE ranging from 10-15% acrylamide was performed according to the 
molecular weight of the protein sampled. Acrylamide was made as a mixture of aciylamide 
and bis-acrylamide in a ratio of 29:1. Resolving (lower) gels ranging from 10% to 15% 
were made in resolving gel buffer containing 1% w/v ammonium persulphate (BDH) and 
0.1% TEMED (Sigma). The mixed gels were poured between glass plates in a SDS-PAGE 
gel chamber (BHD) and allowed to polymerize. Stacking (upper) gels were prepared in a 
similar way using stacking gel buffer containing ammonium persulfate and TEMED. 
Electrophoresis was performed in SDS-PAGE buffer. Protein samples were mixed with 2x- 
concentrated SDS-sample buffer and heated to 100°C for 10 minutes prior to loading on 
gels. Protein molecular- weight markers (Rainbow marker, range 14-200 kD, Amersham) 
were loaded on the gel to compare molecular weight of specific proteins within the 
samples. Electrophoresis was carried out at 5mA/cm-gel length and allowed to continue 
until the bromophenol blue dye of the SDS sample buffer reached the bottom end of the 
gel.
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2.3.6 Coomassie Blue staining of SDS-PAGE gels
SDS-PAGE gels were stained in 0.5% Coomassie brilliant blue R250 (Sigma) 
containing 40% methanol, 10% glacial acetic acid for 1 hour at room temperature. The gels 
were then destained in 50% methanol, 10% glacial acetic acid for 4-5 hours changing the 
destaining solution several times until the gel-background was clear and protein bands 
clearly visible. The stained gels were transferred to filter paper (Whatman 3MM) and dried 
at 80°C under vacuum. For SDS-PAGE gel purification of sIL-15Ra, gels were stained in a 
0.5% aqueous solution of Coomassie brilliant blue for 10 minutes and destained in H2O 
until the protein band of interest was clearly visible followed by protein extraction from the 
gel as described before.
2.3.7 Western blot analysis of proteins
For Western blot analysis, protein samples were electrophoresed in 10-15% SDS- 
PAGE. A piece of nitrocellulose membrane (BioRad) was cut to fit the SDS-PAGE gel and 
soaked in Western blot transfer buffer for 10 minutes. Two pieces of filter paper (Whatman 
3MM) were cut slightly larger than the gel, soaked in transfer buffer and placed facing the 
cathode of an electroblotter (Hoeffer, USA). The gel was then placed on top of the pre­
soaked filter paper and the membrane placed on top of the gel avoiding air bubbles. Two 
farther pieces of filter paper were cut to cover the membrane lying on top of the gel. 
Proteins contained in the gel were transferred to the nitrocellulose membrane by applying a 
constant current of 0.4mA/cm^ of gel area at 6°C overnight. After the transfer, the 
nitrocellulose membrane was incubated in 2% BSA/low salt wash buffer for 2 hours at 
room temperature.
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To detect IL-15 binding to sIL-15Ra, recombinant simian IL-15 (a gift of 
Immunex, Seattle, WA) was added at 20ng/ml in 1%BSA/low salt wash buffer. Binding 
was allowed to proceed at room temperature for 1 hour. The membrane was then washed 
for 2x10 minutes in low salt wash buffer, 2x10 minutes in high salt wash buffer and again 
2x10 minutes in low salt wash buffer. Binding of IL-15 was detected with mouse anti­
human IL-15 mAb (MAB 647, R&D Systems, Oxon, U.K.) at lOOng/ml for 1 hour at room 
temperature followed by washes as described above. Avidin-peroxidase, (1/1000 dilution 
in low salt wash buffer) was added and the membrane incubated shaking at room 
temperature for 30 minutes. After another series of washes the signal was developed by 
enhanced chemiluminescence (Amersham International, Little Chalfont, U.K.) and 
exposed to film (Kodak, X-omat).
To detect native IL-15Ra from total protein extracts of J774 cells, polyclonal rabbit 
anti-sIL-15Ra antiserum was diluted 1:2000 in 1%BSA/low salt wash buffer and applied 
to the membrane for 1 hour gently shaking at room temperature. Following washes 
described before, donkey anti-rabbit IgG (HRP conjugated, fi'om SAPU, Carluke, UK) was 
added for 1 hour at room temperature. After additional washes immuno-reactive bands 
were visualized using the enhanced chemiluminescence system (ECL, Amersham) 
described before.
To detect IL-15Ra-IgGi-Fc fusion protein expression from COS-7 cell culture, 
purified fusion protein was subjected to 10% SDS-PAGE and Western blot. After transfer, 
the membrane was incubated in 10% w/v milk powder/low salt wash buffer for 2h at room 
temperature. The membrane was then washed once in low salt wash buffer before adding 
either anti-c-myc mAh (HRP) (Invitrogen, Netherlands) or goat anti-rabbit IgG (HRP)
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(SAPU, Carluke, UK) at 1:2000 dilutions in 5% w/v milk powder in low salt wash buffer 
followed by shaking at room temperature for 2 hours. The membrane was then washed 
2x10 minutes in low salt wash buffer, 2x10 minutes in high salt wash buffer and again 
2x10 minutes in low salt wash buffer before enhanced chemiluminescence as described 
before.
2.4 In vivo models
2.4.1 Ethical considerations
All animal experimentation was carried out under a project licence provided by the 
UK Home Office and was performed to address scientific questions that could not be 
investigated by in vitro studies alone. Mice were obtained from Harlan, UK and kept in 
designated facilities within the University of Glasgow.
2.4.2 Induction of collagen-induced arthritis in DBA/1 mice
Bovine type II collagen (Sigma) was dissolved at 4mg/ml in lOOmM acetic 
acid/PBS at 4°C overnight. 25mg of H37 mycobacterium TB (Difco, USA) was ground 
using a pestle and mortar and mixed with 5ml CFA. Dissolved collagen was added to the 
mix in equal volumes to give a final concentration of 2mg/ml. The mixture was passed 
through a syringe needle several times to mix. Male DBA/1 mice (6-8-wk-old, Harlan 
Olac, Bicester, U.K.) received 200 pg of bovine type II collagen, prepai'ed this way, by 
intra-dermal injection on day 0. After 21 days they received a second injection of collagen 
(200pg in PBS) intra-peritoneally (i.p.). Daily injections of sIL-15Ra (10 or 40 
pg/mouse/day) or human serum albumin (HSA) (40 pg) were administered i.p. for 2 wk 
starting on day 22. Mice were monitored daily for signs of arthritis, for which severity
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scores were derived as follows: 0 = normal, 1 = erythema, 2 = erythema plus swelling, 3 = 
extension/loss function, and total score = sum of four limbs. Paw thickness was measured 
with a dial-caliper (Kroeplin, Munich, Germany).
2.5 Tissue culture and in vitro assays
2.5.1 Buffers and solutions
ES cell Ivsis buffer
lOmM TrisHCl, pH 7.7 / lOmM EDTA / lOmM NaCl / 0.5% SDS / lOOpg/ml 
proteinase K 
Tiwpsin Solution
Ix Trypsin/EDTA (Gibco, BRL) diluted 1:5 in PBS, containing 1% chicken serum
2.5.2 Culture and stimulation of J774 cells
Murine macrophage J774 (American Type Culture Collection (ATCC), USA) cells 
where grown in RPMI 1640 (supplemented with 2mM L-glutamine, 100 U/ml penicillin, 
100 U/ml streptomycin, 25mM HEPES, 10% PCS). 10  ^cells were stimulated for 18 h with 
recombinant murine IFNy (100 U/ml, a kind gift of Dr. G. Adolf, Bender Wien, Austria), 
washed twice with PBS and harvested using a plastic cell scraper. The cell suspension was 
centrifuged at 450x g and total RNA was prepared as described previously.
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2.5.3 Determination of sIL-15Ra bioactivity in CTLL and DIO assay
Cytotoxic T cells CTLL (American Type Culture Collection (ATCC), Rockville, 
MD) and D10.G4.1 (a T-helper cell line, Kaye et aL, 1984 / ATCC) cell lines were grown 
in RPMI 1640 (supplemented with 2mM L-glutamine, 100 U/ml penicillin, 100 U/ml 
streptomycin, 25mM HEPES, 10% PCS, lOng/ml recombinant hIL-2). 24 hours prior to 
the experiment, recombinant IL-2 was withdrawn from the culture. To block IL-15 activity 
in vitro, cells were cultured in 96-well plates (Nunc, Roskilde, Denmark) with 0.1 ng/ml 
(for CTLL) or l.Ong/ml (for DIO) of recombinant simian IL-15, which were concentrations 
that had been previously titrated for optimal proliferation. Recombinant sIL-15Ra (200 
ng/ml) was added to triplicate cultures which were then incubated at 37°C in 5% CO2 for 
up to 72 h. [^H]-thymidine incorporation over the final 6 h of culture was measured in a 
beta-plate counter (Wallac Oy, Turku, Finland).
2.5.4 Culture and stimulation of murine spleen cells
Spleen cells were cultured at 2 x 10  ^ cells/ml for up to 96 h in RPMI 1640 (Life 
Technologies) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 U/ml 
streptomycin, 25 mM HEPES buffer, and 10% FCS (all fi'om Life Technologies) at 37°C 
in 5% CO2. Cells were stimulated either with graded concentrations of type II collagen or 
with concanavalin A (ConA) (1 pg/ml, Sigma). Proliferation assays were perfoimed in 
triplicate in U-bottom 96-well plates (Nunc) as previously described. Supernatants from 
parallel triplicate cultures were stored at -70°C until estimation of cytokine content by 
ELISA.
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2.5.5 Culture and maintenance of COS-7 cells
COS-7 cells (Welcome Research Laboratories, London, UK) were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco BRL) containing 10% FCS, 100 
U/ml penicillin, 100 U/ml streptomycin and 2niM L-glutamine (Gibco BRL).
2.5.6 Stable transfection of COS-7 cells by electroporation
COS-7 cells were gi'own to confluence in 2xl65cm^ tissue culture flasks (Costar) 
and washed twice with PBS. Cells were trypsinised to obtain a single cell suspension and 
counted in a Neubauer cell counting chamber. 10  ^ cells were resuspended in 500pl PBS 
and the cell suspension transferred into an electroporation cuvette. 40pg of Pvul- 
lineralized IL-15Ra-IgGi-Fc expression construct (IL-15Ra-IgGi-Fc in pcDNA3.1 
expression vector) was added and the cells tmnsfected by electric pulse (250V / 960p,F) in 
a BioRad gene puiser. Following electroporation, the cells were allowed to stand at room 
temperature for 10 minutes and transferred to 6ml pre-warmed DMEM. The cells were 
then equally distributed into 6x100mm tissue culture dishes containing 9ml DMEM and 
incubated at 37“C / 5% CO2 for 24 hours.
2.5.7 Selection of G418-resistant COS-7 cells
24 hours after electroporation, cells were grown in DMEM containing 500pg/ml 
G418 for 14 days. Cell culture medium was replaced every two days. Wlren G418 resistant 
colonies were visible, cells from each culture dish were treated with Ix trypsin/EDTA to 
obtain a single cell suspension and washed twice in PBS. After centrifugation at 45Ox g the 
cells were resuspended in 5ml DMEM and transferred to a 25cm^ tissue culture flask.
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2.5.8 Transient transfection of COS-7 cells by lipofection
Transient transfection of COS-7 cell was employed to produce and purify 
recombinant IL-15Ra-IgGi-Fc as an alternative method to stable transfection of COS-7 
cells with the IL-15Ra-IgGi-Fc expression construct. The objective of transient protein 
expression was to obtain a higher yield of recombinant protein due to increased number of 
plasmid copies per cell compared to cells permanently transfected with the same construct. 
A commercially available transfection kit was employed to obtain COS cells expressing 
IL-15Ra-IgGi-Fc (Qiagen, SuperFect). In brief, 2-8x10^ COS-7 cells were passaged into a 
25cm^ tissue cultm*e flask one day before transfection. On the following day, 5pg non- 
lineralized plasmid DNA were mixed in 30pl SuperFect solution and complex formation 
was allowed to occur for 5-10 minutes at room temperature. Cell culture medium was 
added after this incubation period and the cells were incubated with the transfection mix 
for 2-3 hours at 37“C and 5% CO2. The cells were then washed with pre-warmed PBS and 
cultured in fresh medium for 2-3 days.
2.5.9 Freezing, thawing and long-term storage of COS-7 cells
Cells were allowed to reach confluence in 25cm^ tissue culture flasks and washed 
twice in PBS. After treatment with Ix trypsin/EDTA, the cells were centrifuged at 450x g 
and resuspended in 1.5ml Ix freezing medium (20% FCS / 10%DMSO). The cells were 
then transferred into 3 freezing vials and placed in a pre-cooled rack at -80“C overnight. 
The next day, frozen cells were transferred into liquid nitrogen for long-term storage.
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2.6 Gene targeting techniques
2.6.1 Culture and maintenance of murine Embryonic Stem (ES) cells
El 4/2 ES cells (E14/2-129SV, Center of Genomic Research, Edinburgh, UK) were 
cultured in BHK21 Glasgow Modified Eagle’s Medium (GMEM) (Gibco BRL). The 
medium was supplemented with 10% ES cell-qualified FCS (Gibco BRL), ImM sodium 
pyruvate, ImM non essential amino-acids, O.lmM p-mercaptoethanol, 100 U/ml penicillin, 
100 U/ml streptomycin and lOOU/ml DIA/LIF (Gibco BRL). Tissue culture flasks were 
coated with 0.1% gelatin / PBS (Sigma) for 10 minutes prior to usage.
2.6.2 Transfection of ES cells by electroporation
E l4/2 ES cells were grown to confluence in 4xl65cm^ tissue culture flasks (Costar) 
and trypsinised to obtain a single cell suspension. Cells were than washed twice in PBS. 
Cells were counted in a Neubauer cell counting chamber and the cell number adjusted to 
10® cells in 500pi PBS. 5pi and 20pl of cell suspension respectively were transferred into 
gelatinized 100mm tissue culture dishes (Costai*) containing 10ml of pre-warmed ES cell 
culture medium as non-transfection controls. The remaining cell suspension was 
transferred into an electroporation cuvette. 150pg of Ao^/-lineralized targeting construct 
prepared as described previously were added and the cells electroporated by applying an 
electric pulse (800V, 3.0pF) in a BioRad gene-pulser. After incubation at room 
temperature for 10 minutes the cells were transferred into 20ml of pre-warmed ES cell 
culture medium. The cells were then evenly distributed into 20 gelatinized 100mm cell 
culture dishes containing 9 ml ES cell culture medium and incubated at 37° / 5% CO2 for 
24 hours.
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2.6.3 Selection of geneticin (G418) resistant ES cell colonies
Selection of ES cell colonies resistant to G418 (Sigma) began 24 hours after 
transfection. Electroporated ES cells were cultured in ES cell culture medium containing 
300pg/ml G418 for approximately 10 days until ES cell colonies appeared. The medium 
was replaced every second day during this period. G418 resistant ES cell colonies were 
picked into 48 microwell plates (Costar) coated with 0.1% gelatin, expanded and split into 
one 48- and two 24 microwell plates when confluent. The 48-microwell plate was fi'ozen in 
situ when cells reached confluence while ES cells from 24 microwell plates were used for 
genomic DNA preparation for. Southern analysis and PGR.
2.6.4 Preparation of genomic DNA from ES cells
Genomic DNA from cells grown in 24 microwell plates was prepared by washing 
cells twice with PBS before adding 300pl ES cell lysis buffer. Plates were sealed with 
parafilm and incubated at 55®C overnight. The lysate was then transferred to 1.5ml 
Eppendorf tubes, extracted once with buffer saturated phenol (Gibco BRL) and twice with 
chloroform. Genomic DNA was precipitated by adding 2 volumes of ethanol and inverting 
the tube several times before centrifugation at 13,000x g for 10 minutes. DNA pellets were 
washed with 70% ethanol, dried at room temperature for 5 minutes and resuspended in 
lOOpl TE buffer at 4“C overnight.
2.6.5 Screening for targeting events by Southern hybridization
ES cell clones that had undergone homologous recombination with the targeting 
construct were identified by Southern hybridization. Genomic DNA derived from
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electroporated and selected ES cell clones was subjected to digestion with restriction 
endonuclease XhoL Restricted gDNA was separated on agarose gels and transferred to 
nylon membranes as described previously. A 0.9kb DNA fragment, derived from subclone
6.1 by digestion with E'coRI and Xhol, was used as a radiolabeled external probe to 
hybridize with a 7kb gDNA fi-agment corresponding to the wild type lL-15Ra allele. 
Targeted mutation of the IL-15Ra locus by homologous recombination with the targeting 
construct was expected to result in the hybridization of the 5’ DNA-probe with a 4.2kb 
fragment due to the insertion of aATzoI site into the targeted locus.
2.6.6 Expression of Cre recombinase in targeted ES cells
To delete loxP site flanked sequences in targeted ES cell clones, cells were 
transiently transfected with the plasmid pCAG-Cre-IP (a kind gift of Dr. A. Smith, 
Edinburgh). This plasmid expresses Cre recombinase and puromycin acetylase {pac). 
Puromycin is capable of killing non-resistant ES cells within 48 hours of culture and is 
therefore particularly suitable for selection for transient transfection events. ES cell clones 
were grown to confluence in 75cm^ tissue culture flasks. 10^  cells, trypsinised to obtain a 
single cell suspension, were subjected to electroporation in a BioRad Gene puiser using 
20pg of non-lineralized pCAG-Cre-IP expression plasmid at 800V, 3.0pF.
Electroporated cells were grown in gelatinized 10mm tissue culture dishes in the 
absence of G418 for 8-10 days replacing. Culture medium was replaced every second day. 
l.Opg/ml puromycin (Sigma) was added to the culture medium 24 hours after 
electroporation for a period of 72 hours.
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2.6.7 Detection of Cre-mediated recombination events
Single ES cell colonies where picked, transferred to 48 microwell plates and 
expanded as described before. Duplicates were made in 48 microwell plates and the cells 
frozen for short-term storage as described before. Genomic DNA from duplicated clones 
was prepared as described previously and used in PCR analysis to detect Cre-mediated 
recombination events of loxP site flanked DNA sequences. PCR oligonucleotides were 
designed to amplify the loxP-flanked region of the target sequence. The 3’oligonucleotide 
(3’wt-l) was designed to hybridize outside of the DNA segment covered by the targeting 
construct. The 5’oligonucleotide was located within the targeted DNA segment (3.5revR- 
33).
2.6.8 Hybridization, freezing, storage and thawing of ES cells
Short term storage of ES cells in 48 microwell plates. Cells grown to confluence in 
48 microwell plates were washed twice with PBS and trypsinised with 200pl Ix 
tiypsiiVEDTA (Gibco BRL) to obtain a single cell suspension. One volume of Quench 
(50% FCS / 50% ES cell culture medium) was added to terminate tiypsin digestion. 400jal 
2x freezing medium (20% DMSG in ES cell culture medium) were added, the cell 
suspension mixed well and the plates frozen at -80°C placed in a rack tightly fitted with a 
filling material to allow the cooling to proceed slowly. Cells frozen in that way were kept 
for up to 3 weeks.
Long term storage of ES cells in liquid nitrogen. Cells grown to confluence were 
trypsinised to obtain a single cell suspension and washed twice in PBS. Cells were 
resuspended in Ix freezing medium containing 20% FCS / 10% DMSG and transferred
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into freezing vials. The cell suspensions were then frozen at ~80°C in a pre-cooled rack 
before transferring the vials to liquid nitrogen.
Thawing of ES cells. Cells frozen in 48 microwell plates were thawed by adding 
1.5ml pre-warmed ES cell culture medium and gently pipetting up and down. Cells were 
allowed to attach to the microwell bottom for approximately 6 hours before replacing the 
medium with fresh ES cell culture medium.
ES cells frozen in liquid nitrogen were thawed by successively adding pre-warmed 
medium thereby thawing the fr'ozen cells rapidly and transferring them into 10ml of pre- 
warmed medium. Cells were then pelleted at 450x g in a table centrifuge (Mirage 2000), 
resuspended in 5ml of fresh ES cell cultiue medium and transferred to a gelatinized 25cm  ^
tissue culture flask.
2.7 Statistical analysis
Statistical analysis was perfonned using Minitab software for Macintosh or PC. 
The analyses were performed using the log-rank test, Mann-Whitney U test, or Student's t 
test as indicated.
2.8 List of plasmid vectors
Plasmid vectors used for screening, cloning, expression of recombinant proteins or 
transfection experiments are listed below.
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Chapter 3
Cloning and expression of recombinant IL-15 receptors
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3.1 Cloning and expression of soluble IL-15Ra
3.1.1 Introduction
The general approach underlying the cloning of sIL-15Ra was to express a soluble 
fragment of the cytokine receptor lacking the native leading sequence, transmembrane 
region and cytoplasmic tail. The resulting recombinant protein was designed to only 
contain the protein binding motif and Pro/Thr-rich region of IL-15Ra. A bacterial 
expression system was chosen to allow inducible, large scale expression under relatively 
uncomplicated culture conditions. To facilitate purification, a His-tag encoded by the 
expression vector system (Qiagen, pQE vector) was used. The recombinant protein could 
therefore be affinity-punfied using a metal-agarose chelate system. As sIL-15Ra was 
found to be best purified under denaturing conditions, refolding of the recombinant protein 
after purification was done in a high-salt (2% w/v NaCl) PBS buffer.
3.1.2 Cloning of the cDNA insert encoding sIL-lSRa
Murine cDNA was prepared from mRNA extracted fr'om IFNy-stimulated murine 
macrophages (J774) by RT-PCR. The nucleotide sequence encoding sIL-15Ra was 
obtained by nested PCR. The first amplification round yielded a 723bp cDNA fragment but 
also some unspecific products (Figure 3.1 A). The second amplification round was done 
using the first PCR product as a template. This second amplification resulted in a PCR 
product of 541bp (Figure 3.1 B). This band was extracted from the gel and subjected to 
endonuclease restriction by Bam ^l and Sail and subsequently cloned both into the 
pBluescript and pQE30 vector (Figure 3.1 C). Both vectors carrying the DNA insert 
encoding sIL-15Ra were used to transform competent E. coli of the DH5a and M l5
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strains. Single bacterial colonies derived from these transformations were picked and 
cultured for small-scale preparations for plasmid DNA. The sequence identity was verified 
by DNA sequencing. The final product contained 194 amino acid residues, 173 of which 
encode the “Sushi” domain (also referred to as “short consensus repeat” or GP-I motif) 
(Davie et aL, 1986, Anderson et aL, 1995), linker, and Pro/Thr rich region of the native IL- 
15Ra (see Figure 3.3 for schematic representation).
B
723bp-
541bp-
+
Figure 3.1 A nested PCR approach was employed to clone the cDNA encoding sIL- 
15Ra. The amplification round yielded a 723bp PCR product but also resulted in 
unspecific amplification of cDNA resulting in a DNA-smear visible on the agarose-gel
(A). The PCR product obtained in the amplification round was used as a template for 
the 2"^  PCR reaction resulting in a 541 bp PCR product (B) which, following digestion with 
BamYil and SaB was purified via agarose gel electrophoresis (C) and cloned in the pQE30 
vector (- without; + with insert).
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A
B
1 - ATGAGAGGAT CGCATCACCA TCACCATCAC GGATCCGGCA CCACGTGTCC
5 1 - ACCTCCCGTA TCTATTGAGC ATGCTGACAT CCGGGTCAAG AATTACAGTG
1 0 1 - TGAACTCCAG GGAGAGGTAT GTCTGTAACT CTGGCTTTAA GCGGAAAGCT
1 5 1 - GGAACATCCA CCCTGATTGA GTGTGTGATC AACAAGAACA CAAATGTTGC
2 0 1 - CCACTGGACA ACTCCCAGCC TCAAGTGCAT CAGAGACCCC TCCCTAGCTC
2 5 1 ACTACAGTCC AGTGCCAACA GTAGTGACAC CAAAGGTGAC CTCACAGCCA
3 0 1 - GAGAGCCCCT CCCCCTCTGC AAAAGAGCCA GAAGCTTTCT CTCCCAAATC
3 5 1 - AGATACCGCA ATGACCACAG AGACAGCTAT TATGCCTGGC TCCAGGCTGA
4 0 1 - CACCATCCCA AACAACTTCT GCAGGAACTA CAGGGACAGG CAGTCACAAG
4 5 1 - TCCTCCCGAG CCCCATCTCT TGCAGCAACA ATGACCTTGG AGCCTACAGC
5 0 1 - CTCCACCTCC CTCAGGATAA CAGAGATTTC TCCCCACAGT TCCAAAATGA
5 5 1 - CGAAAGTCGA C CTG GAG CCA AGC TTA ATT AGC TGA
1 - MRGSHHHHHH GTTCPPPVSI EHADIRVKNY SVNSRERYVC NSGFKRKAGT
5 1 - STLIEC V INK NTNVAHWTTP SLKCIRDPSL AHYSPVPTVV TPKVTSOPES
1 0 1 - PSPSAKEPEA FSPKSDTAMT TETAIMPGSR LTPSQTTSAG TTGTGSHKSS
1 5 1 - RAPSLAATMT LEPTASTSLR IT E ISP H SSK MTKVDLQLQPSLIS*
Figure 3.2 Complete cDNA insert nucleotide sequence encoding IL-15Ra (A). Insert 
sequences are underlined, start and stop codon encoded by pQE30 expression vector are 
marked in bold. The 5’His tag encoded by vector sequence is double underlined.
Amino acid sequence of sIL-15Ra (B). The complete protein constitutes 194 amino 
acid residues. Sequences encoded by the cDNA insert are underlined (dashed; Sushi 
domain; thick: linker/hinge; dotted: Pro/Thr rich region). The N-terminal 6xHis tag 
encoded by pQE30 is double underlined, * indicates the C-terminus of the amino acid 
sequence.
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3.1.3 Expression of sIL-15Ra in the E. coli M15 strain
The pQE30 bacterial expression vector carrying the DNA insert encoding sIL- 
15Ra was used to transform competent E. coli of the M l 5 strain. 12 single bacterial 
colonies were picked and subjected to rapid screening for recombinant sIL-15Ra protein 
expression. Clone N^ 4 was identified to show both maximal expression levels and a 
protein product of 26kD which was not visible in the unstimulated control (without IPTG) 
and was subsequently used for all sIL-15Ra preparations.
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Figure 3.3 Schematic representation of sIL-15Ra (A) compared to native IL-15Ra (B). 
The recombinant sIL-15Ra includes the protein-binding motif, linker and Pro/Thr-rich 
region of the native IL-15Ra but lacks its leading sequence, transmembrane region and 
cytoplasmic domain.
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3.1.4 Purification of sIL-15Ra under denaturing conditions
The sIL-15Ra recombinant protein proved to be purified most efficiently under 
denatuiing conditions. Attempts to purify sIL-15Ra under native conditions did not yield 
satisfactory amounts of recombinant protein. Following purification under denaturing 
conditions, sIL-15Ra was dialyzed to allow refolding and removal of urea in the 
preparation. The recombinant protein was insoluble in PBS at concentrations exceeding 
250fj.g/ml. The NaCl concentration of the dialysis buffer was subsequently raised to 2% 
(w/v) to increase solubility resulting in an optimal concentration of 400pg/ml after dialysis. 
The yield of recombinant protein ranged between l.Omg and 1.2mg of sIL-15Ra per liter 
of bacterial culture. Purity of the protein preparation was assessed by SDS-PAGE followed 
by Coomassie Blue staining. The possible presence of EPS due to contamination of the 
recombinant protein derived from the expression culture was measured using the Limulus 
test (Sigma). Binding of sIL-15Ra to recombinant simian IL-15 was demonstrated in 
ELISA and Western blot analysis.
3.1.5 Specific binding of sIL-15Ra to IL-15
ELISA and Western blot were employed to demonstrate specific and high affinity 
binding of sIL-15Ra to IL-15, In ELISA, sIL-15Ra was coated to the ELISA plate at 4°C 
overnight. Simian IL-15 was added at various concentrations and binding to sIL-15Ra was 
detected using an anti-human IL-15 mAb. IL-15 was detectable to a minimal concentration 
of 25pg/ml and bound to sIL-15Ra in a dose dependent manner (Figure 3.4). However, 
sIL-15Ra did not bind to murine IL-2 when added to the sIL-15Ra-coated plates and 
developed by anti-murine IL-2 mAb. The recombinant sIL-15Ra was also tested in 
Western blot analysis. In Western blot, sIL-15Ra was subjected to SDS-PAGE and
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transferred on nitrocellulose membrane. Similar to the detection method used in ELISA, 
simian IL-15 was added and the signal developed using an anti-human IL-15 mAh. A 
single protein band of approximately 26kD which corresponded to the major band seen on 
Coomassie Blue stained SDS-PAGE gels was observed (Figure 3.5).
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Figure 3.4 Binding of IL-15 to sIL-15Ra in ELISA. 2 pg/ml of sIL-15Ra were coated 
on ELISA plates. Simian IL-15 bound strongly to sIL-15Ra up to a minimal concentration 
of 25pg/ml. Soluble IL-15Ra did not bind to murine IL-2. Data expressed as mean ± SEM.
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Figure 3.5 Coomassie blue staining (A) and Western blot analysis (B) of sIL-15Ra. 
Recombinant sIL-15Ra has a molecular weight of 26kD shown in SDS-PAGE and 
Coomassie Blue staining loading 250, 120 or 60ng of sIL-15Ra (A). The sIL-15Ra bound 
to simian IL-15 in Western Blot analysis (B). 60, 30 and 15ng of sIL-15Ra were run on 
SDS-PAGE and subjected to Western blotting. Simian IL-15 was added and binding to a 
26kD protein band was detected using anti-human IL-15 mAb.
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3.1.6 Bioactivity of sIL-15Ra in CTLL and DIO assays
The recombinant sIL-15Ra was assessed for its ability to inhibit IL-15-induced 
proliferation of CTLL and DIO cells. IL-15Ra was originally cloned from DIO cells (Giri 
et al, 1995) and appears to over-express the high affinity IL-15R exhibiting between 5000 
and 15000 high affinity binding sites for IL-15 on each cell. Addition of 200ng of sIL- 
15Ra reduced IL-15 induced proliferation by up to 90% depending on IL-15 concentration 
(Figure 3.6 A). Optimal inhibition was achieved for CTLL cells stimulated with O.lng/ml 
(B) and DIO cells stimulated with l.Ong/ml (C) of simian IL-15 for 72h. Addition of sIL- 
15Ra did not inliibit IL-2 dependent proliferation. Addition of IL-15 over lOng/ml 
reversed the inliibitory effect of sIL-15Ra.
IL-15/sIL-15Ra 
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Figure 3.6 (A) Inhibitory effect of sIL-15Ra on IL-15 induced proliferation of DIO
cells. Cells were stimulated with increasing concentrations of IL-15 containing 200ng/ml 
of IL-15Ra or IL-15 alone. (B) Inhibition of CTLL proliferation at O.lng/ml of IL-15. (C) 
Inhibition of DIO proliferation at l.Ong/ml of IL-15. Data are expressed as mean ± SEM 
for triplicate cultures.
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3.1.7 Gel-purification of sIL-15Ra
Soluble IL-15Ra was purified via SDS-PAGE prior to immunization of animals for 
polyclonal antibody production. Gel purification removed all additional protein bands 
previously visible in Coomassie Blue stained acryamide gels when high amounts of sIL- 
15Ra were run in SDS-PAGE. Approximately 80% of the protein loaded on the gel could 
be recovered after gel purification.
^  ^  io o —<■ rn
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Figure 3.7 Gel purification of sIL-15Ra for rabbit-immunization. Various amounts of 
gel-purified sIL-lSRa were run on SDS-PAGE to demonstrate purity prior to immunization 
of rabbits for polyclonal antibody production.
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3.1.8 Polyclonal anti-sIL-lSRa-antibody production
Polyclonal antibodies detecting sIL-15Ra were raised in a rabbit following the 
immunization protocol described in chapter 2. Gel purified recombinant sIL-15Ra was 
also used to generate sheep-anti-sIL-15Ra-Ab by a commercial company (SAPU, UK). 
Polyclonal antisenim derived from the sheep was made available to the Dept, of 
Immunology and purified via sequential precipitation by ammonium-sulfate as described 
before (see Chapter 2 and below).
Rabbit serum was obtained by bleeding on day 24 p.i. and anti-sIL-15Ra antibody 
titers compared with titers of pre-immune serum by ELISA. The specificity of raised 
rabbit-antibody was confirmed by Western blot analysis taking total protein extract of J774 
cells stimulated with LPS/IFNy as a sample. To determine if rabbit-anti-sIL-15Ra 
anti serum interacts with the 6xHis tag of the recombinant protein, recombinant murine IL- 
18 (a kind gift of Dr. X.Q. Wei, Dept, of Immunology), purified using the same 
purification system employed for sIL-15Ra was used as a control. In ELISA rabbit 
antiserum bound to sIL-15Ra at detectable levels up to a dilution of 1:4000, whereas pre- 
immune serum did not bind to sIL-15Ra (Figure 3.8 A). In Western Blot analysis rabbit- 
anti-sIL-15Ra strongly bound to several protein bands ranging between 55kD and 60kD 
corresponding to the molecular weight of native IL-15Ra (Giri, et al., 1995). Recombinant 
IL-18 was not detected by rabbit-anti sIL-15Ra-antiserum (Figure 3.8 B). Anti-sIL-15Ra- 
antibodies from rabbit and sheep were tested for their ability to interfere with the binding 
of sIL-15Ra to simian IL-15. In CTLL proliferation assays, antiserum derived from sheep 
but not rabbit-anti-sIL-15Ra antiserum inhibited the bio activity of sIL-15Ra by restoring 
IL-15-induced proliferation indicating that sheep anti-sIL-15Rct antiserum detected 
epitopes contained within the protein binding motif of sIL-15Ra (Figure 3.8 C).
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Figure 3.8 (A) ELISA demonstrating the detection of sIL-15Ra coated on the plate by
unpurified polyclonal anti-sIL-15Ra-Ab raised in rabbit. Data are presented as mean ± 
SEM. (B) Western blot analysis using polyclonal anti-sIL-15Ra-Ab to detect native IL- 
15Ra in protein extracts of J774 cells stimulated with LPS/IFNy. Murine recombinant IL- 
18 containing a C-terminal histidine-tag was used as a negative control peptide. (C) CTLL 
proliferation assay. Sheep but not rabbit anti-sIL-15Ra antiserum inhibited sIL-15Ra- 
mediated reduction of IL-15-induced proliferation. Data are presented as mean ± SEM.
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3.1.9 Purification of polyclonal anti-sIL-15Rot antibodies
Rabbit-anti-sIL-15Ra IgG was purified from serum derived from an immunized 
rabbit upon completion of the immunization procedure. A commercially available Protein 
A-IgG purification kit (Sigma, USA) was used. Following the protocol recommended by 
the manufacturer serum IgG could be purified from crude serum resulting in a final 
concentration of 1 mg/ml.
Sheep-anti-sIL-15Ra antibodies were purified fr'om serum derived from an 
immunized sheep (SAPU, UK) using sequential precipitation of crude serum with 
ammonium-sulfate. Four sample fractions were generated corresponding to 50% 
(NH4)2S04 pellet and supernatant and 30% (NH4)2S04  pellet and supernatant fractions, 
respectively. The fractions were tested for their ability to serve as capture antibody to 
detect sIL-15Ra in ELISA. Using sequential precipitation with saturated (NH4)2S04 
solution it was concluded that the 30% (NH4)2S04 pellet fraction contained most of the 
sIL-15Ra binding ability. Coating of a 1:500 dilution of the 30% pellet fraction resulted in 
a stronger binding signal than coating of crude sheep-anti-sIL-15Ra antiserum, therefore 
demonstrating an enrichment of anti-sIL-15Ra through the precipitation procedure (Figure 
3 . 9 ) .
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Figure 3.9 ELISA for sIL-15Ra detection using different purification fractions derived 
from sequential precipitation of sheep-anti-sIL-15Ra antiserum with aqueous, saturated 
(NH4)2S0 4 . Crude serum was precipitated first with 50% (v/v) (NH4)2S04 , centrifuged and 
resuspended in PBS. 30% (v/v) (NH4)2S04  was added to the resuspended protein and the 
resulting precipitated fraction was resuspended in PBS. Aliquots of all four fractions were 
dialyzed in PBS prior to coating on ELISA plates. Amounts of sIL-15Ra added in graded 
dilution were measured as described before. Data are expressed as mean OD 630 ± SEM.
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3.1.10 Half-life of sIL-lSRa in vivo
To use sIL-15Ra as an anti-inflammatory agent, the time dming which sIL-15Ra 
remains in the blood- of an injected individual is an important factor for the design of 
effective treatment schedules. The biological half-life of sIL-15Ra was measured in vivo. 
Following administration of 80p,g of sIL-15Ra into DBA/1 mice by i.p. injection, serum 
fi'om these mice was taken at 2h, 6h, 12h and 24h post injection (n-3 per time point). The 
individual serum concentration of sIL-15Ra for each mouse was measured by ELISA and 
compared to a standard. Figure 3.10 shows that, following a single i.p. injection of sIL- 
15Ra, the recombinant protein was rapidly cleared from the bloodstream. Two hours after 
injection, sIL-15Ra-serum levels had declined to approximately 20ng/ml, followed by a 
10-fold reduction four hours later. The assay is limited by the sensitivity of the polyclonal 
antibodies raised in rabbit and sheep with a detection limit of 1 ng/ml of sIL-15Ra. Since 
comparatively low levels of sIL-15Ra are required to block IL-15 mediated proliferation 
of T cells in vitro, low serum concentration of the recombinant protein below 1 ng/ml may 
still block IL-15 frmction in vivo.
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Figure 3.10 Half-life of sIL-15Ra in vivo. The highest semm level of sIL-15Ra was 
detected 2 hours after injection and was followed by a rapid clearance of sIL-15Ra horn 
the circulation. Serum sIL-15Ra levels reached the detection limit of approximately 
1 ng/ml 5-7 hours after injection.
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3.2 Cloning and expression of IL-15Ra-IgGi-Fc
3.2,1 Introduction.
A second recombinant IL-15 receptor was obtained by expressing. IL-15Ra as an 
IgGl-Fc fusion protein in a mammalian expression system. This was undertaken under the 
objective to increase the half-life of recombinant IL-15Ra, which was relatively short for 
sIL-15Ra reflecting the efficient clearance of a small protein in vivo. In comparison to sIL- 
15Ra, an IL-15Ra-IgGl-Fc fusion protein would be much larger due to the increased 
number of amino acid residues and the potential for glycosylation on IgGl-Fc in the 
mammalian expression system. Secondly, any post-translational modifications which ai'e 
necessary for function, would be more likely to be present in a protein expressed in 
mammalian cells than in bacterial expression systems. The increased molecular weight and 
possible interactions of IL-15Ra-IgGl-Fc with endogenous Fcy receptors was also likely to 
result in an increased half-life in vivo. These reasons make an IL-15Ra-IgGl-Fc fusion 
protein a desirable reagent as an IL-15 antagonist. Hence, a construct was cloned that 
expresses the murine IgGl-Fc ftised to IL-15Ra under the control of the hCMV promoter.
3.2.2 Cloning of the cDNA insert encoding IL-15Ra-IgGi-Fc
Murine cDNA encoding IgGi-Fc was prepared by RT-PCR from DBA/1 spleens of 
mice that had undergone collagen-induced arthritis. PGR amplification using specific 
primers resulted in a DNA fragment of 944bp. This fragment was cut by restriction 
endonucleases Xhol and Eco'Bl using the restriction enzyme sites contained within the 
primer sequences. The restricted product was cloned into the mammalian expression vector 
pcDNA3.1. The cDNA encoding the IL-15Ra fragment was cloned using a nested PCR
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approach on the same murine cDNA used for IgGi-Fc cloning. The first amplification 
round yielded a 723bp fragment, which was used as a template in a second PCR reaction, 
which resulted in a single PCR product of 668bp. This product was restricted by Xbal and 
Xhol endonucleases and cloned into the pcDNA3.1 vector, which already contained the 
cDNA fragment encoding IgGi-Fc. The final product contains a 1623bp fragment, which 
encoded a 541 amino acid residue protein, 37 of which are encoded by vector sequences. 
The protein product has a predicted molecular weight of 66kD. The sequence identity of 
the cloned product was confirmed by DNA sequencing and restriction enzyme mapping, 
(see Figure 3.12 for schematic representation of IL-15Ra-IgG 1 -Fc)
A B C D E
Figure 3.11 Cloning of the IL-15Ra-IgGi-Fc cDNA. A nested PCR was performed on 
DBA/1 cDNA derived from spleen cells by RT-PCR to obtain the DNA insert encoding 
IL-15Ra. A first amplification round yielded a product of 723bp (A) but also resulted in 
unspecific amplification. This product was used as a template in a second amplification 
round and resulted in a PCR product of 668bp (B) which was subjected to restriction 
enzyme digestion by Xbal and Xhol and cloned into the pcDNAS.l vector (C). Murine 
IgGl-Fc was cloned by PCR from DB/Vl spleen cDNA resulting in a product of 944bp 
(D), which was cut by Xhol and EcoBl and cloned into pcDNAS.l already containing IL- 
15Ra-cDNA (E).
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Figure 3.12 Schematic representation of IL-15Ra-IgGi-Fc. The fusion protein includes 
the leader sequence, binding domain and Pro/Thr rich region of IL-15Ra (A) and the Fc 
part of murine IgGi at its C-tenninus (B). Fusion of these two components results in the 
expression of a 66kD protein (C).
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A
1 - CGTTGGGTCA CTGCTGGGGA CAATTGGCCA TGGCGTGGGG GGAGGTGGGG
5 1  - GGCTATGGAG TCCAGGCCAT TCCTGTGTTG GTGGTGGTGG TGTTGGTAGT
1 0 1 - GTTGCTCCCG CTGAGGGTGA CGCCGGGCAC CAGGTGTGGA GGTGGGGTAT
1 5 1 - CTATTGAGCA TGCTGACATC CGGGTCAAGA ATTAGAGTGT GAAGTGGAGG
2 0 1 - GAGAGGTATG TCTGTAACTC TGGCTTTAAG GGGAAAGGTG GAAGATGGAC
2 5 1 - CCTGATTGAG TGTGTGATCA ACAAGAACAC AAATGTTGGG GAGTGGAGAA
3 0 1 - CTCCCAGCCT CAAGTGCATC AGAGACCCCT GGGTAGGTGA GTAGAGTGGA
3 5 1 - GTGCCAACAG TAGTGACACC AAAGGTGACC TGAGAGGGAG AGAGGGGGTG
4 0 1 - CCCCTCTGCA AAAGAGCCAG AAGCTTTCTC TGGCAAATGA GATAGGGGAA
4 5 1 - TGACCACAGA GACAGCTATT ATGCCTGGCT GGAGGGTGAG ACGATGGGAA
5 0 1 - ACAACTTCTG CAGGAACTAC AGGGACAGGC AGTGAGAAGT GGTGGGGAGG
5 5 1 - CCCATCTCTT GCAGCAACAA TGACCTTGGA GGGTAGAGGG TGGAGGTGGG
6 0 1 - TCAGGATAAC AGAGATTTCT CCCTCGAGGG TGAGGCTGGG ATGGGTGGTG
6 5 1 - AAGGGCTATT TCCCTGAGCC AGTGACAGTG AGGTGGAAGT GTGGATGGGT
7 0 1 - GTCCAGCGGT GTGCACACCT TCCCAGCTGT GGTGGAGTGT GAGGTGTAGA
7 5 1 - CfCTGAGCAG CTCAGTGACT GTCCCCTCCA GGAGGTGGGG GAGGGAGAGG
8 0 1 - GTCACCTGCA ACGTTGCCCA CCCGGCCAGC AGGAGGAAGG TGGAGAAGAA
8 5 1 - AATTGTGCCC AGGGATTGTG GTTGTAAGCC TTGGATATGT AGAGTGGGAG
9 0 1 - AAGTATCATG TGTCTTCATC TTCCCCCCAA AGGGGAAGGA TGTGGTGAGG
9 5 1 - ATTACTCTGA CTCCTAAGGT CACGTGTGTT GTGGTAGAGA TGAGGAAGGA
1 0 0 1 - TGATCCCGAG GTCCAGTTCA GCTGGTTTGT AGATGATGTG GAGGTGGAGA
1 0 5 1 - CAGCTCAGAC GCAACCCCGG GAGGAGCAGT TGAAGAGGAG TTTGGGGTGA
1 1 0 1 - GTCAGTGAAC TTCCCATGAT GCACCAGGAC TGGGTGAATG GGAAGGAGTT
1 1 5 1 - CAAATGCAGG GTCAACAGTG CAGCTTTCCC TGGCGGGATG GAGAAAAGGA
1 2 0 1 - TCTCCAAAAC CAAAGGCAGA CCGAAGGCTC GAGAGGTGTA GAGGATTGGA
1 2 5 1 - CCTCCCAAGG AGCAGATGGC CAAGGATAAA GTGAGTGTGA GGTGGATGAT
1 3 0 1 - AACAGACTTC TTCCCTGAAG ACATTACTGT GGAGTGGGAG TGGAATGGGG
1 3 5 1 - AGCCAGCGGA GAACTACAAG AACACTCAGC GGATGATGGA GAGAGATGGG
1 4 0 1 - TCTTACTTCG TCTACAGCAA GCTCAATGTG GAGAAGAGGA AGTGGGAGGG
1 4 5 1 - AGGAAATACT TTCACCTGCT GTGTGTTACA TGAGGGGGTG GAGAAGGACG
1 5 0 1 ATACTGAGAA GAGCCTCTCC GAGTGTGGTG GTAAATGAAT TGGAGGAGAG
1 5 5 1 TGGACTAGTG GATCCGAGCT GGGTAGGAAG GTTGGGGGGG AAGAAAAAGT
1 6 0 1 CATCTCAGAA GAGGATCTGA ATAGGGGGGT GGAGGATGAT GATGATGATG
1 6 5 1 ATTGA
Complete nucleotide sequence of IL-15Ra-IgGi-Fc (legend overleaf).
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B
1 - MASPOLRGYG VOAIPVLLLL LLLLLLPLRV TPGTTCPPPV SIEHADIRVK
5 1 - NYSVNSRERY VCNSGFKRKA GTSTLIECVI NKNTNVAHWT TPSLKCIRDP
1 0 1 - SLAHYSPVPT VVTPKVTSQP ESPSPSAKEP EAFSPKSDTA MTTETAIMPG
1 5 1 - SRLTPSQTTS AGTTGTGSHK SSRAPSLAAT MTLEPTASTS L R IT E IS P S R
2 0 1 - VTLGCLVKGY FPEPVTVTWN SGSLSSGVHT FPAVLQSDLY TLSSSVTVPS
2 5 1 - STWPSETVTC NVAHPASSTK VDKKIVPRDC GCKPCICTVP E V SSV F IF P P
3 0 1 - KPKDVLTITL TPKVTCVVVD ISKDDPEVQF SWFVDDVEVH TAQTQPREEQ
3 5 1 - FNSTFRSVSE LPIMHQDWLN GKEFKCRVNS AAFPAPIEKT ISKTKGRPKA
4 0 1 - PQVYTIPPPK EQMAKDKVSL TCMITDFFPE DITVEWQWNG QPAENYKNTQ
4 5 1 - PIMDTDGSYF VYSKLNVQKS NWEAGNTFTC SVLHEGLHNH HTEKSLSHSP
5 0 1 GKRIPPHWTS GSELGTKLGP EOKLISEEDL NSAVDHHHHH H*
Figure 3.13 (A) Nucleotide sequence of IL"15Ra-IgGi-Fc. Coding nucleotide sequence
is underlined. The AT G start and TGA stop codons are in bold. The central Xhol and 3 ’ 
EcoBl site are underlined in bold. Vector sequence encoding the myc epitope is double 
underlined. Vector sequence encoding His-tag is underlined dotted.
(B) Predicted amino acid sequence of IL-15Ra-IgGi-Fc. Thick: IL-15Ra signal 
peptide; single: IL-15Ra domain; dotted: IgGi-Fc domain; double: myc epitope; * 
indicates the C-terminus of the protein.
3.2.3 Expression of IL-15Ra-IgGi-Fc in COS-7 cells
COS-7 cells stably transfected with the IL-15Ra-IgGi~Fc expression construct 
were separated into single colonies by limiting dilution. 48 colonies were picked and 
analyzed for recombinant fusion protein expression by DOT blot. Another 48 colonies 
from non-transfected COS-7 cells were taken as a negative control. A total of 6 COS-7 cell 
colonies were identified for maximal IL-15 binding capacity and pooled for large-scale 
expression cultures (Figure 3.14). Using Protein A affinity purification, the recombinant
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fusion protein was found to be present in cell lysis preparations rather than in culture 
supernatants. Approximately lOpg of recombinant protein was obtained per 162cm^ flask 
of confluent COS-7 cells (2x10^).
Since stable transfection of COS-7 cells with the plasmid encoding. IL-15Ra-IgGr 
Fc resulted in a low yield and poor IL-15 binding capacity of the resulting protein, 
transient transfection of COS-7 cells using the non-lineralized expression plasmid was 
performed to increase the copy number of plasmid per cell. Culture supernatant from 
small-scale transfections in 25cm^ tissue culture flasks was collected 48 hours after 
transfection. Anti-IL-15 activity within the supernatant was measured by ELISA and 
proliferation assay and compared to cell culture supernatant firom COS-7 cells transfected 
with pcDNA3.1 vector alone.
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Figure 3.14 DOT blot for the selection of COS-7 colonies expressing maximum 
quantities of IL-15Ra-IgGi-Fc. Supernatants from clones of transfected and untransfected 
COS cells were transferred onto nylon membrane. Expression of recombinant protein was 
detected by adding simian IL-15 and anti-human-IL-15mAb as a detecting antibody.
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3.2.4 Detection of IL-15Ra-IgGi-Fe in Western Blot
Preparations of COS-7 cell lysates and culture supernatants that had undergone 
Protein A affinity purification were analyzed by Western blot to demonstrate IL-15Ra- 
IgGi-Fc protein expression. Detection of recombinant protein by a monoclonal antibody 
recognizing the c-myc epitope contained within the pcDNA3.1 expression vector and a 
monoclonal antibody directed against murine IgG both resulted in the same protein double 
band of 66kD (Figure 3.15). No additional bands were visible using these two detection 
systems. Both antibodies showed a higher expression level of recombinant fusion protein 
in cell lysates than in culture supernatants. The molecular weight of the COS-7 product 
was confirmed by Coomassie blue staining of Protein A purified protein resulting in a band 
of 66kD. No protein band was visible in preparations derived from untransfected COS-7 
cells.
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Figure 3.15 Western blet analysis of IL-15Ra-IgGi-Fc prepared from COS-7 cell 
culture supernatants (sn) and COS-7 cell lysates (lys). The recombinant fusion protein was 
purified by binding to Protein A coated sephadex beats (Sigma, USA). Two different 
detecting antibodies were used to show IL-15Ra-IgGi-Fc expression in Western blot 
analysis. An HRP-conjugated mAb directed against the myc epitope (A) binds to a 12 
amino acid residue sequence encoded by the 3’ nucleotide sequence of the pcDNA3.1 
vector. A second HRP conjugated antibody is directed against murine IgGl (B). Both 
antibodies detected the same protein band of 66kD. The band intensity suggests that IL- 
15Ra-IgGi-Fc is only partially secreted in COS-7 cell cultures and preferentially remains 
within the cells. The molecular weight of the product was reconfirmed by SDS-PAGE 
followed by Coomassie blue staining (C).
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3.2.5 Specific binding of IL-lSRa-IgGi-Fc to IL-15 in ELISA
The specific binding of IL-15Ra-IgGi-Fc to IL-15 was measured by ELISA by its 
ability to neutralize binding of IL-15 to sIL-15Ra bound to micro titer plates. The cell 
culture supernatants of COS-7 cells transfected with either pcDNA3.1 alone or the 
complete IL-15Ra-IgGi-Fc expression construct where collected 48h after transient 
transfection. Graded dilutions of the different cell culture supernatants were added to 
microtiter wells that had been previously coated with sIL-15Ra. Simian IL-15 was added 
to a final concentration of 500 pg/ml. IL-15 that bound to immobilized sIL-15Ra was 
detected by adding an anti-IL-15 biotinolated mAb. The amount of IL-15 bound to 
immobilized sIL-15Ra was compared to an IL-15 standard. Cell culture supernatant from 
COS-7 cells transfected with the IL-15Ra-IgGi-Fc expression construct but not pcDNA3.1 
vector neutralized the binding of IL-15 to immobilized sIL-15Ra up to a dilution of 
approximately 10 fold. The ability of free sIL-15Ra to compete with the binding of IL-15 
to immobilized sIL-15Ra was used as a positive assay control. Free sIL-15Ra reduced the 
binding of IL-15 to immobilized sIL-15Ra at a minimal concentration of 40pg/ml (Figure 
3.16). Therefore, these results show the presence of an anti-IL-15 activity in culture 
supernatant of cells transfected with the IL-15Ra-IgGi-Fc expression plasmid.
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Figure 3.16 Neutralizing effect of cell culture supernatant from IL-15Ra-IgGrFc- 
transfected cells on IL-15 binding by sIL-15Ra. Cell culture supernatant contained an anti- 
IL-15 activity up to a minimal dilution of approximately 10 fold. Cell culture supernatant 
from COS-7 cells transfected with pcDNA3.1 alone did not contain anti-IL-15 activity. 
Free sIL-I5Ra competes with immobilized sIL-15Ra at a minimal concentration of 
40pg/ml. Data are expressed as means of triplicates ± SEM.
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3.3 Summary
The cDNA encoding the extracellular domain of IL-15Ra was cloned from the 
murine macrophage cell line J774 by RT-PCR. Sequence analysis of the cloned cDNA 
fi*agment confirmed 100% sequence identity with murine IL-15Ra. Expression of the 
peptide encoded by the cDNA fragment as a histidine-tagged recombinant protein in a 
bacterial expression system resulted in a product of 26kD. This protein bound to simian IL- 
15 in ELISA and neutralized the IL-15 induced proliferation of the T cell lines CTLL ana 
DIO. Polyclonal antibodies against sIL-15Ra have been raised in rabbit and sheep and 
used to determine the half-life of sIL-15Ra in the murine bloodstream.
A second cDNA fragment encoding IL-15Ra extracellular domain has been cloned 
from DBA/1 spleen cells by RT-PCR. The cloned cDNA has been linked to a cDNA 
fragment encoding murine IgGi-Fc, which has been derived from DBA/1 spleen cells by 
RT-PCR. The resulting cDNA-construct was cloned into a mammalian expression vector 
and used to express IL-15Ra-IgGi-Fc in COS-7 cells. The resulting peptide had a 
molecular weight of 66kD and could be detected by antibodies against murine IgGl and 
the myc epitope encoded by the expression vector. Culture supernatant of COS-7 cells 
transiently transfected with the expression construct contained an anti-IL15 activity, which 
was not found in culture supernatant derived from cells transfected with the empty vector 
alone.
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Chapter 4 
Soluble IL“15Ra in collagen-induced arthritis
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4.1 Introduction
The presence of IL-15 in the RA synovium has been previously demonstrated 
(Mclnnes et al., 1996). In the synovium, IL-15 may recruit and activate synovial T cells in 
the relative absence of IL-2. Following IL-15-mediated activation, synovial T cells induce 
TNFa synthesis by macrophages through cognate interactions indicating ah important role 
for IL-15 in the inflammatory cascade within the synovium (Mclnnes et al., 1997). 
Recombinant sIL-15Ra was therefore used to antagonize IL-15 functions in a murine 
model of RA, collagen-induced arthritis (CIA). The project was carried out in collaboration 
with Dr, Bemai'd Leung, Dept, of Immunology, The results were published jointly under 
shared first authorship (Ruchatz, et al., 1998, reprint attached). In this study it was 
demonstrated that sIL-15Ra prevented the development of CIA and had a profound effect 
on the immunological response generated by the disease.
4.2 Administration of sIL-15Ra prevents the development of CIA
The effect of sIL-15Ra administration on CIA in susceptible male DBA/1 mice 
was monitored since the immunopathogenesis of CIA closely resembles RA. Mice injected 
intradermally with type II collagen in Freund's complete adjuvant developed severe 
arthritis when challenged i.p. 21 days later with collagen. The incidence and severity of 
disease development was markedly suppressed in mice that received daily i.p. injections of 
40jJ,g of sIL-15Ra beginning on the day after collagen challenge (day 22) in comparison 
with controls which received HSA (see Figure 4.1; legend shown on page 147). Histologic 
examination of the hind limb joints from HSA-treated mice revealed massive mononuclear 
and polymorphonuclear infiltration of the synovial membrane with synovial hyperplasia 
and adjacent bone erosion. Administration of sIL-15Ra markedly suppressed each of these 
parameters (Figure 4,2).
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Figure 4.1. (legend for figure on previous page) sIL-15Ra inhibited the development of 
CIA. Collagen-primed DBA/1 mice were randomly divided into groups of 10, challenged 
on day 21, and given 14 daily i.p. injections of 40pg of sIL-15Ra (O)or 40(ig of HSA (#) 
starting on day 22. Mice were monitored daily for disease progression, which was 
quantified as mean clinical score (A), mean number of artliritic paws (B), or mean paw 
thickness (C). Values are mean ± SEM. At the end of treatment (day 36), 20% of mice 
developed mild CIA in the sIL-15Ra-treated group compared with 90% which developed 
severe CIA in the HSA control group (p < 0.05). The total number of sIL-15Ra-treated 
mice was 29, while the total number of HSA control mice was 19.
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Figure 4.2. Administration of sIL-15Ra significantly reduced articular inflammation and 
destruction. Immediately following 14 days of sIL-15Ra administration, hind limbs (five 
mice/group) were removed, formalin-fixed, decalcified, and hematoxylin and eosin sections 
were prepared (day 36). Histologic appearances in the knee, carpus, and interphalangeal 
joints in parallel sections (HSA, n = 17; sIL-15Ra, n = 13) were scored independently (0-3) 
by two treatment-blinded histologists (data are mean ± SD). Extensive erosion (p < 0.002), 
inflammatory infiltration (p < 0.001), and synovial hyperplasia (p < 0.001) were observed in 
HSA-treated animals (B) (%40 magnification), but were usually absent in sIL-15Rpc 
recipients (C) (%40 magnification).
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4.3 Immunologie consequences of sIL-15Ra administration
To further explore the effect of sIL-15Ra on immunologic responses, spleen ceils 
from mice that had been treated with 40 pg of sIL-15Ra or control HSA were harvested 
after 2 wk of treatment (day 36) and cultured with type II collagen in vitro. Cells from 
arthritic mice that received control protein proliferated vigorously in response to collagen 
in a dose-dependent manner. This proliferative response was significantly reduced in 
cultures of cells from mice treated with sIL-15Ra (p < 0.001). Cells from the sIL~15Ra- 
treated mice produced less IFNy than cells from control HSA-treated mice, which indicates 
a suppression of Thl responses. Moreover, IL-4 was undetectable, and XL-10 levels were 
low (100-120 pg/ml) and indistinguishable between the groups, suggesting that the 
mechanism of disease suppression by sIL-15Ra was not by the preferential enhancement 
of Tli2 responses. IL-6 production was significantly suppressed in sIL-15Ra-treated 
animals compared with HSA controls. TNT a  synthesis was not detected, which was 
consistent with previous observations that the collagen-stimulated expression of TNFa in 
vitro occurs primarily during the early acute phase of CIA (Courtenay et al., 1980). 
However, the T cell mitogen. Con A, stimulated equally high levels of both proliferation 
and IFNy, IL-4, IL-10, and IL-6 production by spleen cells from both groups of mice, 
indicating that suppression of the immune response was Ag-specific (Figure 4.3).
Commensurate with the above observations, sera from sIL-15Ra-treated mice 
showed a significant reduction of cytokine levels. Serum samples taken on day 36 were 
analyzed for the presence of IL-4, IL-5, IL-6, IL-10, TNFa and IFNy. Whereas IL-4 and 
IL-5 were undetectable in sera from both treatment groups, TNFa levels were similarly 1 
low in both groups. Again, this finding is compatible with earlier reports showing that
upregulation of TFNa in CIA occurs only transiently at the early stage of the disease. |
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However, sera from mice treated with sIL-15Ra contained significantly less IFNy than 
those from control mice. Similarly, IL-6 and IL-10 levels were reduced in mice that had 
received sIL-15Ra when compared with mice treated with HSA (Figure 4.4).
Humoral responses were clearly modified, since serum anti-collagen Ah 
concentrations were significantly reduced in sIL-lSRa recipients. This was particularly 
apparent for the IgG2a isotype which is consistent with the preferential suppression of the 
Thl-type immune response that predominates in CIA (Figure 4.5).
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Figure 4.3 Assessment of in vitro responses against collagen from mice treated with 
sIL-15Ra or HSA. Spleen cells (pooled from five mice per group) were collected from 
sIL-15Ra-treated or HSA-treated mice at the end of the 2-wk treatment phase (day 36) and 
cultured with graded concentrations of collagen for 96 h. T cell proliferation (A), which 
was determined by ^[HJthymidine uptake, is expressed as mean stimulation index ± SEM 
of triplicate cultures (medium conti'ol ranged from 3500 to 5000 cpm). Supernatants from 
parallel cultures were collected after 72 h. IFNy (B) and IL-6 (C) levels were measured by 
ELISA and expressed as mean ± SEM. *p < 0.05.
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Figure 4.4 Serum cytokine levels in sIL-15Ra and HSA treated mice. Sera from 5 
mice were pooled and collected on day 36. Serum cytokine concentrations were measured 
by ELISA. Data are mean ± SEM. *p < 0.05, **p < 0.005, Maim-Whitney test.
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Figure 4.5 Assessment of serum anti-collagen Ab responses in sIL-15Ra-and HSA- 
treated mice. Anti-collagen Ab titers from mice treated with sIL-15Ra (O) or HSA (• ) ;  
total IgG (A), IgGl (B), and IgG2a (C) were measured at the end of treatment (day 36) by 
ELISA. Data are from pooled serum (five mice per group) and are expressed as mean 
absorbance (OD 630) from doubling dilutions ± SEM, Wilcoxon rank test.
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4.4 Discontinuation of sIL-15Ra administration facilitates disease expression
To determine the duration of disease suppression, sIL-15Ra administration was 
withdrawn after 14 days. CIA was detected clinically at 5 to 7 days after the cessation of 
treatment, and 90% of previous sIL-15Ra recipients developed CIA that was 
indistinguishable from the control HSA-injected group after 10 days. Thus, treated mice 
developed acute phase CIA soon after the discontinuation of sIL-15Ra injection. This 
observation was reflected in immune responsiveness in vitro. Two weeks after the 
cessation of treatment (day 50), spleen cells from sIL-15Ra recipients produced higher 
concentrations of IFNy and IL-6 in response to collagen, while T cell proliferation in both 
groups was similar. Spleen cells from sIL-15Ra recipients were compared either with 
parallel cultures from HSA-treated controls, which were in the chronic phase of CIA at that 
point, or with spleen cell responses obtained earlier from littermates at the end of sIL- 
15Ra treatment (day 36). Thus, treatment with sIL-15Ra clearly suppressed the 
development of acute CIA (Figure 4.6).
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Figure 4.6 At 14 days after the cessation of treatment (day 50), spleen cells (pooled 
from three mice per group) from sIL-15Ra-treated mice or HSA-treated mice were 
cultured with collagen as described previously. Withdrawal of sIL-15Ra leads to the loss 
of suppression of collagen-induced proliferation of spleen cells of mice previously treated 
with sIL-15Ra (A). IFNy (B) and IL-6 (C) synthesis in parallel cultures was determined by 
ELISA, *p <0.05, Mann-Whitney test.
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4.5 Injection of slL-15Ra induces the development of anti-sIL-15Ra antibodies
Continuous sIL-15Ra injection in vivo led to the production of anti-sIL-15Ra auto­
antibodies in DBA/1 mice. Anti-sIL-15Ra activity was detected in serum of mice injected 
with 40pg of recombinant protein per day over a period of 14 days. The titer of anti-sIL- 
15Ra auto-antibodies was measured by ELISA. In serum from DBA/1 mice treated with 
either high or low dose of sIL-15Ra for over 14 days, an anti-sIL-15Ra antibody activity 
was detectable up to a serum dilution of 1:60,000. No anti-sIL-15Ra antibody activity was 
found in semm of mice treated with HSA or in normal serum of control mice that had not 
undergone CIA (Figure 4.7 A). In Western blot analysis (B), diluted serum from DBA/1 
mice continuously injected with sIL-15Ra specifically detected recombinant sIL-15Ra in 
Western blot. However, anti-sIL-15Ra antibodies contained in this serum also bound to 
recombinant IL-18 (a kind gift of Dr. X.Q. Wei), which had been used as a control protein 
due to its similar purification procedme and C-terminal 6x His tag. As the DBA/1 mice, 
from which the serum was obtained had not been injected with rIL-18, these results 
indicate that anti-sIL-15Ra auto-antibodies were also directed against the 6x His tag.
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Figure 4.7 (A) ELIS A showing anti-sIL-15Ra antibody titers in serum derived from
different treatment groups compared to titers in normal serum. Titers where comparable in 
high and low dose sIL-15Ra treatment group, whereas no anti-sIL-15Ra activity could be 
detected in normal serum or in serum of mice treated with HSA. Titers are expressed as 
mean absorbance (OD 630) from doubling dilutions ± SEM.
(B) Western Blot showing anti-IL-15Ra activity of serum derived from DBA/1 
mice after 14 days of injection of sIL-15Ra. Anti-sIL-15Ra Ab contained within the 
serum detected a minimal amount of 0.075pg of sIL-15Ra run on SDS-PAGE. However, 
human recombinant IL-18, expressed in the pQE30/M15 expression system was also 
detected, suggesting that the 5’terminal His-tag that is contained in both proteins is the 
epitope recognized by antibodies within the serum.
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To determine if anti-sIL-15Ra antibodies directly inhibited the bioactivity of sIL- 
15Ra, CTLL cell proliferation assays were performed. IL-15-induced proliferation of 
CTLL cells was perfonned as described previously. Serum from DBA/1 mice injected with 
either HSA (Figure 4.8, A) or sIL-15Ra (B) for 14 days was added to sIL-15Ra in various 
dilutions prior to adding the recombinant sIL-15Ra to the CTLL cell cultures to block IL- 
15-induced proliferation. IL-15 strongly stimulated CTLL proliferation as measured by 
their [^H]-thymidine uptake. Addition of 200ng/ml of sIL-15Ra strongly inhibited 
proliferation induced by either 0.1 or l.Ong/ml of simian IL-15. The inhibitory effect of 
sIL-15Ra could be overcome by adding excess IL-15 (lOng/ml). Murine semm of both 
treatment groups was added to the cultures containing sIL-15Ra at various dilutions. 
Neither semm of mice that had received HSA nor serum from sIL-15Ra-treated mice 
interfered with the inhibitory effect of sIL-15Ra on IL-15-induced CTLL cell 
proliferation. Semm derived from sIL-15Ra-treated animals was also compared to anti- 
sIL-15Ra-antisera raised in sheep and rabbit for its capacity to block the inlribitory effect 
of sIL-15Ra on IL-15-induced proliferation of CTLL cells (C). Using a similar approach, 
anti-sIL-15Ra-antiserum derived from either sheep, rabbit or DBA/1 mice that had 
undergone CIA as described before was added to CTLL cells cultured in the presence of 
l.Ong/ml IL-15 and 200ng/ml sIL-15Ra. Only sheep-anti-sIL-15Ra was able to restore IL- 
15-induced proliferation of CTLL cells. Neither murine, nor rabbit-antisera inhibited the 
bioactivity of sIL-15Ra. Anti-sIL-15Ra antibodies in semm of treated mice did therefore 
not interfere directly with the IL-15-binding domain of sIL-15Ra but are likely to be 
directed against the 6xHis tag.
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Figure 4.8 CTLL cell proliferation assay showing the effect of murine serum from 
HSA-treated (A) and sIL-15Ra-treated (B) DBA/1 mice on sIL-15Ra-mediated inhibition 
of IL-15-induced proliferation. Anti-sIL-15Ra Ab derived from serum of mice treated with 
sIL“15Ra did not interfere with the inhibitory effect of sIL-15Ra on CTLL cell 
proliferation, (C) Effects of sheep-, rabbit-, and murine anti-sIL-15Ra-antisemm on sIL- 
15Ra bio activity. Only sheep-antiserum restored IL-15-induced proliferation of CTLL 
cells and thus inhibited sIL-15Ra. Data are means of triplicates ± SEM.
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4.6 Summary
The sIL-15Ra was used as a therapeutic agent in murine collagen induced arthiitis. 
Administration of sIL-15Ra prevented the onset of CIA in terms of paw thickness, severity 
and incidence in male DBA/1 mice. When compared to mice that received human serum 
albumin, sIL-15Ra-treated mice showed less cell infiltration into the synovium and 
reduced articular erosion. The inhibitory effect of sIL-15Ra on CIA was reflected by the 
immunological responses of spleen cells from mice treated with sIL~15Ra in terms of 
collagen-induced proliferation and cytokine production. Treatment with sIL-15Ra also 
resulted in a reduction in senim cytokine levels and antigen-specific IgG synthesis. This 
was particularly pronounced for anti-collagen IgG2a production. Cessation of treatment 
with sIL-15Ra resulted in the development of acute CIA within 10 days in mice that 
previously received sIL-15Ra. Administration of sIL-15Ra therefore effectively inhibited 
the onset and development of acute CIA.
Continuous injection of sIL-15Ra led to the development of anti-sIL-15Ra 
antibodies in treated mice. These antibodies bound to sIL-15Ra in Western blot analysis 
and ELISA but also interacted with a control protein also containing a 6x histidine-tag. 
However, anti-sIL-15Ra antibodies in serum of treated mice did not interfere with the 
biologic activity of sIL-15Ra to inhibit IL-15-mediated proliferation of CTLL cells.
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Chapter 5
Conditional mutagenesis of IL-lSRa in embryonic stem cells
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5.1 Introduction
The generation of knockout mice by homologous recombination frequently begins 
with the cloning of a cDNA fragment encoding the gene-product in question. The cDNA is 
used as a radiolabeled probe to screen a murine genomic library in order to obtain clones 
containing at least part of the gene to be mutated through gene targeting. Detailed 
information on the organization of the gene to be targeted, especially intron/exon 
organization, restriction enzyme sites and the location of sequences possibly to be used as 
homologous regions for the targeting construct is required to develop a strategy for the 
generation of the desired mutation. Once the desired gene is cloned and sufficiently 
characterized, the second step usually involves cloning of a targeting construct and the 
development of potential DNA probes or PCR oligonucleotides that can be employed to 
screen for homologous recombination events. In conventional gene targeting, a targeting 
construct is made to delete a crucial part of a gene by replacing it with the targeting 
construct. The created mutation generally leads to the loss of gene function. Once a 
targeted ES cell clone has been identified among ES cells permanently transfected with the 
targeting construct, the process of introducing targeted ES cells into the blastocyst and of 
generating chimeras carrying the desired mutation begins. Homozygous knockout mice can 
be generated subsequently by breeding the heterozygous offspring of chimeras.
The Cre/loxP system, which allows the conditional mutagenesis of genes targeted 
by homologous recombination requires a construct different from the ones used in 
conventional gene targeting approaches. To take advantage of the Cre/loxP system, crucial 
parts of the gene to be targeted have to be flanked by loxP sites. Consequently, a targeting 
constiuct designed to introduce these changes into the genome requires an additional 
cloning step in which a loxP site has to be placed into the inti'on sequences surrounding 
exons crucial for function of the gene product. Further loxP sites that allow the complete
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excision of flanked sequences by Cre-mediated recombination can be placed suiTounding 
the Neo selection marker cassette. When the Cre/loxP targeting construct is introduced into 
the ES cell genome by homologous recombination the targeted locus still encodes a fully 
functional gene product. Deletion of the Neo selection marker cassette in vitro after gene 
targeting further reduces the risk of impaired gene function of the targeted locus. In vitro 
deletion of all loxP site flanked sequences by transient transfection of ES cells with a Cre- 
expressing plasmid vector can also occur. In this case, targeted ES cells will lack both the 
selection marker cassette and crucial parts of the targeted gene. Mice homozygous for the 
mutation introduced can be generated similarly to the procedure used in conventional gene 
targeting.
In this targeting experiment, a lambda phage-mouse genomic library (from 129Sv 
mice) was screened to obtain clones encoding IL-15Ra. Subclones were made in the 
pBlueScript vector to characterize the gene by sequencing, restriction enzyme digest and 
Southern blotting. For the targeting construct, loxP sites were placed around exon 2 of the 
IL-15Ra gene. This exon encodes the binding domain of the native receptor and thus is 
particularly suited for gene targeting. The Neo selection marker cassette was placed 
between the 5’ and 3’ homologous regions of the targeting constiuct and was also flanked 
by loxP sites. A 5’ external DNA probe was used to screen for targeting events after 
transfection of ES cells with the targeting construct. ES cells from targeted clones were 
transfected with a plasmid expressing Cre-recombinase (pCAG-Cre-IP). Cre-recombinase- 
mediated deletion of the loxP site flanked Exon 2 and the Neo selection marker cassette 
was determined by PCR screening.
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5.2 Screening of the XFIXII mouse genomic library
The phage titer of the X,FIX II mouse genomic library was determined to be 4x10^ 
p.f.u./mL Accordingly, 50,000 p.f.u. were used to infect competent E. coli XL IB lue cells 
and plated on 5x150mm Petri dishes containing LB-agar. Using the radiolabeled cDNA 
encoding sIL-15Ra as a probe to screen for Vphage clones containing the IL-15Ra gene, 
6 putatively positive groups of lambda clones were identified. In a subsequent secondary 
screening, using the sIL-15Ra-cDNA as a radiolabeled probe, only 3 of these lambda 
clones showed an amplified positive signal and could be picked as single lambda clones. 
However, the second screening result was confirmed using a third screening round. During 
the third screening, nearly all lambda phage plaques showed a strong signal when 
hybridized with the sIL-15Ra-cDNA radiolabeled probe. As a result of the screening, thi-ee 
lambda clones were identified that strongly hybridized with sIL-15Ra-cDNA.
5.3 Mapping and subcloning of the gene encoding murine IL-15Ra
In order to obtain a restriction map of the X phage clones derived from library
screening, lambda DNA was prepared fi'om these clones. Digestion of lambda DNA with 
several different restriction endonucleases revealed that two of the thi'ee clones obtained 
were identical and showed the same restriction digest pattern. The two non-identical 
lambda clones were named clone N^3 and N^6 containing DNA inserts of 13.6kb and 
14.4kb respectively (Figure 5.1 A). Southern blot analysis of lambda DNA obtained from 
clone N“3 and N-6 was performed using the cDNA encoding sIL-15Ra as a radiolabeled 
probe to detect restriction fragments containing the gene encoding IL-15Ra (Figure 5.1 B). 
Southern blot analysis showed that a 4.5kb EcdRl t Sali and a 3.5kb EcoKL fragment from 
lambda clone N^3 contained sequences that hybridized to sIL-15Ra-cDNA, For lambda
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clone 1SP4, one EcoRl ! Sali fragment of 2.2kb could be identified. Following this 
observation, DNA from both lambda clone N-3 and N^6 was used for restriction enzyme 
digestion by E'coRI and EcoKL / Sail and the resulting fragments were subcloned into the 
pBlueScript vector. An additional subclone was obtained from lambda clone N^3 using 
restriction endonucleases BamHl and Hi?idUl resulting in a fragment of 2.4kb. The 
following pBlueScript clones were obtained and transformed into E. coli strain DH5a for 
bacterial culture and small-scale preparation of plasmid DNA.
Table 5.1 List of subclones obtained from lambda clones 3 and 6.
Lambda clone Subclone number Molecular weight Restriction enzymes
3 3.1 4.5kb EcoKl / Sail
3 3.2 3.8kb Ecom
3 3.3 2.8kb EcoKl
3 3.4 1.9kb EcoBJ / Sail
3 3.5 0.9kb EcoKl
6 6.1 6.5kb EcoRl
6 6.2 2.8kb EcoBJ
6 6.3 2.2kb Ecom  / Sail
6 6.4 2.0kb Ecom  / Sail
6 6.5 0.9kb Ecom
3 3-BH-2.4 2.4kb BamHl I Hindlll
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Following subcloning of Ecdm  and EcomJSall fragments from lambda clones, 
double-stranded DNA sequencing was used to sequence all clones using external 
oligoucleotides T7 and reverse primer whose annealing sites are contained within the 
pBlueScript vector. Sequencing the 5’ and 3’ ends of the subcloned inserts showed that the 
two lambda clones were overlapping in a total of 7.6 kb with lambda clone N-6 containing 
6.8kb of DNA positioned 5’ of lambda clone N-3. Using different combinations of 
restriction endonucleases, detailed restriction maps were obtained for each sub clone 
(Figure 5.2). The information obtained by restriction enzyme mapping and double stranded 
DNA sequencing was used to construct a detailed map of the IL-15Ra locus as contained 
within the lambda clones identified during library screening.
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Figure 5.1 (A) Restriction enzyme mapping and subcloning of lambda clones 3 and 6
using a variety of restriction endonucleases.
(B) Southern blot analysis of lambda clone 3 and 6 DNA using radiolabeled sIL- 
15Ra-cDNA as a probe.
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Figure 5.2 Schematic representation of lambda clones 3 and 6. The clones overlapped 
in a total of 7.6kb. EcoKL and EcoKL/Sall fragments were subcloned into pBlueScript SK"^  
as indicated in table 5.1. A further pBlueScript subclone, 3-BH-2.4, was derived from 
lambda clone 3 by digestion with Hindlll and BamBl. Subclones 3.2 and 6.3 contain exon 
DNA encoding IL-15Ra. The Sail sites flanking the inserts originate from the À-FIXII 
library linker sequence.
5.4 Genetic organization of the IL-15Ra locus
Plasmid DNA from pBlueScript subclones containing inserts previously identified 
in Southern blot analysis using the sIL-15Ra-cDNA as a probe was subjected to double 
stranded DNA sequencing. In addition to the external sequencing oligonucleotides T7 and 
Reverse primer, 17-mer oligonucleotides derived from the sIL-15Ra-cDNA sequence were 
used to identify nucleotide sequences containing IL-15Ra exon DNA. Following this 
approach, two exons encoding the protein-binding motif, linker and most of the Pro/Tlir 
rich region were identified.
Intron/exon boundaries and nucleotides surrounding exon DNA were sequenced. 
17-mer oligonucleotides based intron sequences were designed in order to obtain 
additional sequence information on the intron/exon organization of the IL-15Ra locus.
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In conjunction with the genomic organization of IL-15Ra in both humans and mice, the 
two exons identified were named exon (E) 2 and 3. E2 contains 197bp encoding 65 amino 
acids, whereas E3 contains 92bp accounting for 30 amino acid residues. Only one of the 
four intron-exon boundaries conformed to the known GT/AG donor/acceptor site rule, 
essentially maintaining the consensus sequence described by Mount (1982). E2 was found 
in both sub clone 3.2 as well as in subclone 6.3, whereas E3 was only contained within 
subclone 3.2. No further exons encoding IL-15Ra were found in any of the other 
subclones derived from lambda phage library screening. The distance between the two 
exons as well as their relative positions within subclones 3.2 and 6.3 were determined by 
PCR using 17-mer oligonucleotides originally designed for DNA sequencing on plasmid 
DNA derived from pBlueScript subclones 3.2 and 6.3.
197 bp
Subclone 3.2
92 bp
Figure 5.3 Detailed map of exon 2 and 3. Exon 2 contains 197bp, exon 3 contains 
92bp. Both exons identified are located within E'coRI subclone 3.2. Schematic map drawn 
to scale.
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Table 5.2 Intron-exon boundaries of IL-15Ra exon 2 and exonS.
5’ Intron Exon size 3’ Intron
tttgca GGC ACC 197bp (Exon2) CATC AG taagta
tctagg AGACCC 92bp (ExonS) CAAAAG gtagga
5.5 Construction of the IL-lSRa-targeting construct
To target the IL-15Ra locus in ES cells by homologous recombination, the 
Cre/loxP system for conditional mutagenesis was employed. In order to use this 
technology, the targeting construct had to contain loxP sites flanking cmcial parts of the 
IL-15Ra for Cre-mediated recombination. The targeting construct also contained a Neo 
selection cassette mediating G418 resistance, which was also flanked by loxP sites to allow 
for its removal after targeting. The construct contained a 5’ homologous arm of 3.7kb and 
a 3’ homologous arm of 3.4kb with the Neo selection cassette cloned between them. The 
targeting construct also contained a HSV-tk gene located at the 3’ end. The 3’homologous 
ann was prepared by cloning the loxP site of the pBS64 vector into the pBlueScript vector 
using restriction endonucleases Pstl and BamBl. The resulting pBlueScript clone was 
named pBlueScript-lox. The 3.8kb DNA insert of subclone 3.2 was excised by EcoBl and 
cloned into the pBlueScript-lox. Both the cloning of loxP and the subsequent cloning of the 
3:8kb DNA insert was confirmed by DNA sequencing. The resulting pBlueScript clone 
was named Lox3.2. PCR was performed on Lox3.2 using the T7 and KPN-1 primer, 
resulting in a 400bp product. This PCR product was cut by restriction endonucleases Kpnl 
(restriction site introduced through PCR with the KPN-1 primer) and EcoBl (restriction 
site contained in the pBlueScript vector) and cloned into the pBlueScript vector. The 400bp 
DNA-fragment was cloned as a 3’external probe in Southern hybridization to confirm 
targeting events in ES cells. In a second PCR amplification, primers KPN-IR
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(complementary to KPN-1) and Reverse Primer were used to amplify a 3.4kb product. This 
fragment was cut by restriction enzymes BamBl and Xhol to obtain a 2.2kb fragment 
(=Lox2.2) 2inàXhoVKpnl to obtain a 1.2kb fragment, respectively, which were cloned into 
pBlueScript using these restriction enzyme sites. To clone the 3ToxP sites of the targeting 
construct, the pBlueScript clone containing the 1.2kb XhoVKpnl fragment was cloned into 
pBlueScript-lox. After deletion of the Xhol site by nuclease SI digestion and re-ligation, 
the resulting pBlueScript clone was named Loxl.3. Loxl.3 was cut by BamBl and blunt - 
ended by nuclease SI digestion. The 1.3kb DNA fr'agment containing the loxP site was 
released from pBlueScript by Kpnl and purified via agarose-gel electrophoresis. Lox2.2 
was cut by Xhol and digested with nuclease SI to delete the Xhol-siXQ. Following the Xhol 
deletion, Lox2.2 was cut by Kpnl and the Loxl.3 fragment purified previously was cloned 
into Lox2.2 by Kpnl and blund-end ligation. The results of the cloning procedure were 
confimied by DNA sequencing. The thus finalized 3’homologous ami was excised from 
pBlueScript and cloned into pPNTLoxPNeo (p293) hy Xbal and Kpnl resulting in a 3.4kb 
fragment (Figure 5.5).
To clone the 5’homologous aim, the 0.9kb insert of subclone 3.5 was excised by 
EcoBl and purified. Subclone 3.3 was cut by EcoBN and dephosphoiylated by calf 
intestine phosphatase (CIP). The purified 0.9kb EcoRI fragment of subclone 3.5 was 
subjected to nuclease SI digestion to remove 3’overlapping nucleotides before cloning it 
into the EcoBN restricted subclone 3.3. The orientation of the 0.9kb insert was verified by 
DNA sequencing. The resulting 3.7kb insert was excised from the pBlueScript vector by 
digestion with Notl and Xhol and cloned into the pPNTLoxPNeo (p293) vector already 
containing the 3.4kb 3’homologous arm (Figure 5.4). The resulting tai'geting constmct was 
analyzed by DNA sequencing and restriction enzyme digestion to verify the cloning 
procedure. The targeting constmct was lineralized with restriction endonuclease Notl prior 
to transfection of ES cells.
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2.8kb
Z
0.9kb
1
(resulting in deletion of EcoRl sites)
Cloning of blund ended 0.9kb 
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EcoRY. Orientation of insert 
confirmed by sequencing. 
Excision by Notl / Xhol
Figure 5.4 Flow-chart describing the cloning strategy for the 5’ homologous region of 
the targeting construct using the pBlueScript subclones of the lambda clone containing part 
of the gene encoding IL-15Ra.
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Figure 5.5 Flow-chart describing the cloning strategy for the 3’ homologous region of 
the targeting construct using the pBlueScript subclones of the lambda clone containing part 
of the gene encoding IL-15Ra. Dotted lines symbolize multiple cloning sequences of the 
pBlueScript vector.
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5.6 Targeting of the IL-15Ra locus in embryonic stem cells
Transfection of ES cells with the lineralized targeting construct by electroporation 
and subsequent selection with G418 resulted in the generation of G418-resistant ES cell 
clones. Negative selection by gancyclovir reduced the number of ES cell clones five fold. 
Four electroporation-experiments yielded a total of 946 ES cell colonies, which were 
picked and expanded in 48 well tissue culture plates. When confluent, ES cell clones were 
duplicated for short term freezing and gDNA extraction. Southern blot analysis with the 5’ 
external DNA probe was used to screen for correct integration events tlirough homologous 
recombination. A total of 4 ES cell colonies were identified as positive in a first screening 
round showing the wild-type 7kb and additional 4.2kb band in Southern blot hybridization 
after Xhol digest (Figure 5.6). Clones identified were thawed to obtain sufficient cells for 
long term storage and further analysis. To reconfirm the first screening result, the four ES 
cell clones obtained were subjected to a second Southern blot hybridization using the 5’ 
external DNA probe. Only one clone, N- 122-34, was identified as positive in this second 
screening round (Figure 5.7 A). The 3’ external DNA probe which was cloned after PCR 
amplification of subclone 3.2 (see Figure 5.5) was not suitable for the reconfmnation of 
3’targeting events by Southern blot analysis of gDNA derived from clone N- 122-34 
(Figure 5.7 B). This may be due to repetitive intron sequences contained within the probe 
leading to non-specific hybridization to differentially digested gDNA fragments and 
resulted in smear bands after Southern blot analysis. ES cell clone N° 122-34 was 
subjected to Cre-mediated recombination in order to generate clones suitable for blastocyst 
injection. The correct 3’ integration of the targeting construct was confirmed by PCR 
analysis of gDNA derived from clone N- 122-34 after Cre-mediated recombination using a 
pair of external and internal PCR oligonucleotides (see page 177 and Figure 5.9).
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Figure 5.6 Schematic representation of the complete targeting construct. The construct 
contains a Neo selection marker cassette which is flanked by the 5’ and 3’ homologous 
regions. The 3’homologous region contains loxP sites flanking exon 2 of the IL-15Ra 
gene. The 5’ external DNA probe hybridized with a 7kb fragment in wild-type DNA in 
Southern blot analysis. Correct integration of the targeting construct results in the 
hybridization of the probe with an additional 4.2kb band after digestion with Xhol. 
Hybridization of the 3’ external DNA probe with gDNA digested with EcoRl results in a 
3.8kb band for the wild-type allele. Correct integration of the targeting vector with should 
lead to the hybridization of the 3’ probe with an additional 1.5kb fi'agment due to the 
introduction of an EcoRl site between exon 2 and exon 3.
176
y.
7 kb
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Figure 5.7 (A) Correct integration of the targeting construct within the genome of
clone 122-34 was confirmed by Southern blot analysis using the radiolabeled external 
5’probe. Genomic DNA obtained from clone 122-34 was digested by restriction 
endonuclease Xhol and separated by agarose-gel electrophoresis. In Southern blot analysis, 
the radiolabeled 5’external oligonucleotide probe hybridized to a 4.2kb (1) band in 
addition to the 7kb band representing the wild type allele (2). (B) The 3’ external DNA 
probe cloned after PCR amplification (Figure 5.5) proved to be unsuitable for Southern 
blot analysis and did not show specific hybridization to gDNA digested with EcoRl.
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5.7 Cre-recombinase mediated excision of loxP site flanked sequences in vitro
Deletion of loxP site flanked sequences was achieved by transient transfection of 
tai'geted ES cells with a plasmid expressing Cre and a selection marker gene confening 
resistance to puromycin. This plasmid, pCAG-Cre-IP, containes a polycistronic gene 
encoding Cre recombinase and puromycin acetylase (Pac) which are separated by an 
internal ribosomal entry site (1RES). Twenty four hours after electroporation of the 
targeted ES cell clone 122-34 with pCAG-Cre-IP, transfected cells were selected by adding 
l.Ogg/ml puromycin (Sigma) for 72 hours. After this period, resistant cells were allowed to 
form colonies in GMEM containing neither G418 nor puromycin. Suiwiving colonies were 
picked and expanded in 48 well plates. Genomic DNA was prepared and analyzed for Cre- 
mediated deletion of loxP flanked sequences by PCR using the 3.5rev-R and 3’wt-l primer 
pair. Possible Cre-mediated recombination events and their detection by PCR are shown in 
Figure 5.8.
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Figure 5.8 Transfection of targeted ES cells with Cre recombinase could theoretically 
result in several different Cre-mediated recombination events. In comparison to the wild 
type allele (A) in the targeted allele, both Exon 2 of the IL-15Ra gene as well as the Neo 
selection marker cassette are flanked by loxP sites (B). Cre-mediated excision of the Neo 
selection marker only (C) leads to a PCR product of 3.3kb. This deletion is desired in terms 
of creating a mouse model capable of expressing native IL-15Ra minimizing possible 
impairment of expression resulting from the presence of the Neo selection marker within 
the intron sequences separating exon 1 and 2. A further possible Cre-mediated 
recombination event would excise Exon 2 and surrounding intron sequences resulting in a 
PCR product of 3.1kb still including the Neo selection marker (D). A third possibility of 
Cre-mediated recombination would result in a PCR product of 0.9kb. This recombination 
event would excise both exon 2 and Neo selection marker cassette creating a ‘knockout’ 
allele incapable of expressing a functional IL-15Ra protein (E).
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The transfection of ES cell clone 122-34 with pCAG-Cre-IP and subsequent 
selection with puromycin resulted in a total of 17 ES cell colonies. Genomic DNA from 
these clones was used in PCR reactions to analyze Cre-mediated recombination events. To 
detect Cre-mediated recombination events of the targeted allele and to confirm the 
successful 3’targeting event of the IL-15Ra locus using the targeting construct, specific 
PCR oligonucleotides 3.5 revR and 3’wt-l were used, 3’wt-l being located downstream of 
the targeting construct (see Figure 5.8). All 17 clones obtained resulted in a PCR product 
of 0.9kb indicating a complete deletion of the loxP site flanked sequences including both 
the Neo selectable marker and exon 2 (see Figure 5.8 E). Genomic DNA from clone 122- 
34 prior to transfection with the Cre-expression plasmid resulted in a PCR product of 3.2kb 
using the same set of oligonucleotides. This band corresponds to the non-targeted wild type 
allele. However, in the same PCR reaction, the DNA fi'agment corresponding to the 
targeted allele of 122-34 prior to Cre-mediated recombination could not be amplified. This 
is likely to be due to a preferential amplification of the wild type allele, which is 2.0kb 
smaller than the targeted allele due to the insertion of the Neo selectable marker gene 
inserted into the targeted allele. Furthermore the deletion of the Neo selection marker 
cassette from the targeted allele using Cre-recombinase could not be achieved. All 17 
clones obtained after transfection with the Cre-expression plasmid resembled 
recombination events involving the two most distant loxP sites introduced resulting in a 
PCR product of 0.9kb (Figure 5.9). The Cre mediated excision of the selectable marker 
cassette only would have resulted in a PCR product of 3.3kb in addition to the 3.2kb wild 
type band. This may be due to the strong promotor used to drive Cre-expression and the 
resulting high efficiency of Cre-mediated recombination within the targeted stem cell 
allele.
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3.2kb -
122-34 clones 1-17
- 0.9kb
Figure 5.9 Cre mediated recombination on 122-34 clones 1-17. PCR using 3.5revR-33 
and 3’wt-l primer pair results in a single product of 0.9kb indicating the complete deletion 
of the loxP flanked DNA-segment. Prior to Cre mediated recombination, the same set of 
PCR oligonucleotides results in a DNA product of 3.2kb corresponding to the wild type 
allele of IL-15Ra.
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5.8 Summary
A cDNA fragment encoding the extracellular domain of murine IL-15Ra was used 
as a radiolabeled probe to screen a murine Xphage genomic libraiy by plaque 
hybridization. Two Xphage clones were found that contained exon 2 and exon 3 of the 
murine IL-15Ra gene spanning a total of 21.4kb. However, no further exons encoding IL- 
15Ra were found in these A.-phage clones. Restriction enzyme mapping, Southern blot 
analysis, sub cloning and DNA sequencing was used to obtain a map of the gene segment 
contained in the Xphage clones. A gene-targeting vector, which contains loxP sites on both 
sides of exon 2 of the IL-i5Ra-gene was constimcted. The targeting construct also 
contained a positive {Neo) selection marker cassette flanked by loxP sites, and a HSV-?k 
gene at its 3’ end. Homologous recombination of the targeting construct with the IL-15Ra 
gene locus in ES cells resulted in the replacement of the targeted gene segment by the 
construct in one of 946 G418-resistant ES cell clones screened by Southern blot analysis. 
Cre mediated recombination in this clone resulted in the complete deletion of all loxP 
flanked sequences after transient transfection of targeted ES cells by a Cre-expression 
plasmid in vitro.
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Chapter 6 General Discussion
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6.1 Cloning and expression of recombinant IL-15Ra-fusion proteins
The cDNA encoding sIL-15Ra was cloned from a murine macrophage cell line by 
RT-PCR. A nested PCR approach was employed to introduce restriction enzyme sites into 
the cDNA fragment that allowed the cloning into a vector suitable for inducible bacterial 
expression. Sequence analysis showed that the cloned cDNA fragment had 100% identity 
with the corresponding sequence published for murine IL-15Ra (Giri, et al., 1994). The 
bacterial expression system was chosen for its relative simplicity and suitability for high 
yield production of recombinant protein. Purification of the recombinant protein was 
facilitated by the N-terminal 6xHis tag allowing the purification of sIL-15Ra by metal- 
affinity chromatography. The His-tag purification system offers the advantage of 
conformation-independent purification procedures and mild elution conditions. The 6xHis 
tag is encoded by the pQE30 expression vector, which was used to express sIL-15Ra. This 
vector allows a high transcriptional rate of recombinant material under the T5 promotor 
and confers resistance to ampicillin. To avoid the potentially toxic effects of recombinant 
material on the E. coli host strain and resulting decrease in culture growth and yield of 
recombinant protein, the bacterial host strain requires the presence of high levels of the lac 
repressor protein. This repressor is encoded by the low copy plasmid pREP4 (Farabaugh, 
1978), which also confers resistance to the antibiotic kanamycin. The presence of lac 
repressor inhibits the constitutive expression of recombinant protein. Expression is induced 
by the addition of IPTG to the culture medium. IPTG binds to the lac repressor and 
inactivates it. The use of two antibiotics in the culture medium ensures that both plasmids 
(pREP4 and pQE30) are present in the host strain resulting in tight control of recombinant 
protein expression. For the expression of sIL-15Ra, induction periods of 4-5 hours were 
found to be optimal for high yield of recombinant protein (1.0-1.2 mg/ liter of culture 
volume). Small-scale preparations of recombinant protein demonstrated that sIL-15Ra was
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contained within the insoluble fraction of the bacterial lysate. Insolubility often occurs as a 
problem when expressing eukaryotic proteins in a bacterial system, due to the 
sequestration of highly expressed recombinant protein in insoluble inclusion bodies. It has 
therefore been necessary to purify sIL-15Ra under denaturing conditions followed by a 
refolding step to obtain a biologically active protein. This refolding procedure was not 
found to interfere with the ability of sIL-15Ra to bind to IL-15. To increase solubility and 
to avoid the unwanted precipitation of purified sIL-15Ra the refolding procedure was 
performed in a buffer containing high salt (2% w/v NaCl).
The ability of sIL-15Ra to specifically bind IL-15 was demonstrated in Western 
blot analysis, ELISA and proliferation assays. Furthermore, anti-sIL-15Ra antibodies 
raised in sheep interfered with the binding of sIL-15Ra to IL-15. Addition of sIL-15Ra 
did not have any activating effect on any cell type tested (murine spleen, CTLL or DIO cell 
lines). Intraperitoneal injection of sIL-15Ra up to a maximal dose of SOgg did not have 
any visible pathogenic effect on mice. Using anti-sIL-15Ra antibodies raised in rabbit and 
sheep in ELISA, the half-life of sIL-15Ra in the bloodstream of DBA/1 mice was 
measured. Although the assay sensitivity was limited to approximately Ing/ml of sIL- 
15Ra in murine serum, it was clear that sIL-15Ra was very rapidly cleared from the
■i;
bloodstream. As a consequence of this, a novel IL-15Ra-IgGi-Fc fusion protein was 
cloned. It has previously been observed that the fusion of cytokines or their receptors to 
immunoglobulin heavy chain-constant regions can prolong the biological half-life in vivo 
(Nickerson, et a l, 1996; Wooley, et al, 1993). The IL-15Ra-IgGi-Fc fusion protein was 
cloned from DBA/1 spleen cells by RT-PCR. The cDNA encoding the extracellular 
domain of IL-15Ra was obtained using a nested PCR approach introducing restriction 
enzyme sites into the cDNA fragment to facilitate cloning. The cDNA encoding IgGi-Fc 
was cloned from reverse transcribed RNA after a single PCR amplification introducing
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appropriate restriction endonuclease sites into the cDNA fragment for cloning. Both cDNA 
fragments were cloned into the pcDNA3.1 vector (Invitrogen) and DNA sequencing was 
performed to confirm the sequence identity of the fused cDNA inserts. A mammalian 
expression system was chosen for the production of the recombinant protein enabling post- 
translational modification to express a functional IgGi-Fc domain. A flinctional IgGi-Fc 
would retain the ability to bind to endogenous FCyR on murine lymphocytes, thereby 
enhancing the anti-IL-15 effect in the site of inflammation without causing the activation 
of FcyR-mediated activation since IL-lSRa-IgGi-Fc bound to FcyR would not lead to the 
receptor-crosslinking required for activation. The pcDNA3.1 vector contains a gene 
conferring resistance to G418 and encodes the myc epitope allowing detection of 
recombinant protein by anti-myc antibodies (Invitrogen). The recombinant protein is 
expressed under the control of the hCMV promotor.
Stable transfection of COS-7 cells did not result in high-level recombinant protein 
expression. Although transfected COS-7 colonies were screened for maximum production 
of IL-15Ra-IgGi-Fc fusion protein by DOT blot, large-scale culture and purification of the 
recombinant protein by affinity to protein A only yielded very small amounts of protein. A 
potentially toxic effect of IL-15Ra-IgGi-Fc protein expression in COS-7 cells could also 
be a reason for the relatively low yield of recombinant protein after stable transfection. In 
this case, selection of expression colonies by DOT blot may have excluded high-yield 
colonies due to the toxicity of the protein. However, IL-15Ra-IgGi-Fc fusion protein could 
be readily detected in Western blot analysis. COS-7 cells poorly secreted the recombinant 
protein, which may be due to the use of the native IL-15Ra leader peptide within the IL- 
15Ra-IgGi-Fc expression construct. The relatively low yield of recombinant protein in 
stably transfected COS-7 cells may be partly explained by the downregulation of the
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hCMV promotor over time after transfection, which has been demonstrated to occur in 
many transfected cell types.
To increase the efficiency of recombinant protein expression by increasing the 
number of plasmid copies per cell, transient transfection of COS-7 cells was performed. 
Supernatant of transiently transfected COS-7 cells effectively neutralized the binding of 
sIL-15Ra to IL-15, whereas supernatant from COS-7 cells transfected with pcDNAS.l 
alone did not contain anti-IL-15 activity. Taken together, these data indicate that IL-15Ra- 
IgG]-Fc fusion protein is expressed in COS-7 cells and is functional in terms of binding to 
IL-15 and containing an active IgGi-Fc domain as shown by its interaction with protein A 
and the anti-murine IgGi mAh in Western blot analysis. However, the low yield of IL- 
15Ra-IgGi-Fc fusion protein has so far prevented its use in vivo. Expression and secretion 
of IL-15Ra-IgGi-Fc fusion protein may be increased by employing a different leader 
peptide, which may prevent the potentially toxic effect of accumulation of the recombinant 
protein within the host cell or its premature degradation in the cytoplasm. Furthennore, the 
use of different expression vector systems (e.g. baculovirus) may or different promoters 
used to drive recombinant protein expression may increase the yield of IL-15Ra-IgGi-Fc 
production to enable in vivo experimentation.
6.2 Recombinant sIL-15Ra in collagen-induced arthritis
IL-15 mediates pleiotropic effects on a variety of immune cells (Tagaya, et al.,
1996). However, unlike IL-2, with which it shai*es partial functional homology, IL-15 may 
be generated not only by cells within the immune system but also by cells belonging to 
other tissues, including kératinocytes and synoviocytes (Mclnnes, et al., 1996; Thurkow, et 
a l, 1997; Mohamadzadeh, et a l, 1995). By this means, host tissues may contribute 
significantly to the regulation of protective or autoimmune responses. The functional
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effects of IL-15 that have been demonstrated thus far include the activation of NK cells 
and neutrophils and the autocrine regulation of macrophages indicating an important role 
for IL-15 in early, innate host defense (Carson, et al., 1995; Girard, et al., 1996; Alieva, et 
al., 1997). However, IL-15 additionally induces the activation of T cell blasts and will 
support the maturation and isotype switching of B-lymphocytes. Thus, a role in the 
development of antigen-specific responses might be predicted, although formal evidence of 
this role in vivo has not yet been demonstrated. IL-15 expression has been detected in 
several human diseases including RA, pulmonary sarcoidosis, inflammatory bowel disease, 
and chronic active hepatitis, providing circumstantial evidence for a role in clironic 
immunopathology (Mclnnes, et aL, 1996; Kirman and Nielsen, 1996, Agostini, et al., 
1996, Thurkow, et al., 1997). The mechanisms whereby IL-15 could be involved in such 
inflammatory tissue destruction have not been clearly defined. Results obtained in this 
thesis indicate that IL-15 expression is required for the induction of erosive inflammatory 
arthritis following a challenge of collagen-primed DBA/1 mice. Moreover, both the altered 
semm Ig levels detected and the in vitro evidence for suppressed spleen cell proliferation 
and cytokine production indicate that the collagen-specific response was at least partly 
dependent on IL-15. Since IL-15 induces T cell chemotaxis in vivo and in vitro (Wilkinson 
and Liew, 1995; Mclnnes, et aL, 1996) and induces proliferation, adhesion molecule 
expression, and cytokine production in vitro (Kanegane and Tosato, 1996; Mclnnes, et al.,
1997), it is possible that IL-15 mediates effects in inflammatory arthritis, at least in part, 
through its activities on antigen-specific T cells. Several recent data have provided 
suggestive evidence for antigen-driven T cell clonal expansion in patients with long­
standing RA (Schmidt, et aL, 1996; Scotet, et aL, 1996). Further possible explanations 
include the alteration of antigen-presentation or subsequent T cell costimulation, since both 
peripheral blood- and skin-derived dendritic cells are known to express IL-15 (Jonuleit, et 
aL, 1997), or the modification of adjuvant activity, since IL-15 up-regulation has been 
detected during mycobacterial infection (Jullien, et aL, 1997).
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The CIA model provides an opportunity to study the relative contribution of 
immune pathways to the development of inflammatory arthritis. Using this approach, 
previous studies have demonstrated a role for Thl cells and several proinflammatory 
cytokines, including TNPa and IL-1 in disease development (van den Berg, et aL, 1994; 
Simon, et aL, 1994; Williams, et aL, 1994; Mauri, et aL, 1996; Mussener, et aL, 1997). 
Such observations in rodents are clearly of relevance, since subsequent clinical trials with 
neutralizing antibodies against TNFa and soluble TNFR have demonstrated efficacy in 
human RA (Elliott, et aL, 1994; Rankin, et aL, 1995) and implied a pivotal role for TNFa 
in RA pathogenesis, IL-15 is capable of "bystander" activation of RA synovial T cells. 
After this activation, these cells may produce cytokines, including TNFa, either directly or 
through cognate interaction with adjacent macrophages (Mclnnes et aL, 1997). Thus, IL-15 
could act upstream from TNFa in orchestrating the production of inflammatory cytokines 
in the chronically inflamed RA synovium. The data presented here provide direct evidence 
in vivo that IL-15 can also play a pivotal role in the development of inflammatory arthritis. 
Beside its postulated function in innate immunity (Carson, et aL, 1995; Girard, et aL, 
1996), a critical role in the modulation of acquired immunity is suggested for IL-15. IL- 
15Ra administration effectively suppressed collagen-specific responses that were 
measured in vivo by serum Ig and in vitro by spleen cell responses. This finding was 
unexpected, since the mice used were IL-2 replete. IL-15 and IL-2 share occupancy of the 
IL-2/15Rp-chain and the common y-chain and transduce similar JAK1/3-STAT3/5- 
dependent pathways thereafter (Johnston, et aL, 1995), leading to the suggestion that some 
functional redundancy might exist. However, the sIL-15Ra chain did not exhibit any 
binding to IL-2 in vitro nor did it inhibit IL-2-mediated CTLL proliferation, making it 
unlikely that cross-reactivity could explain our observations. Rather, it is likely that early 
IL-15 production during antigen-challenge is necessary for the normal development of
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specific immune responses. The availability of sIL-15Ra and the availability of mice 
lacking IL-15Ra (Lodolce, et aL, 1998) may facilitate future studies to investigate the 
precise relationship and functional overlap between IL-2 and IL-15.
In DBA/1 mice, the continuous administration of sIL-15Ra on a daily basis led to 
the development of anti-sIL-15Ra antibodies. This was unexpected since cDNA from a 
murine cell line was used for the cloning and expression of sIL-15Ra. However, anti-sIL- 
15Ra antibodies derived from mice treated with sIL-15Ra did not inhibit the neutralizing 
activity of the recombinant protein on IL-15 in vitro. Western blot analysis also indicated, 
that the immunogenicity of slL-15Ra may be caused by the non-isogenic 6xHis fusion 
domain encoded by the pQE30 vector, which was used to purify sIL-15Ra by affinity 
binding. This is despite the claim that the 6xHis tag confers low immunogenicity (Qiagen). 
It cannot be excluded that serum anti-sIL-15Ra antibodies facilitated the clearance and 
neutralization of the sIL-15Ra in vivo and may even have had a stimulatory effect on 
endogenous IL-15Ra. The problem of anti-sIL-15Ra antibodies in treated mice may be 
overcome by the cloning of a minimal peptide fragment capable of neutralizing IL-15 
efficiently without containing ‘foreign’ peptide sequences. The development of alternative 
treatment schedules for sIL-15Ra in CIA may also provide a tool to circumvent the 
development of anti-sIL-15Ra antibodies, which might neutralize the effects of the IL-15 
antagonizing agent.
Thus, sIL-15Ra profoundly suppressed the development of CIA and markedly 
inliibited the onset of the humoral and Thl cell-mediated anti-collagen response. These 
results provide important in vivo data, which show a role for IL-15 in inflammatory 
arthritis and suggest that antagonists to this cytokine could be of therapeutic benefit.
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6,3 Conditional mutagenesis of IL-15Ra in ES cells
Gene targeting through homologous recombination provides a powerful tool to 
analyze the function of defined gene products in vivo. In the field of Immunology, gene 
targeting technology has contributed substantially to the current understanding of how cells 
of the immune system develop, how receptor activation related signals are processed 
within immune cells and how immune cells respond to activating stimuli. Gene targeting 
has thus become a common approach in obtaining functional information for newly found 
cytokines and other immune mediators. The phenotypic observations made from mutant 
mice that ai'e deficient for a specific cytokine have provided important evidence for the 
involvement of these cytokines in specific immune responses to pathogens and in 
autoimmunity. The recently developed Cre/lox system allows the generation of mice that 
are mutant for specific target genes in a tissue specific and/or inducible manner. One clear 
advantage of this technique is the possible avoidance of generating mutants that lead to 
prenatal mortality. However, as previous targeting experiments show, the deficiency for 
specific immune mediators using conventional gene targeting techniques is unlikely to 
result in embryonic lethality. On the contraiy, the high degree of redundancy observed for 
the functions of many cytokines may lead to mutant mice that are phenotypically very 
similar to wild type mice. However this has not been the case where cytokines have been 
found to mediate developmental processes in the maturation of the immune system (e.g. 
LTa/b, IL-2, IL-15Ra). In these targeting experiments, the broad effect of the gene 
product has led to a phenotype in mutants, that could be characterized even without 
exposing mutant animals to exogenous immunologic stimuli (Komer, et al., 1997; 
Alimzhanov, et a l, 1997, Lodolce, et al., 1998). The Cre/lox system enables the generation 
of tissue specific mutants where the lack of a specified gene product can be studied in an
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otherwise wild-type animal. The system is thus providing the opportimity to obtain a more 
accurate mutant phenotype where secondary side effects of the generated mutation can be 
reduced to a minimum. The rapidly growing collection of Cre-transgenic mice that express 
the recombinase either constitutively or upon induction may make conditional mutagenesis 
become more suitable for the broad application of gene targeting. In this thesis, conditional 
mutagenesis of the IL-15Ra locus was used in an attempt to generate ES cell clones that, 
after germ line transmission, result in either "nuW mutants or conditional mutants for IL- 
15Ra when crossed with a Cre-transgenic animal. Unlike IL-2Ra, IL-15Ra is expressed in 
many types of tissue indicating potential functions for IL-15 outside the immune system. 
The Cre/lox system has therefore been chosen for the targeting of IL-15Ra so as to allow 
studies on the effect of IL-15Ra mediated functions in immune cells alone. Although mice 
lacking IL-15Ra have been generated using conventional gene targeting techniques, this 
data liaKnot yet been available by the time, the conditional mutagenesis of IL-15Ra was 
undertaken. As demonstrated for the IL-2/IL-2R system the deletion of a cytokine receptor 
may result in a more pronounced biological phenotype than the deletion of the 
coiresponding cytokine (Schorle, et aL, 1991; van Parjis, et aL, 1997, Suzuki, et aL, 1997). 
Therefore the high affinity IL-15Ra rather than IL-15 itself has been selected as a target. 
The major experimental steps to conditionally target IL-15Ra in ES cells are discussed 
here.
The gene encoding IL-15Ra has been characterized by using the cDNA encoding 
the extracellular domain of IL-15Ra as a radiolabeled probe to screen a murine genomic 
library. Two lambda clones were identified that contained genetic material encoding IL- 
15Ra. However only two out of seven exons that have been described for the IL-15Ra 
gene (not including alternative splicing variants) (Anderson, et aL, 1995) were contained 
within these clones. These two exons corresponded to the coding exon/protein domain
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structure described for human IL-15Ra and encoded essential parts of the extracellular 
protein-binding domain of IL-15Ra. No other exon DNA was detected in either of the 
lambda clones found after library screening. Since exon 2 contains genetic material 
encoding crucial parts of the protein-binding motif of IL-15Ra most likely to mediate the 
binding of IL-15, exon 2 was selected as a target for conditional mutagenesis. The 
targeting vector was designed to flank exon 2 by loxP sites. The targeting construct also 
contained a positive selection marker cassette placed 5’ of exon 2, which was flanked by a 
5 ’ loxP site and the loxP site upstream of exon 2.
Integration of transferred DNA into the chromosomes of mammalian cells occurs 
much more frequently by non-homologous rather than by homologous recombination. This 
effect impedes the detection and isolation of cells where the rare targeting events have 
occurred (Capecchi, 1989). Although the exact mechanism by which homologous 
recombination occurs is not well understood, several factors are known to influence the 
efficiency of homologous recombination in gene targeting experiments. These factors, 
most importantly the isogenic natui*e of the construct, length of the homologous region and 
transcriptional activity of the target locus therefore influence the design of targeting 
constructs commonly used to generate genomic alterations.
The frequency of homologous recombination is know  to be influenced by the 
degi'ee of variation between intrinsic genomic DNA segments and the corresponding 
homologous part of the targeting construct (te Riele, et aL, 1992). The number of 
polymorphic variations in genetic material derived from different mouse strains could 
therefore lead to a decrease in targeting efficiency if the targeting construct is prepared 
from DNA derived from a different mouse strain than the ES cells that are used to generate 
the mutation. Polymorphisms are most likely to occur in non-transcribed introns, rather
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than in coding exon sequences. In this targeting experiment, both the E l4/2 ES cells and 
the XFixII genomic library are derived from the 129SV strain. However, the relatively 
complicated cloning procedure required to generate the 3’homologous region of the 
targeting construct and the 3’-loxP site may have resulted in a reduction of targeting events 
due to the insertion of pBlueScript-DNA derived from the MCS of lambda derived 
subclones.
The length of the DNA segment homologous between targeting vector and target 
gene is also known to influence the frequency of homologous recombination events 
(Thomas and Capecchi, 1987;. Hasty, et aL, 1991). A positive correlation has been shown 
to exist between the length of the homologous region and the frequency of recombination 
events. Conventional targeting constructs that contain a selectable marker cassette flanked 
by two homologous regions usually contain 5-1 Okb of DNA homologous to the target 
sequence. In this targeting experiment, the 5’ homologous region was composed of 3.7kb, 
whereas the 3’homologous region contained 3.1 kb, resulting in a total of 6.8kb. 
Asymmetry of homologous regions used to clone the targeting construct may be preferred 
to allow PCR screening for targeting events. In this targeting experiment, successful PCR 
screening for genomic alterations generated by the targeting construct could only be 
employed after Cre-mediated recombination, which caused the shortening of the PCR 
template compared to the wild-type allele and thus preferential amplification in PCR j 
analysis. Prior to Cre-mediated recombination, PCR screening for 3’targeting events 
proved difficult. This may have been caused by the relatively long PCR template of the 
putative targeted allele, which was approximately 2kb longer than the wild type allele (due 
to the presence of the Neo cassette). Amplification could not be achieved even when long 
range DNA polymerases were used.
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Some evidence exists that homologous recombination is more likely to occur in gene 
loci that are transcriptionally active during the time of the gene targeting experiment 
(Mansour, et a l, 1988; Johnson, et a l, 1989; Nickoloff, et a l, 1990). Attempts were made to 
detect the presence of IL-lSRa-mRNA in ES cells by RT-PCR. However, no mRNA 
encoding IL-15Ra could be detected using this method. The low efficiency of homologous 
recombination events in IL-15Ra targeting may therefore be due to the fact that the gene 
encoding IL-15Ra is silent in ES cells. Selectable marker cassettes are frequently used in 
gene tai'geting experiments to enrich targeted ES cell clones in culture since their presence 
within the targeting construct does not appear to negatively influence the frequency of 
targeting events (Mansour, et a l, 1990). In this targeting experiment, a negative selection 
marker gene (HSV-&) was placed at the 3’ end of the targeting construct. The constmct also 
contained a Neo selection marker gene placed between the 5’ and 3’ homologous region. 
Random integration of the construct should result in ES cell clones that are both G418 
resistant and sensitive to gancyclovir since the presence of the HSV-tk gene converts 
gancyclovir into a toxic derivative (Mansour, et a l, 1988). Recombination between the 
homologous regions of the targeting constmct and the endogenous gene locus does not result 
in the integration of the HSV-tk gene, hi this targeting experiment, the use of gancyclovir 
reduced the number of clones obtained after electroporation by approximately 5 fold. A 
further emichment of targeting events by up to 100 fold can be achieved using promotor trap 
vectors that take advantage of the transcriptional machinery of the endogenous gene locus to 
drive the expression of the positive selection marker gene following homologous 
recombination (Mountford, et a l, 1994). However, promotor trap vectors require the target 
gene locus to be transcriptionally active, which is not the case for IL-15Ra.
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Southern blot analysis was used to screen for targeting events. Hybridization of the 5’ 
external DNA probe with gDNA derived from ES cell clones resulted in a 7kb band for the 
wild type, and 4.2 kb band for the targeted IL-15Ra allele due to the insertion of a Xhol site 
5’ of the Neo selection marker cassette. The restriction endonuclease Xhol was used to 
fragmentize gDNA prior to Southern blot analysis. This has proved difficult, since the low 
frequency of Xhol sites in murine gDNA may result in poor digestion and fragment 
separation leading to an insufficient signal in Southern blot analysis. However, it has been 
necessary to use this approach since the hybridization of a putative 3’ external probe (located 
at the 3’ end of subclone 3.2) resulted in unspecific binding to ‘smear’ bands in Southern blot 
analysis. This may be due to the presence of large AT-nucleotide repeats within the 3’ 
external probe often found in intron sequences which can lead to nonspecific hybridization. 
A PCR approach was therefore used to reconfirm the 3’ integration event of the targeting 
construct following Cre-mediated recombination.
Cre-mediated recombination was performed in vitro by transiently transfecting 
targeted ES cells with a Cre-expression plasmid. Initial experiments using the Cre- 
expression plasmid pBS185 (Gibco, BRL) did not result in clones that had undergone Cre- 
mediated recombination events, although approximately 200 ES cell clones were analyzed 
by PCR. This may have been due to the lack of a selectable marker for pBS 185-transfected 
ES cells. Since the desired Cre-mediated recombination in targeted ES cells would result in 
the deletion of the Neo selection marker cassette, G418 was unsuitable for selecting ES 
cells that had been transfected with Cre-expression plasmid. Using pBS185, ES cells had 
to be diluted sequentially and cultured in the absence of G418 to obtain ES cell colonies. 
To select for Cre-transfected ES cells after electroporation, the Cre-expression plasmid 
pCAG-Cre-IP was used. This plasmid expresses Cre recombinase under the CAG promotor 
and also contains the gene encoding puromycin-acetylase ipac). Puromycin is capable of 
killing non-resistant ES cells within 48 hours of culture and is therefore particularly
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suitable for the selection of transient transfection events (Taniguchi, et aL, 1998). Selection 
with puromycin resulted in only 17 ES cell colonies, indicating that the transfection rate 
(approximately 10  ^ cells used for electroporation) had been very low. All clones obtained 
exhibited the same Cre-mediated deletion resulting from recombination between the most 
5’ and 3’ loxP sites and subsequent excision of both the loxP flanked exon 2 of the IL- 
15Ra gene and the selectable marker cassette {Neo). This may be due to the fact that Cre- 
expression under the CAG promotor is very efficient and therefore results in total rather 
than partial excision of loxP site flanked sequences in transfected cells. PCR analysis using 
a pair of internal and external oligonucleotides results in a PCR product of 0.9kb.
Conditional mutagenesis of the IL-15Ra gene has therefore led to the generation of 
two ES cell clones. The first clone contains loxP sites flanking coding exon 2 of the IL- 
15Ra gene. This exon encodes the major part of the protein binding ‘Sushi’ domain 
thought to mediate the binding of IL-15 to its receptor. The clone also contains the Neo 
selectable marker cassette, which is also flanked by loxP sites. It has been reported that the 
presence of a selectable marker gene may occasionally interfere with gene expression 
(Artelt, et al., 1991). However, the selectable marker gene in the IL-15Ra locus is 
positioned within the large intron sequence separating exon 1 and exon 2 and may 
therefore not have any adverse effect on the expression of a functional IL-15Ra in 
homozygous mice. This clone may therefore provide the possibility to generate mice that 
are suitable for conditional targeting experiments by crossing to Cre-transgenic mice, e.g. 
Ick-Cre. However, it may be advantageous to generate ES cell clones lacking the Neo 
cassette by employing a Cre-expression plasmid where Cre is placed under the control of a 
weak promotor. Also, the optimization of transfection conditions may lead to an increase 
in Cre-transfected clones providing the possibility to detect Aeo-deficient ES cell clones by 
PCR screening. A second ES cell clone results from Cre-mediated recombination of the
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targeted ES cell clone. In this clone, the targeted allele is lacking exon 2 and the selectable 
marker cassette. Germ line transmission and subsequent generation of homozygous mice 
would result in IL-15Ra-deficient animals.
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6.4 Conclusions
The present study is separated into two major components. Firstly, soluble, 
recombinant IL-15 receptors were cloned and expressed to use as IL-15 antagonists in vitro 
and in vivo. The second part of this project has focused on the generation of a targeted ES 
cell clone to obtain a murine model lacking IL-15Ra by conditional mutagenesis.
Using a bacterial expression system, recombinant sIL-15Ra was successfully 
produced in suitable quantities. A mammalian expression system was used to produce an 
IL-15Ra-IgG-Fc fusion protein but this approach did not result in the desired yield 
although both proteins bound IL-15 specifically. Soluble IL-15Ra was successfully used 
as a therapeutic agent in murine collagen induced arthritis. These results further support 
evidence that IL-15 present in the rheumatoid synovium may exacerbate disease pathology, i 
probably by stimulating the production of TNFa. Recombinant antagonists to IL-15 may 
therefore have a therapeutic potential in human rheumatoid aithritis.
Using the Cre/lox system of conditional mutagenesis, two ES cell clones have been 
generated. The first clone contains all functional exons encoding IL-15Ra. Exon 2 is 
flanked by loxP sites. This clone should allow for conditional mutagenesis of the IL-15Ra 
locus in mice derived from this clone. The second ES cell clone results fiom Cre mediated 
deletion of ioxP site flæiked sequences deleting exon 2 of the IL-15Ra gene and the Neo 
selection marker cassette. Mice derived from this clone should not express a fiinctional IL- 
15Ra protein. The murine model generated using these clones may provide a useful tool to |istudy the effects of IL-15-mediated immune responses in vivo.
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6.5 Future studies
The following points provide a possible framework for future studies aiming to 
further investigate the potential of recombinant IL~15Ra proteins as therapeutic agents in 
vivo as well as for basic investigations of the functions of IL-15 in the murine model.
Identification of the minimal binding domain of IL-15Ra to specifically interact 
with IL-15 in vivo. Crystal structure analysis of putative binding domains for the 
design of therapeutic antagonists.
Optimization of expression of IL-15Ra-IgGi-Fc fusion protein and subsequent in 
vivo analysis of its therapeutic potential in CIA.
Identification of therapeutic properties of IL-15 antagonists in murine models of 
autoimmune disease where IL-15 has been characterized as a putative causative 
agent.
Generation of mutant mice using the ES cell clones generated. Analysis of 
phenotypic results of the deletion in T cell specific and general IL-15Ra knockout 
mice.
The recombinant sIL-15Ra is currently employed in a number of studies undertaken in 
different laboratories aiming to elucidate the role of IL-15 in different disease models in 
vivo. The names and addresses of collaborators using the sIL-15Ra are listed below.
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The role of IL-15 in cardiac allograft rejection:
Prof. J.A. Bradley, Dept of Surgery, Addensbrooke’s Hospital, Cambridge, UIC.
Host defense against viral pathogens:
Dr. C. Biron, Division of Biology and Medicine, Brown University, USA.
The role of IL-15 in inflammatory bowel disease:
Dr. F. Powrie, Dept, of Sui'gery, University of Oxford, Oxford, UK.
The role of IL-15 in HSV infection:
Dr. H. Nishimura, Research Institute for Disease Mechanism and Control, Nagoya, 
Japan
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